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Abstract 
Nrf2 is a transcription factor that, under conditions of chemical stress, is able to 
evade its cytosolic repression and translocate to the nucleus to initiate the 
transcription of a battery of cytoprotective genes, such as those involved in the 
detoxication of xenobiotics.  Nrf2 has previously been shown to afford protection 
against chronic and acute renal injury, yet, relatively little is known about the 
mechanism by which Nrf2 affords this protection, and the extent of its 
transcriptional roles in the kidney.  This thesis seeks to further our understanding of 
the physiological, pharmacological and toxicological roles of Nrf2 in the kidney. 
Using an iTRAQ-based proteomic approach to quantify protein expression levels in 
the kidneys of Nrf2+/+ and Nrf2-/- mice, acutely treated with vehicle or the potent 
Nrf2 inducer CDDO-Me (3 mg/kg), we demonstrated that 189 proteins were 
differentially expressed in the Nrf2-/- mouse kidney, compared to Nrf2+/+, and 42 
proteins were differentially expressed in the CDDO-Me treated Nrf2+/+ mouse 
kidney, compared to vehicle.   The key finding was that the kidneys of Nrf2-/- mice 
are deficient in proteins that mediate cellular redox balance, the metabolism of a 
range of xenobiotics, and the regulation of core metabolic processes, including 
energy metabolism and the synthesis and recycling of amino acids.  Functional 
demonstration of a reduction in energy metabolism was demonstrated by assessing 
total NADPH and GSH, of which Nrf2-/- mouse kidneys had 35% and 30% less than 
their Nrf2+/+ counterparts, respectively.  A single acute dose of CDDO-Me failed to 
augment the expression of proteins, other than Nqo1, that were shown to be 
regulated by Nrf2 at the basal level in the mouse kidney, however qPCR analysis of 
these kidneys revealed that CDDO-Me has an effect at the transcriptional level 
which has not fully translated within the timeframe of this study.  In summary, we 
have provided evidence that Nrf2 regulates the expression of an array of proteins 
that contribute to cell defence and the maintenance of homeostasis in the kidney, 
supporting current interest in Nrf2 as a novel therapeutic target in a number of 
renal diseases. 
MicroRNAs are a recently discovered RNA-regulatory element that show promise in 
their use as biomarkers of physiological and pathological events.  In order to 
provide insight into the microRNAs under Nrf2 control in the kidney, we performed 
an unbiased microRNA array analysis on kidney homogenates from Nrf2+/+ and Nrf2-
/- mice, treated with vehicle or CDDO-Me, and then validated several promising 
microRNA candidates using targeted qPCR analysis.  Of particular note are miR-
466h-3p, the expression of which was significantly increased in the CDDO-Me 
treated Nrf2+/+ mouse kidney and decreased in the Nrf2-/- mouse kidney, compared 
to their respective controls, and miR-28c and 144, which were both significantly 
decreased in the CDDO-Me treated Nrf2+/+ mouse kidney, and increased in the Nrf2-
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/- mouse kidney. This novel analysis represents the first step in characterising the 
renal Nrf2 microRNA-ome, which could reveal novel mechanisms of Nrf2 function 
and markers of its activity that could translate to the clinic. 
Recent interest in the use of CDDO-Me as a therapeutic intervention for late-stage 
chronic kidney disease has culminated in a phase III clinical trial (BEACON), which 
was subsequently terminated due to unforeseen adverse cardiac events, of which 
the cause has yet to be identified.  In order to determine whether the drive to 
produce more potent Nrf2 inducers has inadvertently led to the generation of 
inherently more toxic compounds, the relationship between potency towards Nrf2 
and toxicity was evaluated for CDDO-Me and related triterpenoids, and other 
classes of Nrf2 inducer.  Using a rat H4IIE-ARE8L luciferase reporter cell line to 
determine in vitro therapeutic indices, it was discovered that within the compounds 
tested an increase in potency toward Nrf2 of four magnitudes results was 
associated with an increase in toxicity of only two magnitudes, resulting in a 
relative increase in in vitro safety.  This data indicates that it is possible to generate 
potent Nrf2-inducers that are not inherently toxic, and suggests that therapeutic 
targeting of Nrf2 continues to hold promise as a novel treatment for a range of 
diseases. 
In summary, by using a proteomic approach we have identified an array of renal 
Nrf2-regulated proteins that contribute to various cytoprotective and metabolic 
processes in the kidney, supporting current interest in the therapeutic targeting of 
Nrf2 as treatment for renal disease.  Additionally, the microRNAs under Nrf2 
regulation in the kidney have also been identified, and represent the first step in 
fully characterising the Nrf2 microRNA-ome.  Finally, it was shown that the drive to 
produce more potent Nrf2 inducers has not led to the generation of inherently 
more toxic compounds; indeed an increase in potency is associated with a relative 
increase in in vitro safety, suggesting that the targeting of Nrf2 is still a promising 
therapeutic route.   Overall, the work presented in this thesis has furthered our 
understanding of the physiological, pharmacological and toxicological roles of Nrf2 
in the kidney. 
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1.1 Introduction 
 
Acute kidney injury (drug-induced toxicity or ischaemic-reperfusion injury) is 
responsible for approximately 20 % of emergency hospital admissions (Wang et al., 
2012), and the incidence of chronic kidney disease (CKD) in Europe is about 135 per 
1,000,000 population (Hamer et al., 2006), but accounts for over 2 % of the 
European healthcare budget (Hamer et al., 2006).  The kidney is particularly 
susceptible to drug-induced oxidative stress (an imbalance of the redox state of the 
cell provoked by either the induction of the formation of reactive oxygen species 
(ROS) or the prevention of their removal (Park, 1986)) as a result of its anatomical 
structure and physiological roles (Perazella, 2009).  The transcription factor Nrf2 has 
previously been shown to afford protection against acute kidney injury (for a 
review, see (Shelton et al., 2013)) and chronic kidney disease (for a review, see 
(Ruiz et al., 2013)) in a number of experimental models.  Compared to other organs, 
relatively little is known about the mechanisms by which Nrf2 provides this 
protection, and the extent of its transcriptional roles in the kidney.  Such knowledge 
would provide insights into disease mechanisms and inform the use of Nrf2-
modulating drugs as novel treatments for kidney pathologies.  Based on data from 
animal studies and serendipitous observations from clinical trials (Wu et al., 2011b; 
Hong et al., 2012), the potent triterpenoid Nrf2 inducer CDDO-Me has recently 
been investigated as a novel treatment for CKD.  However, the toxicological 
consequences of targeting Nrf2 with chemically reactive drugs have not been fully 
examined.  Such knowledge would inform the design and use of Nrf2 inducers as 
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novel drugs.  To address these research questions, this thesis seeks to determine 
the physiological, pharmacological and toxicological roles of Nrf2 in the kidney. 
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1.2 Kidney physiology 
The kidney maintains the homeostasis of the body, reabsorbing water, glucose, 
amino acids and various electrolytes to maintain correct function and pH of the 
blood (Fig. 1), in addition to regulating waste management via the excretion of 
water and unwanted solutes.  
 
Fig.1: Schematic of a nephron, with major structural areas labelled in black and main reabsorption 
solutes labelled in green.  The filtrate enters the Bowman’s capsule, travelling along the proximal 
convoluted tubule, where the majority of Na
+
, Cl
-
, glucose and proteins are reabsorped.  Due to 
increasing osmolarity in the medulla, H2O passively diffuses out of the filtrate along the descending 
limb of the loop of Henle.  The ascending limb is impermeable to H2O; Na
+
 and Cl
-
 are actively 
transported out of the filtrate to maintain medullary osmolarity.  Na
+
 and Cl
-
 are reabsorped in the 
distal convoluted tubule, as is H2O depending on the presence of anti-diuretic hormone (AVP).  A 
similar process occurs along the collecting duct, before the filtrate is passed into the urine. 
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1.2.1 The glomerulus, Bowman’s capsule and proximal tubule 
The kidney receives approximately 25% of cardiac output (Lote et al., 1996), which 
is filtered through the nephron, the functional unit of the kidney (Fig. 1) via afferent 
and efferent arterioles.  The difference in arteriolar diameter between afferent and 
efferent arterioles causes a heightened pressure in the glomerulus (a modified 
capillary bed), which, combined with a podocytic apical surface and glomerular 
hydrostatic pressure allow for the filtration of the solute into the Bowman’s 
capsule, with large proteins being retained.  The ultrafiltrate, consisting of water, 
smaller proteins and various electrolytes (Na+, K+, HCO3
- , etc.) passes into the 
Bowman’s capsule through its podocyte membrane, and into the proximal tubule 
segment (Fig. 1 and 2).  Lined with proximal tubular epithelial cells, the convoluted 
and straight proximal tubule are responsible for the reabsorption of the majority of 
the ultrafiltrate (Bokenkamp et al., 2011).  Proximal tubular epithelial cells are 
brush border cells, with microvilli lining the apical surface of the lumen 
concentrated with various transporters (Fig 2).  Proximal tubule cells have a high 
requirement for ATP due to their dependence on oxidative phosphorylation for 
energy, and therefore have a relatively high volume of mitochondria (up to 44% by 
cell volume (Bakris et al., 2009)).  The expression of transporters differs between 
the convoluted and straight proximal tubules (Dominguez et al., 1992; Rodriguez-
Mulero et al., 2005), with the majority of glucose and water being reabsorped 
purely by the proximal convoluted tubule section (Hummel et al., 2011).   
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Fig.2: Schematic of proximal convoluted/distal tubule structure.  Transport of major components of 
ultrafiltrate is highlighted.  Transporters (with abbreviations and solute carrier (SLC) family) are: (1) 
Na
+
 dependent glucose transporter (SGLT1/2, SLC5), (2) Na
+
/Cl
-
 symporter (NCCT, SLC12), (3) Na
+
/H
+
 
antiporter (NHE, SLC9)   (4) Na
+
/K
+
 ATPase (ATP1), (5) Na
+
/HCO3
-
 cotransporter (SLC4).  
 
As the filtrate passes along the proximal tubule, the basolateral Na+/K+ ATPase 
drives Na+ out of the proximal tubule cell, into the interstitial space and the blood, 
enabling absorption of further Na+ from the filtrate at the apical pole due to a 
difference in Na+ concentration, and a stoichiometrically regulated negatively 
charged intracellular environment (Nakamura et al., 2014).  Transport of Na+ into 
the proximal tubule cell from the lumen drives reabsorption of filtrate components 
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by secondary active transport (Fig. 2, (Bakris et al., 2009)).  Water reabsorption in 
the proximal tubule segment occurs through net diffusion due to differences in 
osmotic gradient, through aquaporin 1 channels (transmembrane proteins allowing 
for the osmosis of water (Nielsen et al., 2002)) or through inter-cellular junctions 
(Greger, 2000; Bakris et al., 2009).   Approximately 60-70% of Na+ and water is 
reabsorped in the proximal tubule (Greger, 2000). 
 
1.2.2 The loop of Henle 
The loop of Henle acts as a counter-current multiplying system to handle urea, 
achieving a concentration gradient (increasing osmolarity and solute concentration 
from cortex to inner medulla) in the kidney.  The descending limb of the loop of 
Henle is highly permeable to water via aquaporin 1 (membrane water channel 
protein), and less so to filtrate ions, so water diffuses out via aquaporins (Fig. 1, 
(Nielsen et al., 1993)).  Urea concentration increases in the medulla along the 
descending limb, allowing for passive diffusion of water via aquaporins for its 
duration. The filtrate hence becomes more concentrated.  The ascending limb lacks 
aquaporins, and is highly permeable to Na+ and Cl- ions (Nielsen et al., 1993).  Na+, 
K+ and Cl- ions are actively transported into the medullary space along the 
ascending limb, meaning that the space maintains concentration gradient and 
continues to allow the diffusion of water into the medulla along the descending 
limb. Up to 30% of filtered Na+ is reabsorbed along the ascending limb of the loop 
of Henle, and at this point most of the total Na+ in the filtrate has been reabsorbed 
(Brater, 2000).  The filtrate hence becomes more dilute.  
11 
 
1.3.3 The distal tubule and collecting duct 
The function of the distal tubule is primarily regulation of ion balance and pH of the 
filtrate, urine dilution and blood pressure regulation (Eladari et al., 2012).  Na+ ions 
are reabsorped in the distal tubule through coupled secretion of H+ and K+, thereby 
acidifying the filtrate (Fig. 1) (Dantzler, 2003).  Furthermore, the distal tubule is 
responsible for the secretion of ammonia, creatinine and the products of drug 
metabolism into the filtrate.  Distal tubular epithelial cells lack a brush border and 
are relatively impermeable to H2O, however in the presence of AVP secreted from 
the pituitary gland, aquaporin 2 channels are inserted into the distal tubule, 
allowing H2O reabsorption and concentration of the filtrate (Nielsen et al., 2002).   
A region of columnar epithelial cells, known as the macula densa, are located close 
to the afferent and efferent arteriole and glomerulus, and they function to detect 
and modify Na+ levels in the filtrate (Ren et al., 2007).  In response to elevated Na+ 
in the filtrate (potentially due to inefficient reabsorption in the Bowman’s capsule 
and proximal tubule) cells of the macula densa uptake Na+ via apical Na+/K+/Cl- 
transporters, and due to consequent change in osmolarity, H2O diffuses into the 
cells of the macula densa (Komlosi et al., 2004).  The turgidity of the cells induces 
basolateral adenosine release, which induces afferent arteriolar constriction and 
efferent arteriolar dilation (Castrop, 2007; Ren et al., 2007), reducing glomerular 
flow rate and increasing the proportion of Na+ reabsorped at the Bowman’s capsule 
and proximal tubule.  
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Finally, the collecting duct is responsible for fine modulation of filtrate osmolarity, 
chiefly by reabsorbing H2O and Na
+ (Fig. 1), and additionally bicarbonate and 
calcium.  Similarly to the distal tubule, modulation of H2O reabsorption is controlled 
by the release of AVP and subsequent aquaporin insertion and H2O diffusion into 
the normally H2O-impermeable collecting duct in response to dilute urine or 
reduced blood volume.  The filtrate (urine) hence becomes more concentrated 
entering the ureter. 
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1.3 Antioxidant mechanisms of the cell 
 
1.3.1 Oxidative stress 
Drug induced oxidative stress arises when a drug induces the formation of ROS, or 
prevents their removal (Park, 1986; Schafer et al., 2001), leading to an imbalance in 
the redox state of the cell.  Indeed, may drugs provoke off-target effects via the 
generation of ROS (Antoine et al., 2009; Copple et al., 2010a).  The kidney is 
particularly susceptible to oxidative stress due to a relatively hypoxic environment 
experienced by cells in the loop of Henle, and high metabolic activity demonstrated 
by cells involved in absorption and secretion (Perazella, 2009).   
The majority of systemic ROS are generated by the electron transport chain in the 
mitochondria (Pieczenik et al., 2007), however under certain conditions, ROS such 
as superoxide (O2
-), hydrogen peroxide (H2O2), the hydroxyl radical (
●HO) and 
others such as peroxynitrite (ONOO-) and organic hydroperoxides (ROOH) are 
produced, and cause damage to DNA (various lesions, including abasic sites, 
oxidised bases and strand breaks (Shibutani et al., 1991)), and to proteins (primarily 
through the oxidation of cysteine residues (Bandyopadhyay et al., 1994)).   
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1.3.2 The Keap1/Nrf2 antioxidant response pathway 
Whilst the repair of oxidative stress-induced damage (for example through DNA 
base-excision repair or protein degradation) is important for the maintenance of 
cellular homeostasis, the prevention of such damage also critical.  A key mechanism 
of prevention of oxidative stress-induced damage is the Keap1/Nrf2 antioxidant 
response pathway, which initiates the transcription of various antioxidant enzymes 
and proteins in response to oxidative stress. 
The key components of the Keap1-Nrf2 pathway are the antioxidant response 
element (ARE), Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2, Nrf2) and Kelch-
like ECH-associated protein 1 (Keap1).  The ARE is a cis-acting enhancer motif 
located in the promoter regions of Nrf2 target genes (Nioi et al., 2003).  The ARE 
was initially identified as an oxidant-responsive promoter element of the 
detoxicating antioxidant genes glutathione S-transferase A2 (Gsta2) (Rushmore et 
al., 1990) and NADPH: quinone oxidoreductase 1 (Nqo1) (Favreau et al., 1991).  
Originally thought to be a conserved 20 bp sequence, based on alignment of the rat 
Gsta2, Gstp1 and human and rat Nqo1 genes (Wasserman et al., 1997), the ARE is 
now known to comprise four distinct classes of enhancers with differing consensus 
sequences and motifs (Hayes et al., 2010), allowing for more dynamic induction and 
regulation by stressors and transcription factors.  Table 1 gives some examples of 
genes containing the ARE that are known to be regulated by Nrf2. 
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Category Gene Function Reference 
Glutathione 
metabolism 
 
γ-Glutamyl-cysteine 
ligase, catalytic 
subunit (Gclc) 
Rate-limiting enzyme in the synthesis of 
glutathione, catalyzes the conjugation of L-
glutamine and L-cysteine to yield γ-L-
glutamyl-L-cysteine 
(Chan et al., 
2000) 
Glutathione 
peroxidase (Gpx) 
Catalyzes the reduction (by glutathione) of 
H2O2 and other hydroperoxides to water 
(Banning et 
al., 2005) 
Antioxidants 
 
Sulphiredoxin (Srxn) 
Catalyzes the reduction of oxidized cysteine in 
peroxiredoxin, maintaining the latter’s 
antioxidant function 
(Singh et al., 
2009) 
Thioredoxin (Trx) 
Facilitates the reduction of other proteins by 
cysteine thiol–disulphide exchange 
(Kim et al., 
2001) 
Iron 
metabolism 
 
Ferritin (Ft) 
Facilitates storage of iron in a soluble, 
nontoxic form 
(Pietsch et 
al., 2003) 
Heme oxygenase-1 
(Ho-1) 
Catalyzes the degradation of soluble, toxic 
heme 
(Alam et al., 
2003) 
Xenobiotic 
metabolism 
 
 
Glutathione S-
transferase (Gst) 
Catalyzes the conjugation of reduced 
glutathione to exogenous and endogenous 
hydrophobic electrophiles 
(Hayes et 
al., 2000) 
NAD(P)H quinone 
oxidoreductase 1 
(Nqo1) 
Catalyzes the two-electron reduction of 
quinones to hydroquinones, without the 
production of radical species 
(Dinkova-
Kostova et 
al., 2010a) 
UDP glucuronyl 
transferase (Ugt) 
Catalyzes conjugation of lipophilic molecules 
with glucuronic acid, forming water-soluble 
and excretable metabolites 
(Shelby et 
al., 2006) 
Xenobiotic 
transport 
Multidrug 
resistance–
associated protein 
(Mrp) 
Organic anion transporter that mediates the 
cellular export of drugs and other small 
molecules 
(Maher et 
al., 2005) 
  
Table 1: Examples of Nrf2-regulated genes containing an ARE, from (Shelton et al., 2013).   
 
Nrf2 was first isolated in 1994 in a screen for nuclear factor erythroid 2 (NF-E2) 
regulating proteins (Moi et al., 1994).  Nrf2 is a cap ‘n’ collar basic leucine zipper 
(bZip) transcription factor consisting of 605 amino acids (Kim et al., 2012) arranged 
into six functional Nrf2-ECH homology (Neh) domains (Fig. 3).  The Neh1 domain 
facilitates DNA binding to the ARE (Plafker et al., 2010) and contains the bZip motif 
responsible for heterodimerisation with small Maf proteins in the nucleus (Plafker 
et al., 2010). The multifunctional, conserved Neh2 domain contains critical motifs 
that mediate interaction with Keap1, the cytosolic repressor of Nrf2 (Itoh et al., 
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1999).  The Neh3 (Nioi et al., 2005), 4 (Kim et al., 2012) and 5 (Apopa et al., 2008) 
domains contain transactivation motifs and are able to interact with co-activator 
proteins to modulate the cytoprotective signals transduced by Nrf2 (Kim et al., 
2012).  The Neh6 domain regulates Nrf2 turnover in a Keap1-independent manner 
(McMahon et al., 2004).  The other members of the Nrf transcription factor family, 
Nrf1 (Chan et al., 1993) and Nrf3 (Kobayashi et al., 1999), share some structural 
homology with Nrf2, but serve different cellular functions, including the regulation 
of β-globin gene expression, cellular differentiation and inflammation (Biswas et al., 
2010; Chevillard et al., 2011). Moreover, disruption of the Nrf1 gene in vivo is 
embryonically lethal (Biswas et al., 2010), whereas transgenic Nrf2-/- mice grow to 
adulthood with no acute disease phenotype (Chan et al., 1996).  However, Nrf2 
deficient mice have a propensity to be more susceptible to toxic insult than their 
wild type counterparts (Taguchi et al., 2011).  Indicative of a role for Nrf2 in 
modulating sensitivity to inflammation, Nrf2-/- female mice develop autoimmune 
nephritis late into adulthood (Yoh et al., 2001).   
 
 
Fig.3: Nrf2 and Keap1 protein domain structure (Copple et al., 2010a). 
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Keap1, discovered in 1999 (Itoh et al., 1999), is a zinc finger protein comprising of 
624 amino acids forming three major functional domains (Copple et al., 2010a; 
Taguchi et al., 2011) (Fig. 3). The  Bric-à-Brac (BTB) domain facilitates 
homodimerisation  and interaction with the Cullin 3-Ring-box-1 (Cul3-Rbx1) 
ubiquitin E3 ligase complex that enables Keap1 to target Nrf2 for ubiquitination and 
proteasomal degradation (Kaspar et al., 2010) (Zipper et al., 2002; Tian et al., 2012). 
The docking of the Cul3-Rbx1 E3 ligase complex to Keap1 is in part regulated by Cys-
151 in the BTB domain of the latter; mutation of this cysteine reduces Keap1 
affinity for Cul3 without altering its affinity for Nrf2 (Eggler et al., 2009).  A cysteine-
rich intervening region (IVR) separates the BTB domain from the C-terminal double 
glycine repeat (DGR) domain, which comprises six kelch repeats that are required 
for Keap1 binding to the actin cytoskeleton and Nrf2 (Adams et al., 2000).    
 
1.3.2.1 Regulation of the Keap1/Nrf2 pathway 
Under normal cellular conditions (i.e. in the absence of overt stress), Nrf2 is 
sequestered in the cytoplasm by its physical interaction with Keap1 (Fig. 4). 
Specifically, the Neh2 domain of Nrf2 contains critical 29DLG31 and 79ETGE82 motifs 
that permit binding of the transcription factor to the DGR domain of Keap1. The 
79ETGE82 motif has high affinity for Keap1 (Tong et al., 2006) and directs the 
recruitment of Nrf2 to the Keap1 complex (Tong et al., 2006).  The 29DLG31 motif has 
a lower affinity for Keap1, and is thought to orient Nrf2 in the correct position for 
Cul3-directed ubiquitination of any combination of seven lysines residues located 
within the Neh2 domain of the transcription factor (Tong et al., 2007). 
18 
 
Ubiquitination of Nrf2 targets it for proteolysis by the 26S proteasome (Kobayashi 
et al., 2004) and as a result Nrf2 has a relatively short half-life of 10-30 minutes in 
the absence of stress (Itoh et al., 2003; McMahon et al., 2003).  
 
 
Fig.4: Diagram of Keap1/Nrf2 pathway regulation (from (Shelton et al., 2013)).  In the absence of 
stress, Keap1 constitutively targets Nrf2 for proteasomal degradation.  Nrf2 evades Keap1 repression 
following chemical or oxidative stress, and translocates to the nucleus to induce the transcription of 
ARE-containing target genes. 
  
In response to an array of cellular insults, Nrf2 evades repression by Keap1, and 
accumulates within the nucleus via a nuclear localisation signal (Li et al., 2008a). In 
the nucleus, Nrf2 heterodimerises with small Maf proteins (Blank, 2008), masking 
the nuclear export signal of Nrf2 (Li et al., 2008b) and facilitating the transactivation 
of ARE-containing target genes. The molecular trigger for the induction of Nrf2 
appears to be underpinned by its phosphorylation (Niture et al., 2009) and/or redox 
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modification of cysteine residues in Keap1 (Sekhar et al., 2010), of which there are 
27 and 25 in the human and mouse proteins, respectively.  It is known that 
mutation of Cys-151, -273 or -288 of mouse Keap1 renders the protein unable to 
repress Nrf2 or transduce signals for its induction (Zhang et al., 2003; Levonen et 
al., 2004; Wakabayashi et al., 2004; Zhang et al., 2004; Kobayashi et al., 2006; 
Yamamoto et al., 2008). These findings indicate that the structural integrity of 
Keap1 is critical for the efficient regulation of Nrf2 activity, and that the 
modification of these and other cysteines in Keap1 likely underlies the induction of 
Nrf2 under conditions of chemical or oxidative stress (Sekhar et al., 2010). In 
addition, the activity of the Keap1-Nrf2 pathway can be modulated by physical 
interaction of the complex with SQSTM1/p62, (Copple et al., 2010b; Fan et al., 
2010; Jain et al., 2010; Komatsu et al., 2010), which competes with Nrf2 for binding 
to Keap1, and regulates the degradation of Keap1 (Copple et al., 2010b; Bui et al., 
2011), most probably via autophagy (Taguchi et al., 2012). 
 
1.3.2.2 Examples of Nrf2-regulated antioxidant genes and proteins 
Genes and proteins regulated by Nrf2 typically function to maintain redox 
homeostasis.  One of the most well-established Nrf2 target genes, Nqo1, is a 
multifunctional antioxidant enzyme with roles in the two-electron reduction of 
xenobiotic quinones and of vitamin E quinone and ubiquinone (Ross, 2004) to 
hydroquinones, preventing the production of ROS intermediates through redox 
signalling (Dinkova-Kostova et al., 2010a).  Nqo1 is robustly regulated by Nrf2 and is 
often used as a marker of Nrf2 activity (Benson et al., 1980).  Catalase functions to 
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decompose H2O2 to H2O and O2; deficiency of catalase renders the kidney more 
susceptible to oxidative stress (Kobayashi et al., 2005) and catalase is known to be 
regulated by Nrf2 (Zhu et al., 2005).   Glutathione (in its reduced form, GSH) is an 
antioxidant tripeptide containing a thiol group that can detoxify ROS and regulate 
the nitric oxide cycle (Tirmenstein et al., 2000).  GSH also plays an important role in 
the bioactivation and elimination of various xenobiotics, with conjugation mediated 
by a family of glutathione S-transferase enzymes (Rushmore et al., 1990; Hayes et 
al., 2000).  The enzymes responsible for the synthesis and conjugation of GSH, 
namely ɣ-glutamylcysteine ligase, glutathione synthetase, glutathione s-
transferases and glutathione reductase are under Nrf2 control (Pietsch et al., 2003; 
Harvey et al., 2009). 
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1.3.3 Regulation of Nrf2 by MicroRNAs 
 
1.3.3.1 MicroRNA biology 
MicroRNAs (miRNA, miR), which are approximately 21-nucleotides in length (Rana, 
2007), are non-coding regulatory elements, responsible for gene silencing and 
mRNA post-transcriptional regulation.  MicroRNAs derive from transcripts that fold 
back on themselves (Fig. 7) , giving rise to a distinct hairpin structure (Bartel, 2004).   
These primary miRNA transcripts (pri-miRNA) are processed by DROSHA, a nuclear 
RNase (Lee et al., 2003), into shorter 70-nucleotide microRNA precursors (pre-
miRNA).  Following exportation from the nucleus to the cytoplasm by Exportin-5, 
pre-miRNA are cleaved by DICER (a cystosolic RNase (Filipowicz et al., 2008)) into 
mature 21 base pair miRNA duplexes.  One strand is selected (the other, passenger 
strand is degraded) for incorporation into the RNA-induced silencing complex (RISC) 
in a dynamic process that is thought to be due to RISC Argonaute (proteins with 
RNase activity (Filipowicz et al., 2008)) selection preferences (Okamura et al., 2009; 
Meijer et al., 2014).   
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Fig. 7: MicroRNA biogenesis and processing.  Adapted from (Filipowicz et al., 2008). 
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Complimentarity of microRNAs to target mRNA sequences determines the 
mechanism of translational repression.  Animal microRNAs pair with target mRNA 
imperfectly with partial complimentarity, with rules governing base-pairing derived 
from bioinformatic analyses including that the first 2 – 7/8 nucleotides of 
microRNAs (the seed region) have conserved Watson-Crick base pairing with target 
mRNA, and as such are the primary sequence in determining the target mRNA 
(Bartel, 2009).  Additional rules include that a degree of mismatch must be present 
in the middle of the microRNA-mRNA duplex (Grimson et al., 2007) and that there 
should be a reasonable degree of complimentarity of the target mRNA sequence to 
the 3’ sequence of the microRNA (Grimson et al., 2007). 
MicroRNA binding sites in mammalian genes tend to be in the 3’ untranslated 
region (UTR, the section of transcript immediately following a translation 
termination codon) of the target mRNA sequence (Grimson et al., 2007), and 
multiple sites close to each other act cooperatively (Grimson et al., 2007; Filipowicz 
et al., 2008).  The mechanisms by which microRNA repress translation in animals 
are varied (Morozova et al., 2012), and include blocking of ribosomal elongation 
(Nottrott et al., 2006), degradation of nascent peptide (Nottrott et al., 2006), 
deadenylation of the mRNA poly(A) tail (Wu et al., 2006), microRNA-mediated 
reorganisation of chromatin structure (Kim et al., 2008) and complete repression of 
initiation of translation (Filipowicz et al., 2008; Morozova et al., 2012).  MicroRNAs 
display distinct tissue and organ expression patterns (Starkey Lewis et al., 2011), 
and as such are promising candidates for biomarkers of cellular injury, being 
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detectable in various biofluids (Starkey Lewis et al., 2011; Starkey Lewis et al., 
2012). 
 
1.3.3.2 Nrf2 and microRNAs  
At the time of writing, the exact role that Nrf2 plays in the regulation of microRNA 
expression is unclear, however the action of Exportin-5 is thought to be modulated 
by cellular redox status (Crampton et al., 2009), indicating that redox changes can 
alter the biogenesis of microRNAs. 
MicroRNAs have been shown to control Nrf2 and Nrf2-regulated gene expression; 
in silico analysis of the Nrf2 gene revealed 85 putative microRNA binding sites (Papp 
et al., 2012) that could be involved in the downregulation of Nrf2 activity.  miR-28 
(Yang et al., 2011), 144 (Narasimhan et al., 2012)  and 34a (Li et al., 2011b) have all 
been shown to be involved in the downregulation of Nrf2 in various cell lines.  
Overexpression of miR-144 was demonstrated to downregulate Nrf2 protein levels 
in a neuronal cell line (Narasimhan et al., 2012), suggesting a role for microRNA to 
sensitise cells to oxidative stress.  In addition to directly downregulating Nrf2 
mRNA, miR-200a targets Keap1 mRNA in breast cancer cells (Eades et al., 2011), 
indicating that this microRNA is capable of fine-tuning the Nrf2 antioxidant 
response.  There is an implication that Nrf2-regulated genes may be targeted by 
microRNAs; miR-34a regulates microsomal glutathione S-tranferase 1 expression (Li 
et al., 2011b), however prior to the work contained in Chapter 3, there was little 
evidence that modulation of Nrf2 itself modifies microRNA expression.  
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1.4 Nrf2 in the kidney 
Nrf2 expression is primarily localised to the renal cortex (Wu et al., 2011b), which, 
in the context of the nephron (Fig. 1), is indicative of the necessity for high 
expression of various antioxidant and xenobiotic defence genes as the filtrate 
(containing various reactive metabolites) first enters the Bowman’s capsule and 
proximal tubule.  Similarly, Keap1 expression is high in the renal cortex compared 
with glomerular and medullary fractions (Yoshida et al., 2005), likely due to high 
basal Nrf2 expression.  Nrf2-regulated proteins are consequently more localised to 
the cortex (McBride et al., 2005; Wu et al., 2011b; Reisman et al., 2012). 
 
1.4.1 Role of Nrf2 in protection against acute kidney injury 
Acute kidney injury can be defined as an abrupt loss in renal function, via ischaemia 
or toxic insult.  An increasing body of evidence supports a vital physiological role for 
Nrf2 in the kidney in the regulation of prevention against a number of toxic insults 
(Copple et al., 2008).  The induction of injury following drug treatment remains a 
significant clinical problem, accounting for the cessation of multiple promising drug 
targets during development (Choudhury et al., 2006), and as such the requirement 
for understanding the balance between renal adaptation and susceptibility to toxic 
insult must be addressed in the context of Nrf2, both in animal and cell-models.  
Experimentally, Nrf2 induction has been shown to ameliorate acute kidney injury, 
such as drug-induced toxicity ((Wu et al., 2014a); for a review, see (Shelton et al., 
2013)) and ischaemic injury (Liu et al., 2014).  However, as yet Nrf2 induction has 
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not been used to treat acute kidney injury in a clinical setting, likely because more 
research into Nrf2 induction as a preventative as opposed to a reactive therapy has 
been performed to date (Zhang, 2013).   
 
1.4.1.1 Renal ischaemic-reperfusion injury 
Provoked by the cessation and subsequent re-establishment of blood perfusion, 
renal ischaemic-reperfusion (IR) injury generates reactive oxygen species via 
reintroduction of blood to the hypoxic kidney (Leonard et al., 2006), and is 
responsible for approximately half of all acute kidney injury hospital cases (Star, 
1998).  Subsequent oxidative stress and inflammation induce tubular atrophy, 
microvasculature endothelial monolayer disruption and apoptosis  (Fig. 6, (Legrand 
et al., 2008)).  Experimental renal IR injury has been found to elevate a number of 
Nrf2-regulated cell defense genes in wild type mice, but not in the kidneys of Nrf2-/- 
mice (Leonard et al., 2006; Liu et al., 2009).  Pretreatment of Nrf2+/+ mice with the 
small molecule Nrf2 inducers CDDO-Me (Wu et al., 2011b), CDDO-Im (Liu et al., 
2014), sulphoraphane (Yoon et al., 2008) and N-acetylcysteine (Liu et al., 2009; 
Zhang et al., 2014) ameliorates IR injury.  The severity of renal IR injury is 
exacerbated by the loss of Nrf2 (Liu et al., 2009); pre-treating Nrf2-/- mice with GSH, 
N-acetylcysteine (Liu et al., 2009) and CDDO-Im (Liu et al., 2014) reduces IR injury 
when compared to untreated Nrf2-/- mice.  Therefore, Nrf2 has an important role in 
protecting the kidney from oxidative stress that underlies the pathogenesis of renal 
IR injury.   
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1.4.1.2 Cisplatin nephrotoxicty 
The anti-neoplastic agent cisplatin (Fig. 5, 6) is used to treat a diverse range of 
tumours, including sarcomas and lymphomas (Cooley et al., 1994), though its 
therapeutic efficacy is limited by its ability to induce proximal tubular cell injury via 
the induction of oxidative stress and DNA damage (Aleksunes et al., 2010). Cisplatin 
nephrotoxicity is exacerbated in Nrf2-/- mice, measured by kidney injury biomarkers 
and histopathology (Aleksunes et al., 2010), whilst the pre-administration of Nrf2 
inducers has been shown to inhibit cisplatin-mediated nephrotoxicity in wild type 
mice. For example, 3H-1,2-dithiole-3-thione has been shown to induce Nrf2 
expression in mouse renal tubular cells and confer resistance to cisplatin-mediated 
nephrotoxicity (Park et al., 2008).  Furthermore, lycopene (a carotenoid found in 
tomatoes) mitigates the cytotoxic effects of cisplatin by inducing Nrf2-regulated 
genes and inhibiting the pro-inflammatory actions of NF-κB (Sahin et al., 2010a).  
Pre-treatment with the Nrf2-inducing agents epigallocatechin-3-gallate (ECGC) 
(Sahin et al., 2010b) and CDDO-Im (Aleksunes et al., 2010) has also been shown to 
lessen cisplatin-induced nephrotoxicity in rodents.  In a human renal mesangial cell 
line, Nrf2 activation by eriodictyol-7-O-glucoside was found to significantly reduce 
sensitivity to cisplatin toxicity (Hu et al., 2012).   
On the other hand, the antioxidant ginsenoside RG3 prevents the cisplatin-induced 
nuclear accumulation of Nrf2 and subsequent induction of cell defence processes in 
mice, and is currently being investigated as a method of enhancing the 
chemotherapeutic efficacy of cisplatin (Lee et al., 2012b).  Wistar rats have reduced 
sensitivity to cisplatin toxicity following treatment with the polyphenol Nrf2 inducer 
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curcumin and a modified equivalent, difluorinated curcumin (CDF) (Sahin et al., 
2014).  Additionally, compared to curcumin, CDF reduces the expression of pro-
inflammatory renal injury biomarkers to a greater extent (Sahin et al., 2014), 
suggesting that medicinal chemistry can be used to develop less toxic, second-
generation Nrf2-inducing compounds that can enhance the efficacy of (in this 
instance) chemotherapeutics (for further discussion, see Chapter 4).   
 
Fig.5: Chemical structures of nephrotoxins that Nrf2 is known to protect against (Shelton et al., 
2013). 
 
29 
 
1.4.1.3 Heavy metal nephrotoxicity 
The accumulation of naturally occurring and pollutant-derived heavy metals can 
lead to environmental damage, as well as multiorgan toxicity and carcinogenesis in 
humans (Calderon et al., 2003).  Nrf2 has been shown to protect against 
nephrotoxicity induced by numerous heavy metals (Fig. 5), including arsenic (Prabu 
et al., 2012), chromium (Molina-Jijon et al., 2011), and cadmium (Chen et al., 2009).  
Indeed, concomitant treatment with the Nrf2-inducing antioxidant silibinin 
ameliorates sodium arsenite nephrotoxicity in rats (Prabu et al., 2012).  In addition, 
ectopic expression or RNA interference depletion of Nrf2 decreases or increases, 
respectively, the sensitivity of normal rat kidney epithelial cells to cadmium-induced 
oxidative stress (Chen et al., 2009), whereas induction of Nrf2 by curcumin lessens 
the nephrotoxicity of chromium (Molina-Jijon et al., 2011).  Therefore, Nrf2 
protects against the renal injury caused by numerous heavy metals. 
 
1.4.1.4 Cyclosporin A nephrotoxicity 
The immunosuppressant cyclosporin A (Fig. 5) is commonly used to decrease the 
risk of rejection during organ transplantation, but induces nephrotoxicity via an 
upregulation of transforming growth factor-β (TGF-β), which promotes epithelial–
mesenchymal transition and renal fibrosis (Busauschina et al., 2004).  Cyclosporin A 
provokes upregulation of Nrf2-regulated cell defense genes (Louhelainen et al., 
2006; Shin et al., 2010), whereas RNA interference depletion of Nrf2 has a 
detrimental effect on the viability of renal cells exposed to cyclosporin A in vitro 
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(Shin et al., 2010).  Furthermore, sulphoraphane (Shin et al., 2010) and the natural 
antioxidant lipoic acid (Louhelainen et al., 2006) ameliorate cyclosporin A 
nephrotoxicity in rodents by inducing Nrf2-mediated cell defense processes. 
1.4.1.5 Ochratoxin A nephrotoxicity 
The mycotoxin ochratoxin A (OTA, Fig. 5, 6) is carcinogenic and nephrotoxic in 
rodents, with the latter effect provoked by the generation of oxidative stress and 
the induction of tubular degradation and renal cortical fibrosis (Petrik et al., 2003) 
following uptake via OAT1 (Tsuda et al., 1999).  Gene expression and protein 
analysis has indicated that the Nrf2 pathway is downregulated in the kidney of rats 
fed OTA for up to 12 months (Marin-Kuan et al., 2006; Cavin et al., 2007), as well as 
in cultured primary renal proximal tubule cells exposed to the mycotoxin (Cavin et 
al., 2007; Stachurska et al., 2013).  It is thought that the inhibited capacity of the 
Nrf2 pathway to protect against OTA–induced oxidative DNA damage manifests in 
enhanced cytotoxicity in the kidney (Cavin et al., 2007).  In keeping with this 
concept, adenoviral overexpression of Nrf2 has been shown to inhibit the ability of 
OTA to induce oxidative stress and TGF-β expression (Stachurska et al., 2013).  In 
addition, pretreatment with the Nrf2 inducers cafestol–kahweol or coumarin 
ameliorates OTA–induced lipid peroxidation, DNA damage, and cytotoxicity in 
cultured rat tubular cells (Cavin et al., 2007; Cavin et al., 2009), further indicating a 
protective role for Nrf2 against ochratoxin A nephrotoxicity.   
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1.4.1.6 Potassium bromate nephrotoxicity 
Potassium bromate is a food additive with nephrotoxic, mutagenic, and 
carcinogenic side effects. Nephrotoxicity manifests as changes in proximal tubule 
brush border protein functionality and expression, provoking kidney failure (Ahmad 
et al., 2012).  Human primary proximal tubule cells treated with a sublethal dose of 
potassium bromate have an enriched Nrf2-regulated gene complement, in addition 
to elevated expression of genes involved in the glutathione pathway (Limonciel et 
al., 2012).  Furthermore, Nrf2-deficient mice suffer more severe kidney damage as 
compared with wild-type counterparts, following exposure to potassium bromate 
(Jaloszynski et al., 2007).   
 
1.4.1.7 Ferric nitrilotriacetate nephrotoxicity 
Ferric nitrilotriacetate (FENTA) is used experimentally to induce renal damage via 
the generation of iron-mediated oxidative stress and subsequent proximal tubular 
cell necrosis (Umemura et al., 1990).  FENTA has been shown to augment the mRNA 
levels of Nrf2 target genes, including Nqo1, Gclc, and Gstp1/2 in wild-type but not 
Nrf2-deficient mice (Tanaka et al., 2008).  Furthermore, Nrf2-/- mice treated with 
FENTA display significantly reduced glutathione levels, more severe 
histopathological necrosis, and increased blood urea nitrogen and serum creatinine 
levels than wild-type counterparts (Kanki et al., 2008; Tanaka et al., 2008).  
Importantly, pretreatment of wild-type mice with the Nrf2 inducer CDDO-Me 
lessens the renal injury provoked by FENTA (Tanaka et al., 2008), demonstrating a 
protective role for Nrf2 in this form of kidney toxicity. 
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1.4.2 Role of Nrf2 in protection against chronic kidney disease 
The induction of Nrf2 has proven to be protective against pathologies as diverse as 
neurodegeneration (Yang et al., 2009), diabetes (de Souza et al., 2012) and some 
types of cancer (Jeong et al., 2006; Jaramillo et al., 2013), with the small molecule 
Nrf2 inducer dimethyl fumarate recently being licensed for the clinical treatment of 
multiple sclerosis (Lee et al., 2013).  Chronic kidney disease (a progressive loss of 
renal function) is often initially asymptomatic, but can be determined through the 
measurement of renal injury biomarkers such as creatinine clearance and 
proteinuria.  Oxidative stress is critical in the mechanistic progression of CKD, 
inducing inflammation via the activation of NF-κB, which in turn induces further 
oxidative stress through the production of ROS from activated immune cells (Ruiz et 
al., 2013).  Increased ROS production is present in various animal models of CKD, 
including 5/6 nephrectomy rats (Aminzadeh et al., 2014) and Imai rats 
spontaneously developing focal segmental glomerulosclerosis (Kim et al., 2011).  
Constitutive Nrf2 expression is required for the maintenance of an effective redox 
balance, however CKD is associated with impaired Nrf2 activity (Kim et al., 2010; 
Kim et al., 2011; Aminzadeh et al., 2013b).  A lack of Nrf2 functionality further 
contributes to the pathogenesis of CKD, allowing the accumulation of ROS and 
amplifying NF-κB activation.  Targeting the Keap1/Nrf2 pathway to attenuate the 
progression of CKD is therefore a promising clinical strategy. 
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1.4.2.1 Renal fibrosis 
Tubular and interstitial fibrotic injury (Fig. 6) is associated with the end-stage 
progression of CKD. The pathogenesis of fibrotic kidney injury is complex, and 
involves epithelial-to-mesenchymal renal cell transformation mediated via TGF-β 
signalling, which progresses to tubular atrophy and renal fibrosis (Liu, 2006). 
Angiotensin II-mediated suppression of Nrf2 in renal epithelial cells stimulates EMT 
by enhancing the activity of TGF-β, likely due to heightened levels of oxidative 
stress (Kang et al., 2011). The Nrf2 inducer dimethylfumarate and adenovirus-
mediated over-expression of Nrf2 have been shown to decrease alpha-smooth 
muscle actin, collagen and fibronectin expression in TGF-β -treated rat renal 
fibroblasts and mesangial cells (Oh et al., 2012), whilst dimethylfumarate also 
suppresses renal fibrosis in the unilateral ureteral obstruction mouse model (Oh et 
al., 2012). These findings support a role for Nrf2 in protection against renal fibrosis. 
 
1.4.2.2 Focal segmental glomerulosclerosis 
Focal segmental glomerulosclerosis (FSGS, Fig. 6) is a common form of idiopathic 
nephritic syndrome, characterised by induction of oxidative stress, inflammation 
and renal fibrosis, and is the leading glomerular disorder causing end-stage CKD 
(D'Agati et al., 2011). In a mouse model of FSGS, treatment with antroquinolol 
increases renal Nrf2 activity and causes a corresponding inhibition of NF-κB and 
TGF-β1 signalling, leading to a decrease in oxidative stress, proteinuria, epithelial 
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injury and renal dysfunction (Tsai et al., 2011). Therefore, Nrf2 can protect against 
the deleterious effects of FSGS. 
 
1.4.2.3 Diabetic nephropathy 
Diabetic nephropathy (DN) is a chronic disease resulting in kidney hypertrophy, 
tubular atrophy, interstitial fibrosis and glomerular sclerosis (Ayodele et al., 2004). 
Diabetes causes over 1 million deaths per year, and cases of DN increased by 150 % 
between 1994 and 2004 in the US, with similar trends emerging in Europe, Asia and 
developing countries (Ayodele et al., 2004). In animals treated with streptozotocin, 
hyperglycaemia-induced DN is associated with renal fibrosis and elevated levels of 
oxidative stress, which is exacerbated in Nrf2-/- mice (Yoh et al., 2008; Jiang et al., 
2010) and ameliorated in rats treated with the proteasomal inhibitor MG132 (Luo et 
al., 2011), which induces the Nrf2-dependent oxidative stress response by limiting 
the transcription factor’s proteolytic degradation. Furthermore, the Nrf2 inducers 
sulphoraphane (Zheng et al., 2011), resveratrol (Palsamy et al., 2011) and tert-
butylhydroquinone (Li et al., 2011a) reduce renal injury in the streptozotocin-
induced DN mouse model by upregulating the expression of cytoprotective genes 
and downregulating the expression of pro-inflammatory cytokines. Importantly, the 
protective effect of sulphoraphane is lost in Nrf2-/- mice (Zheng et al., 2011). In the 
methylglyoxal-induced DN mouse model, both ankaflavin (Lee et al., 2012a) and 
sulphoraphane (Xue et al., 2008) upregulate Nrf2 target genes and protect against 
experimental diabetes. Moreover, MG132 induces the expression of catalase, 
superoxide dismutase and Ho-1, and lessens proteinuria and renal dysfunction, in 
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the OVE26 mouse model of type 1 diabetes (Cui et al., 2013).  Therefore, induction 
of Nrf2 appears to be a promising strategy for the prevention of DN renal injury (de 
Haan, 2011). 
 
Fig.6: Roles of Nrf2 in protection against various forms of acute and chronic kidney pathology 
affecting discrete areas of the renal nephron. 
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1.4.3 Fumarate and renal cell carcinoma 
In contrast to CKD, renal cancer is associated with an increase in Nrf2 expression, 
which allows tumour cells to survive hypoxic conditions (Ooi et al., 2013).  Nrf2 has 
been shown to play a role in the development of renal cancer driven by genetic 
deficiency of the tumour suppressor gene fumarate hydratase (FH). Indeed, Nrf2 
and its target gene battery have been found to be highly expressed in the kidneys 
of mice in which the renal Fh gene has been conditionally deleted, as well as in type 
2 hereditary papillary renal cell carcinoma tissue from patients carrying 
heterozygous germline Fh mutations (Adam et al., 2011; Ooi et al., 2011). At the 
chemico-biological level, it has been demonstrated that specific cysteine residues 
(including Cys-151 and -288) in Keap1 are succinated as a result of the accumulation 
of fumarate that is associated with deficiency of FH (Adam et al., 2011; Ooi et al., 
2011).  It is thought that the resulting inactivation of Keap1 allows renal Nrf2 
activity to remain unchecked under high fumarate conditions (Adam et al., 2011; 
Ooi et al., 2011).  Somatic (i.e. non-hereditary) papillary renal cell carcinoma is 
associated with mutation of Nrf2 and Cul3 (Ooi et al., 2013), showing a convergence 
with hereditary papillary renal cell carcinoma and demonstrating a degree of 
positive selection of Nrf2 activity by cancerous cells.  Therefore, in keeping with a 
number of reports depicting hyper-activity of Nrf2 in tumours of lung, pancreas, 
breast and endometrium, amongst others (Taguchi et al., 2011), activation of the 
Nrf2 pathway by somatic mutation or by a hereditary deficiency of FH can lead to 
the development of renal cancer. 
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1.5 CDDO-Me: a potent Nrf2 inducer and novel treatment for CKD 
Oleanolic acid is a triterpenoid compound used in Asian medicine with anti-
tumorigenic, anti-inflammatory and cytoprotective properties (Shanmugam et al., 
2014).  Synthesis of structurally similar triterpenoid compounds commenced with 
the modification of the A and C rings of oleanolic acid, with the resulting compound 
CDDO (2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid, (Honda et al., 1998)) 
found to be 400 times more potent than previously designed compounds at 
preventing the production of nitric oxide in mouse macrophages (Honda et al., 
1998).   
At nanomolar concentrations, CDDO and its imidazole derivative CDDO-Im (1-[2-
cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole) were found to induce HO-1 
both in vitro (leukaemic and lung carcinoma cells (Liby et al., 2005)) and in vivo (the 
stomach, small intestine, colon, liver, lung, kidney, and heart of CD-1 mice (Liby et 
al., 2005)).  Compared with oltipraz (an Nrf2 inducing dithiolethione (Kwak et al., 
2001)), CDDO-Im is 100 times more potent as an inducer of Nrf2 and associated 
antioxidant and Phase II metabolism genes in the mouse liver (Yates et al., 2006).   
Further examination of the capacity of CDDO-Im to induce Nrf2 focussed on the 
modulation of the ARE-regulated gene Nqo1 following CDDO-Im treatment of mice 
(Yates et al., 2007).  CDDO-Im treatment induced Nqo1 transcripts at very low 
doses (0.3 μmol/kg), and induced both Nqo1 and Gclc (Glutamine cysteine ligase 
(catalytic subunit)) genes in a variety of mouse organs, including the liver, lung and 
kidney (Yates et al., 2007).  The methyl ester of CDDO (CDDO-Me, methyl 2-cyano-
3,12-dioxooleana-1,9(11)dien-28-oate, also known as bardoxolone methyl) was also 
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shown to be an extremely potent inducer of Nqo1 in the murine small intestinal 
mucosa and liver (Yates et al., 2007).   
Like its parent compound oleanolic acid, CDDO-Me has apoptotic properties (via the 
inhibiton of NF-κB activity and JAK/STAT signalling) in cancer cell lines (Ahmad et 
al., 2006).  A phase I first-in-human clinical trial was set up to determine dose-
limiting toxicity, maximum tolerated dose and various pharmacokinetic and 
pharmacodynamic parameters in patients with solid tumours and lymphomas, with 
a prospective phase II trial to look at efficacy in tumour treatment (Hong et al., 
2012).  In patients receiving CDDO-Me, Nqo1 mRNA transcripts were found to be 
increased in PBMCs, and NF-κB levels were reduced in tumour biopsies (Hong et al., 
2012).  However, an unexpected clinical outcome was an increase in estimated 
glomerular filtration rate (eGFR, a measure of kidney function, (Hong et al., 2012)).  
Research has demonstrated that the production of ROS correlates with the 
progression of CKD (Dounousi et al., 2006), and the Nrf2 pathway is impaired in CKD 
(Kim et al., 2010).  Based on the effect of CDDO-Me on eGFR in this trial, further 
trials were designed to examine the beneficial effects of CDDO-Me in CKD patients.   
A preliminary phase IIa trial was conducted on patients with established moderate 
to severe diabetic nephropathy (Pergola et al., 2011a).  The study was designed to 
determine appropriate dosing of CDDO-Me to improve kidney function, and as such 
the key biomarker measured was eGFR, which was improved following CDDO-Me 
treatment (Pergola et al., 2011a).  No major changes in renal injury biomarkers 
were reported, so a phase IIb trial (BEAM) was conducted (Pergola et al., 2011b).  
This trial enrolled a larger number of patients with CKD, dosed with either a placebo 
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or CDDO-Me, and again a significant improvement in eGFR was reported in patients 
receiving CDDO-Me (Pergola et al., 2011b).   
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1.6 Summary and aims 
Acute kidney injury and chronic kidney disease are a serious clinical burden.  Nrf2 
has previously been shown to afford protection against both acute kidney injury 
(Shelton et al., 2013) and chronic kidney disease (Ruiz et al., 2013) in a number of 
experimental models, and the Nrf2 inducer CDDO-Me as recently been investigated 
as a novel treatment for CKD (de Zeeuw et al., 2013a).  To better understand the 
physiological, pharmacological and toxicological consequences of targeting Nrf2 in 
the kidney, this thesis has tested the following hypotheses: 
Chapter 2: Nrf2 controls multiple proteins involved in the regulation of homeostatic 
processes in the kidney.   
Through proteomic and targeted analysis of kidney tissue from Nrf2+/+ and Nrf2-/- 
mice treated with the Nrf2 inducer CDDO-Me, it is predicted that the renal genes, 
proteins and biological processes under Nrf2 control will be defined, providing 
insights into the physiological roles of Nrf2 in the kidney. 
Chapter 3: Nrf2 controls microRNAs in the kidney. 
The regulation of Nrf2 expression by microRNAs has been demonstrated in a small 
number of studies, but information about the regulation of microRNA expression by 
Nrf2 itself is lacking.  Using a transcriptomic approach, it is predicted that 
microRNAs indicative of Nrf2 activity will be discovered, providing new insights into 
the biology of the Nrf2 pathway as well as revealing novel transcriptional markers 
of Nrf2 activity. 
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Chapter 4: The drive to produce more potent Nrf2-inducing drugs has not led to the 
development of inherently more toxic molecules.   
In order to investigate, based on the adverse events reported in the CDDO-Me 
‘BEACON’ clinical trial (de Zeeuw et al., 2013a), whether the drive to produce more 
potent Nrf2 inducing compounds has unwittingly lead to the development of more 
toxic molecules that could provoke off-target effects in patients, the relationship 
between thiol reactivity (a common feature of many small molecule Nrf2 inducers 
(Bryan et al., 2013)), potency toward Nrf2 and toxicity has been examined for a 
series of triterpenoids and second-generation monocyclic and tricyclic Nrf2 
inducers, which hold promise as novel drug candidates.  
By testing these hypotheses, this thesis seeks to further our understanding of the 
physiological, pharmacological and toxicological roles of Nrf2 in the kidney.  
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Chapter 2 
Proteomic analysis reveals the role of Nrf2 
as a regulator of proteins controlling 
homeostatic processes in the mouse kidney 
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2.1 Introduction 
Acute kidney injury (AKI) is a significant clinical problem, with more than 7% of 
patients developing some form of AKI following admission to hospital (Nash et al., 
2002). Furthermore, the kidney is uniquely susceptible to toxic insult, due to a 
relatively hypoxic environment in the nephron and high metabolic rate (Perazella, 
2009).  As a result of the renal vasculature being exposed to 25% of resting cardiac 
output (Lote et al., 1996), the kidney often encounters and concentrates relatively 
high levels of xenobiotics and their metabolites, of which a number are known to 
suppress renal function. A key mechanism underlying the nephrotoxicity of many 
xenobiotics (examples include cisplatin (Aleksunes et al., 2010), ferric 
nitrilotriacetate (Umemura et al., 1990) and streptozotocin (Jiang et al., 2010)) is 
their ability to induce the generation of reactive oxygen species (ROS) and 
consequent oxidative stress (Shelton et al., 2013).  
Research in this laboratory has previously provided a detailed insight into the 
molecular mechanisms by which Nrf2 protects against drug-induced liver injury, by 
defining the constitutive Nrf2-regulated hepatic proteome (Kitteringham et al., 
2010).  Using an iTRAQ-based proteomic approach, we demonstrated that the 
expression of a number of proteins responsible for the detoxification of 
acetaminophen and other drugs is markedly decreased in the livers of Nrf2-/- mice 
(Kitteringham et al., 2010), consistent with their enhanced sensitivity to the 
hepatotoxicty provoked by these compounds (Chan et al., 2001; Enomoto et al., 
2001; Copple et al., 2008; Liu et al., 2013).  In an extension to this study, we 
recently defined the biological processes that are sensitive to modulation of Nrf2 in 
45 
 
the liver by detailing the hepatic proteins augmented in Nrf2+/+, but not Nrf2-/-, mice 
in response to CDDO-Me (Walsh et al., 2014).  This work revealed that CDDO-Me is 
a highly selective inducer of Nrf2-regulated proteins in the liver, and identified six 
proteins (cytochrome P4502A5 (Cyp2a5), glutathione-S-transferases Mu 1 (Gstm1) 
and Mu 3 (Gstm3), ectonucleoside-triphosphate diphosphohydrolase (Entpd5), 
epoxide hydrolase 1 (Ephx1) and UDP-glucose-6-dehydrogenase (Ugdh)) that were 
both downregulated in Nrf2-/- mice and upregulated by CDDO-Me in Nrf2+/+ mice 
(Walsh et al., 2014). 
Isobaric tag for relative and absolute quantification (iTRAQ)-based proteomics 
(Thompson et al., 2003; Ross et al., 2004) uses tandem mass spectrometry (MS/MS) 
to quantify the amount of proteins from different sources in the same experimental 
run.  Isobaric tags of differing masses (but balanced to the same overall mass) are 
used to stably label digested peptides from up to 8 different samples, which are 
then combined (Fig. 1A, (Unwin, 2010)).   
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Fig. 1: iTRAQ procedure schematic.  (A) Subsequent to a tryptic digest, samples are stably 
labelled with the iTRAQ labelling reagents (B), and combined for tandem mass 
spectrometric analysis (MS/MS, C),  which allows for the identification and quantification of 
sample proteins based on isobaric label ratios. 
 
When analysed simultaneously, the first MS trace represents the same peptide 
from all of the samples at the same mass (Fig. 1B).  Collision-induced dissociation 
facilitates amino acid sequencing (Unwin, 2010), and therefore reveals the peptide 
identity.  The abundance of iTRAQ tag-specific reporter ions, specific to each 
sample, is also quantified, allowing the relative abundance of the particular peptide 
in each of the labelled samples (Unwin, 2010) to be determined, relative to a 
pooled control (Fig. 1B).   
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Despite multiple studies demonstrating the ability of Nrf2 to protect against 
nephrotoxic insult in experimental models (Leonard et al., 2006; Yoon et al., 2008; 
Liu et al., 2009; Wu et al., 2011b; Shelton et al., 2013; Wu et al., 2014a), the 
underlying biological mechanisms by which Nrf2 protects the kidney are not fully 
understood.  To provide a detailed insight into the biological processes controlled 
by Nrf2 in the kidney, we have performed iTRAQ-based proteomic analysis of 
kidney homogenates from Nrf2+/+ and Nrf2-/- mice treated with CDDO-Me or DMSO 
vehicle for 24 h.  Some of the content of this chapter has contributed to a 
manuscript under preparation, “Shelton et al., Integrated Transcriptomic and 
Proteomic Analysis Reveals the Role of Nrf2 as a Key Regulator of Homeostatic 
Processes in the Kidney”. 
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2.2 Methods 
Animals and dosing: Non-fasted male Nrf2+/+ and Nrf2-/- mice (C57BL/6 
background) of 10-12 weeks of age were used throughout the study. Nrf2-/- mice 
express a mutant Nrf2 protein that lacks the C-terminal 280 amino acids that 
constitute the DNA-binding bZip and transactivation domains of the transcription 
factor, thus rendering it functionally inactive (Itoh et al., 1997; McMahon et al., 
2001).  The study was conducted according to the Animals (Scientific Procedures) 
Act 1986 and University of Liverpool local guidelines. Mice were housed at 19-23 °C 
on a 12 hour light/dark cycle, and given free access to food and water.  Six mice of 
each genotype were administered a single intraperitoneal (i.p.) dose of vehicle 
(DMSO, 100 µL/mouse) or CDDO-Me (3 mg/kg, (Walsh et al., 2014)), and sacrificed 
24 h later by exposure to a rising concentration of CO2 followed by cardiac 
puncture. The renal capsule and fat were removed from excised kidneys, which 
were snap-frozen, along with other organs, and stored at -80 °C.  Six samples per 
treatment group ((Nrf2+/+ + DMSO,   Nrf2-/- + DMSO, Nrf2+/+ + CDDO-Me and Nrf2-/- + 
CDDO-Me) were generated.  For the dose-response experiment, two Nrf2+/+ mice 
per treatment group were administered the indicated dose of CDDO-Me (i.p.), and 
culled after 24 hours.  For the time course experiment, four Nrf2+/+ mice per 
treatment group were administered a single i.p. dose of 3 mg/kg CDDO-Me, and 
culled at the indicated times. 
General reagents: Unless otherwise stated, reagents were purchased from Sigma-
Aldrich (UK). 
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Sample preparation: Snap-frozen mouse kidney was cut in half and submerged in 
300 μL iTRAQ buffer (0.5 M triethylammonium bicarbonate/0.1 % sodium dodecyl 
sulphate (SDS)).  A metal bead was introduced to the sample, which was 
subsequently homogenised using the Retsch MM400 homogeniser, at 30/s for 3 
minutes.  The metal bead was removed and sample subsequently underwent an 
overnight freeze-thaw cycle at -80 oC, and sonication (3 x 10 second bursts at 3 μm 
amplitude).  Samples were centrifuged at 12,000 x g for 10 minutes at 4 oC, and the 
supernatant saved and centrifuged again under the same conditions.  The resulting 
sample was diluted by 1/10, and the bicinchoninic acid (BCA) assay was performed 
to determine protein concentration.   
Total protein determination: Protein content was determined using the BCA assay.  
Briefly, a standard curve was made using Bovine serum albumin in 0.9 % saline, and 
plated on Nunc 96 well flat bottomed plates.  1, 3 and 5 μL of sample was plated, 
and 200 μL BCA assay reagent (a ratio of 50:1 bicinchoninic acid solution to copper 
(II) sulphate (4 % wv/v) solution) was added.  Following incubation at 37 oC for 30 
minutes, the plate was read at 570 nM using an MRX microplate reader (Dynex).  
Resulting values were plotted against the concentration curve to generate μg/μL 
values. 
iTRAQ labelling: 8-plex iTRAQ analysis was performed as described (Walsh et al., 
2014).  Samples were diluted to 100 μg protein in 20 μL iTRAQ buffer, and were 
denatured and reduced using 2 μL Tris(2-carboxyethyl)phosphine hydrochloride for 
one hour at 60oC, and sulphydryl groups capped with 1 μL methyl 
methanethiosulphonate (MMTS) for 10 minutes at room temperature.  Four vials of 
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mass spectrometry grade trypsin were reconstituted in 95 μL ddH2O, and 10 μL was 
subsequently added per sample.  Samples were briefly vortexed and incubated for 
12-16 hours (overnight) at 37oC.   
iTRAQ isobaric tag labelling reagents (ABSciex, Massachusetts, USA) were allowed 
to reach room temperature, and reconstituted with 50 μL high-performance liquid 
chromatography-grade isopropanol.  iTRAQ labelling reagents were combined with  
samples, and subsequently vortexed, centrifuged, and incubated for 2 hours at 
room temperature.  All 8 samples were then combined, and 0.5 mL of a cation 
exchange (CEX) buffer (10 mM potassium dihydrogen phosphate/25 % acetonitrile) 
added.  Samples were centrifuged (10,000 RPM for 4 minutes at room temperature) 
to sediment debris, transferred to a 7 mL bijou and made up to 5 mL with CEX 
buffer.  Concentrated phosphoric acid was used to pH the sample to pH 3.  Sample 
was centrifuged again at 10,000 RPM for 4 minutes at room temperature.   
Cation exchange: Cation exchange fractionation was performed using a 
Polysulphoethyl A strong cation-exchange column (200 × 4.6 mm, 5 mm, 300 Å; 
Poly LC, Columbia, MD). Fractions of 2 mL were collected and were dried by 
centrifugation under vacuum (SpeedVac, Eppendorf). Fractions were reconstituted 
in 1 mL of 0.1 % trifluoro acetic acid (TFA) and were subsequently desalted using a 
mRP Hi Recovery protein column 4.6 x 50 mm (Agilent) on a Vision Workstation 
(Applied Biosystems) prior to mass spectrometric analysis. 
 
51 
 
Mass spectrometric analysis: Desalted fractions were reconstituted in 40 μL 0.1 % 
formic acid and 5 L aliquots were delivered into a Triple TOF 5600 (AB Sciex) via an 
Eksigent NanoUltra cHiPLC System (AB Sciex) mounted with a microfluidic trap and 
analytical column (15 cm × 75 μm) packed with ChromXP C18−CL 3 μm.  A 
NanoSpray III source was fitted with a 10 μm inner diameter PicoTip emitter (New 
Objective). The trap column was washed with 2 % acetonitrile (ACN)/0.1 % formic 
acid (FA) for 10 min at 2 μL/min before switching in-line with the analytical column.  
A gradient of 2−50 % ACN/0.1 % FA (v/v) over 90 minutes was applied to the 
column at a flow rate of 300 nL/min. Operating in positive ion mode with survey 
scans of 250 ms, the instrument used an MS/MS accumulation time of 100 ms for 
the 25 most intense ions (total cycle time 2.5 seconds).  A threshold for triggering 
MS/MS of 100 counts per second was used, with dynamic exclusion for 12 seconds 
and rolling collision energy, adjusted for the use of iTRAQ reagent in the Analyst 
method.  Information-dependent acquisition was powered by Analyst TF 1.5.1. 
software, using mass ranges of 400-1600 atomic mass units (amu) in MS and 100-
1400 amu in MS/MS.  The instrument was calibrated after every fifth sample using a 
beta-galactosidase digest. 
Protein detection and analysis: Kidney homogenates were analysed over four 
iTRAQ runs, using two pooled controls per run for normalisation between different 
experimental runs.  Sample allocation to each run was randomised.  Ratios for each 
iTRAQ label were obtained using label 121 as the common denominator.  Data were 
searched using ProteinPilot 4.2 and the Paragon algorithm (AB Sciex) against the 
latest version of the SwissProt database, with MMTS as a fixed modification of 
52 
 
cysteine residues and biological modifications allowed. The data were also searched 
against a reversed decoy database and only proteins lying within a 1 % global FDR 
were included in subsequent analyses. The software R (R-Programming-
Environment, 2005) was used to analyse the data, allowing for simultaneous 
comparisons between multiple treatments using design and contrast matrices via a 
linear regression model.  Mean fold changes were calculated and analysis 
conducted on the log2 fold-change values.  Raw P values (unpaired T test) were 
subsequently used to compare expression between the relevant groups (Nrf2+/+ + 
DMSO v Nrf2-/- + DMSO, and Nrf2+/+ + DMSO v Nrf2+/+ + CDDO-Me).  Proteins 
reported were discovered in at least 4/6 kidney homogenates, with at least a 30 % 
fold change between groups.  Raw P values and a 30% fold change were chosen as 
opposed to determining exact levels of expression (which is affected by inter-
animal variability) to provide insight into hitherto unknown processes regulated by 
Nrf2 in the kidney. 
Pathway analysis: Ingenuity pathway analysis (IPA, Qiagen, UK) was performed to 
reveal biological pathways perturbed during experimental conditions.  Relevant 
iTRAQ data (proteins, log fold changes and P values) was uploaded to the IPA online 
database, and subsequent canonical pathways, P value and ratio are reported.  
Pathways represented by a single gene/protein were excluded for robustness. 
Immunoblotting: Kidney homogenates (20 μg total protein) were loaded onto 
NuPAGE 4-12 % Bis Tris Precast gels (Life Technologies, UK) and proteins were 
subsequently separated using electrophoresis, using the MOPS running buffer      
(50 mM 3-(N-morpholino)propanesulphonic acid (Fisher Scientific), 50 mM Tris 
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Base, 0.1% SDS, 1 mM ethylenediaminetetraacetic acid) with the samples separated 
at  90 V for 10 minutes, then 170 V for 45 minutes.  The gel was transferred to a 
nitrocellulose membrane (Amersham Hybond ECL, GE Healthcare, 
Buckinghamshire, UK) in a tank containing transfer buffer (192 mM glycine, 25 mM 
Tris base and 20 % methanol), a rotating stirrer and ice pack.  Proteins were 
transferred to the membrane at a constant current of 230 mA for 60 minutes.  
Equal loading of protein was ensured using Ponceau red staining, and membranes 
were blocked for overnight with 10 % milk in TBS-Tween solution.  TBS-Tween (TBS-
T) solution contains 150 mM NaCl, 3 mM KCl, 25 mM Tris base and 0.1 % Tween-20, 
pH 7.  Membranes were washed several times with TBS-T, and incubated for 3 
hours with the indicated primary antibodies (1:4000) in TBS-T containing 2 % milk 
(Abcam: Nqo1 (ab2346), Gstm (ab53942), Entpd5 (ab92542), Cat (ab16731) and β-
actin (ab6276)).  Membranes were again washed several times with TBS-T, and 
incubated for one hour with the appropriate peroxidase-conjugated secondary 
antibody (1:10,000) in TBS-T containing 2 % milk.  Enhanced Chemiluminescence 
Plus (GE Healthcare) was used to visualise the level of protein-antibody complex; 
using 2 mL per membrane for one minute. Membranes were dried and exposed to 
X-Ray film (Amersham hyperfilm) for up to 7 minutes to determine protein 
expression.  X-Ray film was subsequently submerged in 20 % Carestream Kodak 
autoradiography GBX developer/replenisher for one minute and then washed in 
water and submerged in Carestream Kodak autoradiography GBS fixer/replenisher 
for one minute. Densitometry was performed using Quantity One 1D Analysis 
Software (BioRad).  Protein bands were normalised to actin expression. 
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Mouse kidney RNA isolation:  Snap-frozen mouse kidney was cut in half and 
submerged in QIAzol (Qiagen, UK), 10 μL/mg of tissue, no more than 30 mg total 
tissue.  A metal bead was introduced to the sample, which was subsequently 
homogenised using the Retsch MM400 homogeniser, at 30 shakes per second for 3 
minutes.  The metal bead was removed and samples incubated at room 
temperature for 5 minutes.  Chloroform (1/5 total volume) was added, and samples 
were shaken vigorously for 15 seconds.  The samples were incubated at room 
temperature for 3 minutes, and centrifuged at 12,000 x g for 15 minutes at 4 oC.  
The upper, aqueous phase was transferred to a new microcentrifuge tube, and 1/2 
volume of isopropanol was added.  The sample was thoroughly vortexed and 
incubated at room temperature for 10 minutes.  The sample was subsequently 
centrifuged at 12,000 x g for 10 minutes at 4 oC, and resulting supernatant 
discarded.  The pellet was resuspended in 1 volume of 75 % ethanol, which was 
then centrifuged at 7,500 x g for 5 minutes at room temperature.  The supernatant 
was discarded, and the pellet air dried for no longer than 3 minutes.  The pellet was 
then resuspended in 20 μL RNase-free water. 
DNase treatment:  DNase treatment was performed on all RNA samples using the 
Ambion DNA-freeTM Kit (Life Technologies, UK).  1/10 volume 10X DNase buffer and 
1 μL DNase I were added to the RNA samples, and incubated at 37 oC for 25 
minutes.  1/10 volume DNase Inactivation Reagent (at least 2 μL) was added to 
samples, and thoroughly mixed.  Samples were incubated at room temperature for 
2 minutes, and mixed occasionally.  Samples were subsequently centrifuged at 
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10,000 x g for 2 minutes at room temperature, and DNase-free RNA removed to 
new eppendorfs. 
RNA quality assessment: RNA quality was assessed using an RNA 600 Nano Kit and 
2100 Bioanalyzer (Agilent), according to manufacturer’s instructions. Electrodes 
were decontaminated using RNaseZap, and pre-prepared gel was allowed to reach 
room temperature (550 μL Agilent RNA 6000 Nano gel matrix had been filtered 
using spin columns, and prepared into 65 μL aliquots).  RNA 6000 Nano dye 
concentrate was centrifuged for 10 seconds at a low speed, and 1 μL added to the 
65 μL aliquot of gel.  The dye-gel mixture was vortexed, and stored in the dark until 
use.  This mixture was subsequently centrifuged at 13,000 x g for 10 minutes at 
room temperature, and 9 μL added to the appropriate well of the Nano chip.  The 
chip was pressurised accordingly, and then 9 μL dye-gel mixture was added to the 
appropriate wells.  5 μL of RNA 6000 Nano marker was added to the appropriate 
wells of the Nano chip.  1 μL of RNA ladder was added to the Nano chip, followed 
by 2 μL denatured (70 oC for 2 minutes) RNA samples.  The Nano chip was 
subsequently vortexed using an IKA vortex mixer at 2400 RPM for 60 seconds, and 
Nano chip was inserted into the 2100 Bioanalyzer (Agilent).  RNA bioanalysis was 
performed, and resultant mRNA electropherogram analysed using the 2100 expert 
software (version B.02.02) to produce an RNA integrity number (RIN), of which 
samples with a RIN of >7 were utilised for reverse transcription to cDNA. 
Reverse Transcription of mRNA: RNA samples were reverse-transcribed (RT) to 
cDNA using the ImProm-II Reverse Transcription System (Promega, UK).  RNA was 
quantified using NanoDrop ND-1000 (Labtech, UK).   1 μg RNA was added to 
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duplicate 200 μL nuclease-free tubes (Starlab, UK) containing 1 μL Oligo dT primer 
and dH2O to make a total volume of 20 μL.  Using a GeneAmp PCR 9700 thermal 
cycler (Life Technologies, UK) the samples were heated to 70 oC for 5 minutes.  A 
master mix was prepared for reverse transcription, containing 8 μL 5X RT buffer, 6.4 
μL 25 mM MgCl2, 1 μL deoxynucleotide triphosphates (dNTPs), 2 μL reverse 
transcriptase and 2.6 μL dH2O per sample.  To control for aberrant reverse 
transcription of contaminated samples, a negative reverse transcriptase master mix 
was prepared, using 8 μL 5X RT buffer, 6.4 μL 25 mM MgCl2 and 5.6 μL dH2O per 
sample.  Duplicate RNA samples subsequently had 20 μL of either reverse 
transcription or negative reverse transcription master mix added, and samples were 
vortexed and centrifuged at 3000 x g for 2 minutes at room temperature.  The 
samples were transferred to the thermal cycler and subjected to a run of 5 minutes 
at 25 oC, 60 minutes at 42 oC and 15 minutes at 70 oC, followed by a 4 oC hold.  
cDNA samples were subsequently diluted with 160 μL dH2O. 
qRT-PCR:  Primers for Nqo1, Gstm1, Gsta3, Cat, Entpd5, Cbr1, Nampt, Dpys, 
Slc22a12 and Ppia were purchased from Eurofins (Luxembourg) and diluted to 10 
μM (sequences detailed in Table 1).  A master mix was prepared using 8.75 μL 
dH2O, 0.5 μL forward primer, 0.5 μL reverse primer, 0.25 μL ROX reference dye and 
12.5 μL SYBR® Green JumpStart™ Taq ReadyMix™.  22.5 μL master mix was added to 
the appropriate wells of a 96 well PCR plate (Starlab, UK), followed by 2.5 μL cDNA 
in duplicate.  The PCR plate was covered with an adhesive seal, and centrifuged at 
2,000 x g for 1 minute at room temperature.  PCR was performed using the ABI 
Prism 7000 Sequence Detection system (Applied Biosystems), for 1 cycle at 95 oC 
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for 2 minutes, 40 cycles of 95 oC for 15 seconds and 60 oC for 1 minute, and then a 
dissociation curve of 95 oC for 1 minute, 65 oC for 2 minutes, 95 oC to 65 oC at 2 
oC/minute, and finally a 4 oC hold.  Resultant Gene CT values were normalised to 
Peptidylprolyl isomerase A (Ppia) expression (Kim et al., 2014).   
 
Gene Primer Sequence 
Ppia Sense 
(forward) 
5’-CAAATGCTGGACCAAACACAAACG-3’ 
Antisense 
(reverse) 
5’-GTTCATGCCTTCTTTCACCTTCCC-3’ 
Nqo1 Sense 
(forward) 
5’-AGCGTTCGGTATTACGATCC-3’ 
Antisense 
(reverse) 
5’-AGTACAATCAGGGCTCTTCTCG-3’ 
Gstm1 Sense 5’-ATACTGGGATACTGGAACGTCC-3’ 
Antisense 5’-AGTCAGGGTTGTAACAGAGCAT-3’ 
Gsta3 Sense 5’-GGTTCCTGGTTTGTTCCTTG-3’ 
Antisense 5’-CTATGGGAAGGACATGAAGGAG-3’ 
Cat Sense 5’-TGGTTAATGCAGATGGAGAGG-3’ 
Antisense 5’-TTGAAAAGATCTCGGAGGCC-3’ 
Entpd5 Sense 5’-GGGCTACCTCACTTCCTTTG-3’ 
Antisense 5’-TCAGTCCCTTTTGCTTCCAG -3’ 
Cbr1 Sense 5’-ACAACCCGCAGAGCATTC-3’ 
Antisense 5’-GTTCGTTTTCATTGTCACCTCTG-3’ 
Nampt Sense 5’-GAATGTCTCCTTCGGTTCTGG-3’ 
Antisense 5’-TCAGCAACTGGGTCCTTAAAC-3’ 
Dpys Sense 5’-TGTGACTATAGCCTGCATGTG-3’ 
Antisense 5’-CGGGCAAGGGTTTTCATTTC-3’ 
Scl22a12 Sense 5’-GAGGGAGACACGTTGACCA -3’ 
Antisense 5’-AAGTCCACAATCCCGATGAG-3’ 
 
Table 1: Primers used for qRT-PCR analysis of mouse kidney tissue.  
 
Quantification of NADPH content: Determination of NADPH content was 
performed using NADP/NADPH-GloTM (Promega).  Whole kidney tissue was lysed in 
a bicarbonate buffer containing 100 mM sodium carbonate, 20 mM sodium 
bicarbonate, 10 mM nicotinamide, 0.05 % Triton X-100 (Thermo Scientific) and 0.5 
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% dodecyltrimethylammonium bromide, and subjected to a 1 h freeze-thaw 
cycle.  Protein content was determined as previously described, and lysates were 
diluted to 1 µg/µL.  50 µL per sample was incubated at 60 oC for 15 min, room 
temperature for 10 min, and then 50 µL 0.2 N HCl/0.25 M Trizma base solution was 
added and gently mixed.  20 µL per reaction was removed to a 96 well white 
luminescence plate (Grenier Bio-One), and 20 µL NADPH reaction buffer was added.  
The plate was gently mixed, and luminescence was determined using the Thermo 
Scientific VarioSkan Flash 3001 device.  Data are expressed as a percentage of 
luminescence in vehicle-treated Nrf2+/+ kidney lysates. 
 
Quantification of GSH content: Total GSH was measured using GSH-GloTM 
(Promega), essentially as described.  Kidney tissues were lysed in PBS containing 2 
mM EDTA (160 mg tissue per mL), and subjected to a 1 h freeze-thaw cycle.  
Samples were subsequently centrifuged at 12,000 RPM for 10 min, and the 
supernatant was used for the assay.  6.25 µL per sample was loaded onto a 96 well 
white luminescence plate, followed by 18.75 µL PBS.  GSH-Glo reaction buffer was 
added at a ratio of 1:1, and the plate was incubated for 30 min at room 
temperature.  To detect GSH, 50 µL luciferin detection reagent was added per well, 
and incubated at room temperature for 2 min before assessing luminescence.  Data 
are expressed as a percentage of luminescence in vehicle-treated Nrf2+/+ kidney 
lysates. 
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Immunohistochemistry: Whole kidneys from Nrf2+/+ mice dosed with DMSO or 
CDDO-Me (3 mg/kg for 24 hours) and Nrf2-/- mice dosed with DMSO (5 per group) 
were excised and preserved in 4 % formalin.  At the Veterinary Pathology Centre 
(The University of Liverpool), samples were longitudinally cut and embedded in 
paraffin.  Serial 4 µm-thick sections were cut and placed on polylysine-coated slides, 
rehydrated through serial passages in solutions at decreasing concentrations of 
alcohol and moved to TBS-T, before quenching endogenous peroxidase activity 
through incubation in 0.3 % hydrogen peroxide.  Anti-Nqo1 antibody (Sigma 
HPA007308) was diluted 1:100 and applied overnight at 4 oC, after blocking non-
specific labelling using a 30 minute incubation at room temperature with 20 % 
normal goat serum.  After washing in TBS-T, swine anti-rabbit HRP EnVisionTM 
polymer detection system (K4011, Dako) secondary antibody was used for 
detection of Nqo1.  Negative control staining was performed with normal rabbit 
serum.  After a 30 minute incubation with the antibody, slides were washed with 
TBS-T, and DAB (3,3-diaminiobenzidine) was added as a chromogen for 10 minutes.  
Slides were counterstained with Papanicolaou haematoxylin and mounted.  For 
each experimental animal, a maximum of 10 non-overlapping microscopic fields of 
the cortex (including at least one glomerulus) and 5 fields of the medulla were 
captured at 100X with a Nikon DS-5Mc camera mounted on a Nikon Eclipse 80i 
microscope, before automated processing with ImageJ software (NIH).  After 
elaboration of an appropriate plug-in for batch measure, colour channel splitting, 
application of colour threshold and measurement of percentage of stained area 
within the microscope fields was consecutively and automatically performed for all 
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images and all experimental groups.  Raw data was analysed in Excel, and an 
unpaired T-test was used to compare between experimental groups. 
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2.3 Results 
2.3.1 Genetic and pharmacological modulation of Nrf2 in the mouse kidney 
In order to verify that the Nrf2 pathway was functional in the kidneys of Nrf2+/+ 
mice and non-functional in Nrf2-/- mice, prior to conducting microarray and iTRAQ 
analysis, we determined the expression level of the established Nrf2 target Nqo1 by 
immunoblotting and qPCR in kidney homogenates from both genotypes, 24 h after 
dosing with vehicle or CDDO-Me (Elangovan et al., 2008). The level of Nqo1 protein 
(Fig. 2A-B) and mRNA (Fig. 2C) was  significantly lower in the kidneys of vehicle-
exposed Nrf2-/- mice, compared with Nrf2+/+ counterparts, consistent with loss of 
Nrf2 function. Moreover, whilst the Nrf2 inducer CDDO-Me provoked the induction 
of Nqo1 24 h after administration to Nrf2+/+ mice, this effect was abrogated in Nrf2-
/- mice (Fig. 2A-C). These data validate our model of genetic and pharmacological 
modulation of Nrf2 in the mouse kidney. 
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Figure 2: Differential activity of Nrf2 in the kidneys of Nrf2+/+ and Nrf2-/- mice.  Mice of the 
indicated genotype were given a single acute i.p. dose of vehicle (DMSO) or CDDO-Me       
(3 mg/kg).  24 h later, Nqo1 levels were determined by (A-B) immunoblotting and (C) qPCR.  
(B) Band volumes were quantified by densitometry and normalised against β-actin.            
(C) Nqo1 mRNA levels were normalised to Ppia.  Data analysis represents mean + S.D. of 
n=6 animals per treatment group.  Statistical analysis was performed with an unpaired T 
test, * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001 ; N.S. not-significant. 
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2.3.2 Definition of the basal Nrf2-regulated renal proteome 
To provide a hitherto unparalleled insight into the proteins controlled by Nrf2 in the 
kidney at the basal level, an iTRAQ-based proteomic analysis was performed on 
kidney homogenates from Nrf2+/+ and Nrf2-/- mice (treated with the vehicle DMSO).  
This proteomic profiling yielded 3684 unique identifications at a FDR of <1 %.  From 
these, 2655 proteins were shown to be quantifiable in at least four mice from each 
experimental group.  Of these, the expression levels of 108 proteins were shown to 
be downregulated (Table 2) and 81 upregulated (Table 3) by at least 30 % (P ≤ 0.05, 
T test) in whole kidney homogenates of vehicle-treated Nrf2-/- mice compared to 
their Nrf2+/+ counterparts (Fig. 3A).  Three of the most substantially down-regulated 
proteins identified in the iTRAQ analysis, Gstm1 (11.5-fold lower in Nrf2-/- vs. Nrf2+/+ 
mice), Cat (4.3-fold lower) and Entpd5 (2.8-fold lower), were further shown to be 
expressed at a lower level in the kidneys of Nrf2-/- mice by immunoblotting of tissue 
homogenates (Fig. 3B-C). Manual interrogation (Fig. 3) and Ingenuity Pathway 
Analysis (Tables 4-5) of the iTRAQ data sets revealed that a substantial number of 
targets that were downregulated in the kidneys of Nrf2-/- mice were known to play 
roles in xenobiotic metabolism (Nqo1, Cyp7b1, Por), the synthesis and conjugation 
of glutathione (Gstm1, Gclc), and the maintenance of cellular redox balance (Cat, 
Prdx1). Furthermore, proteins contributing to a number of core metabolic 
processes, including glycolysis (Tkt, Me1), the supply of NAPDH (Nampt), the 
synthesis and recycling of amino acids (Acy3, Pipox) and the metabolism of 
lipids/fatty acids (Acat1, Faah), were found to be expressed at a lower level in the 
Nrf2-/- kidney (Fig. 4, Tables 4-5).  
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Accession Gene symbol Protein Peptides Fold decrease P value 
P10649 Gstm1 Glutathione S-transferase Mu 1 39 11.48 < 0.001 
P30115 Gsta3 Glutathione S-transferase A3 9 6.19 < 0.001 
P24270 Cat Catalase 111 4.28 < 0.001 
Q6ZQM8 Ugt1a7c UDP-glucuronosyltransferase 1-7C 35 4.06 < 0.001 
Q8QZT1 Acat1 Acetyl-CoA acetyltransferase, mitochondrial 94 3.94 < 0.001 
Q64669 Nqo1 NAD(P)H dehydrogenase [quinone] 1 4 3.57 < 0.001 
Q8R0Y6 Aldh1l1 Cytosolic 10-formyltetrahydrofolate dehydrogenase 62 3.08 < 0.001 
Q60991 Cyp7b1 25-hydroxycholesterol 7-alpha-hydroxylase 8 2.86 < 0.001 
P06801 Me1 NADP-dependent malic enzyme 37 2.83 < 0.001 
Q9WUZ9 Entpd5 Ectonucleoside triphosphate diphosphohydrolase 5 12 2.75 < 0.001 
Q3UNX5 Acsm3 Acyl-coenzyme A synthetase ACSM3, mitochondrial 39 2.74 0.003 
Q9EPL9 Acox3 Peroxisomal acyl-coenzyme A oxidase 3 38 2.72 < 0.001 
Q9DBE0 Csad Cysteine sulphinic acid decarboxylase 19 2.68 0.011 
Q7TNG8 Ldhd Probable D-lactate dehydrogenase, mitochondrial 54 2.62 0.009 
O08709 Prdx6 Peroxiredoxin-6 20 2.42 0.005 
Q9JII6 Akr1a1 Alcohol dehydrogenase [NADP+] 62 2.34 < 0.001 
P17563 Selenbp Selenium-binding protein 1 70 2.24 < 0.001 
P32020 Scp2 Non-specific lipid-transfer protein 24 2.18 0.002 
Q91XE4 Acy3 Aspartoacylase-3 53 2.17 0.004 
Q9R0H0 Acox1 Peroxisomal acyl-coenzyme A oxidase 1 121 2.16 0.005 
P02762 Mup6 Major urinary protein 6 13 2.13 0.042 
P37040 Por NADPH--cytochrome P450 reductase 21 2.04 0.012 
P16858 Gapdh Glyceraldehyde-3-phosphate dehydrogenase 90 2.03 0.026 
Q8C0I1 Agps Alkyldihydroxyacetonephosphate synthase, peroxisomal 24 2.00 < 0.001 
P34914 Ephx2 Epoxide hydrolase 2 58 2.00 0.005 
Q9EQ06 Hsd17b11 Estradiol 17-beta-dehydrogenase 11 23 1.95 0.025 
Q9R0Q9 Mpdu1 Mannose-P-dolichol utilization defect 1 protein 2 1.94 0.002 
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Q8VCN5 Cth Cystathionine gamma-lyase 16 1.93 0.009 
P00329 Adh1 Alcohol dehydrogenase 1 25 1.93 0.007 
Q9D826 Pipox Peroxisomal sarcosine oxidase 38 1.92 0.003 
P56395 Cyb5a Cytochrome b5 30 1.90 0.007 
Q80W22 Thnsl1 Threonine synthase-like 2 23 1.89 0.001 
P11930 Nudt19 Nucleoside diphosphate-linked moiety X motif 19, mitochondrial 57 1.88 < 0.001 
P40142 Tkt Transketolase 51 1.84 0.006 
Q64462 Cyp4b1 Cytochrome P450 4B1 62 1.84 0.008 
P97494 Gclc Glutamate--cysteine ligase catalytic subunit 17 1.82 0.001 
P28665 Mug1 Murinoglobulin-1 36 1.82 < 0.001 
P10639 Txn Thioredoxin 10 1.81 0.019 
Q7TNE1 - CaiB/baiF CoA-transferase family protein C7orf10 homolog 12 1.81 0.003 
O70475 Ugdh UDP-glucose 6-dehydrogenase 11 1.81 0.001 
Q8R1G2 Cmbl Carboxymethylenebutenolidase homolog 15 1.80 0.048 
P51855 Gss Glutathione synthetase 23 1.80 < 0.001 
P35700 Prdx1 Peroxiredoxin-1 27 1.80 0.016 
Q8BH00 Aldh8a1 Aldehyde dehydrogenase family 8 member A1 49 1.79 0.010 
Q9DB29 Iah1 Isoamyl acetate-hydrolyzing esterase 1 homolog 14 1.79 < 0.001 
Q9JLF6 Tgm1 Protein-glutamine gamma-glutamyltransferase K 9 1.78 0.004 
P62960 Ybx1 Nuclease-sensitive element-binding protein 1 21 1.78 0.014 
P47738 Aldh2 Aldehyde dehydrogenase, mitochondrial 72 1.76 0.010 
Q8K0L3 Acsm2 Acyl-coenzyme A synthetase ACSM2, mitochondrial 175 1.74 0.010 
P09103 P4hb Protein disulphide-isomerase 48 1.71 0.024 
Q8BWM0 Ptges2 Prostaglandin E synthase 2 10 1.69 0.002 
P51660 Hsd17b4 Peroxisomal multifunctional enzyme type 2 50 1.67 0.002 
P68372 Tubb4b Tubulin beta-4B chain 57 1.67 0.005 
Q9DBK0 Acot12 Acyl-coenzyme A thioesterase 12 9 1.65 0.015 
Q99KQ4 Nampt Nicotinamide phosphoribosyltransferase 17 1.64 0.008 
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Q64442 Sord Sorbitol dehydrogenase 32 1.63 0.045 
P47199 Cryz Quinone oxidoreductase 50 1.61 0.036 
Q8VCT4 Ces3 Carboxylesterase 3 34 1.59 0.049 
Q60759 Gcdh Glutaryl-CoA dehydrogenase, mitochondrial 27 1.58 0.015 
O08914 Faah Fatty-acid amide hydrolase 1 7 1.57 0.007 
P97447 Fhl1 Four and a half LIM domains protein 1 6 1.57 0.027 
Q9QXZ6 Oatp1a1 Solute carrier organic anion transporter family member 1A1 5 1.55 0.011 
P28271 Aco1 Cytoplasmic aconitate hydratase 48 1.54 0.006 
Q91WC0 Setd3 Histone-lysine N-methyltransferase setd3 3 1.53 0.039 
Q91WS0 Cisd1 CDGSH iron-sulphur domain-containing protein 1 14 1.53 0.003 
Q9DBL7 Coasy Bifunctional coenzyme A synthase 11 1.53 0.017 
Q9DCD0 Pgd 6-phosphogluconate dehydrogenase, decarboxylating 17 1.53 0.023 
Q9EQF5 Dpys Dihydropyrimidinase 4 1.52 0.038 
P11499 Hsp90ab1 Heat shock protein HSP 90-beta 68 1.52 0.049 
P10126 Eef1a1 Elongation factor 1-alpha 1 75 1.51 0.022 
Q921S7 Mrpl37 39S ribosomal protein L37, mitochondrial 5 1.51 0.046 
O55125 Nipsnap1 Protein NipSnap homolog 1 9 1.51 0.014 
Q8BH86 - UPF0317 protein C14orf159 homolog, mitochondrial 25 1.49 0.010 
Q9CPY7 Lap3 Cytosol aminopeptidase 59 1.48 0.036 
Q78JT3 Haao 3-hydroxyanthranilate 3,4-dioxygenase 16 1.47 0.010 
P23953 Ces1c Carboxylesterase 1C 17 1.47 0.026 
O09174 Amacr Alpha-methylacyl-CoA racemase 32 1.46 0.027 
Q9CY58 Serbp1 Plasminogen activator inhibitor 1 RNA-binding protein 2 1.46 0.002 
Q99JW2 Acy1 Aminoacylase-1 16 1.46 0.044 
Q9DBG6 Rpn2 Dolichyl-diphosphooligosaccharide—protein glycosyltransferase 33 1.45 0.030 
P25444 Rps2 40S ribosomal protein S2 11 1.45 0.003 
P58252 Eef2 Elongation factor 2 61 1.44 0.014 
P30412 Ppic Peptidyl-prolyl cis-trans isomerase C 5 1.43 0.007 
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Q8CFZ5 Slc22a12 Solute carrier family 22 member 12 8 1.43 0.021 
Q00612 G6pdx Glucose-6-phosphate 1-dehydrogenase X 8 1.41 0.047 
Q8C1E7 Tmem120a Transmembrane protein 120A 2 1.41 0.001 
Q8VDJ3 Hdlbp Vigilin 20 1.39 0.027 
Q9CYH2 Fam213a Redox-regulatory protein FAM213A 7 1.38 0.003 
Q8BWF0 Aldh5a1 Succinate-semialdehyde dehydrogenase, mitochondrial 13 1.36 0.029 
Q6NZJ6 Eif4g1 Eukaryotic translation initiation factor 4 gamma 1 11 1.36 0.031 
Q80XN0 Bdh1 D-beta-hydroxybutyrate dehydrogenase, mitochondrial 23 1.35 0.009 
Q8R146 Apeh Acylamino-acid-releasing enzyme 21 1.35 0.028 
P62918 Rpl8 60S ribosomal protein L8 7 1.34 0.035 
Q8VC69 Slc22a6 Solute carrier family 22 member 6 5 1.33 0.001 
Q8BGD9 Eif4b Eukaryotic translation initiation factor 4B 3 1.33 0.011 
Q9D517 Agpat3 1-acyl-sn-glycerol-3-phosphate acyltransferase gamma 6 1.33 0.006 
Q80U72 Scrib Protein scribble homolog 3 1.32 0.043 
P50172 Hsd11b1 Corticosteroid 11-beta-dehydrogenase isozyme 1 8 1.31 0.027 
P62889 Rpl30 60S ribosomal protein L30 5 1.31 0.012 
Q91WL5 Cyp4a12a Cytochrome P450 4A12A 9 1.31 0.035 
Q8R050 Gstp1 Eukaryotic peptide chain release factor GTP-binding subunit ERF3A 4 1.31 0.047 
Q9CQ92 Fis1 Mitochondrial fission 1 protein 4 1.31 0.043 
P23116 Eif3a Eukaryotic translation initiation factor 3 subunit A 13 1.31 0.028 
Q9CZU3 Skiv2l2 Superkiller viralicidic activity 2-like 2 5 1.30 0.041 
Q8QZY2 Glyctk Glycerate kinase 13 1.30 0.035 
 
Table 2: Proteins down-regulated in the kidneys of Nrf2-/- mice. The expression levels of 108 proteins were found to be decreased by at least 30 % (P ≤ 0.05) 
in the kidneys of Nrf2-/- mice.  Proteins are ordered by fold decrease in expression in Nrf2-/- compared with Nrf2+/+ mice (n=4-6 animals per group). The 
average number of peptides used for quantification across all iTRAQ runs is shown for each protein.   
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Accession Gene symbol Protein Peptides Fold increase P value 
O88833 Cyp4a10 Cytochrome P450 4A10 10 2.65 0.003 
Q9QYR9 Acot2 Acyl-coenzyme A thioesterase 2, mitochondrial 33 2.56 < 0.001 
Q9WVM8 Aadat Kynurenine/alpha-aminoadipateaminotransferase 39 2.23 < 0.001 
Q9NYQ2 Hao2 Hydroxyacid oxidase 2 9 2.09 0.004 
Q9CR51 Atp6v1g1 V-type proton ATPase subunit G 1 5 2.02 0.003 
P62806 Hist4h4 Histone H4 39 1.98 0.023 
P16406 Enpep Glutamyl aminopeptidase 18 1.97 < 0.001 
Q05793 Hspg2 Basement membrane-specific heparan sulphate proteoglycan core 
protein 
28 1.94 0.001 
Q99K48 Nono Non-POU domain-containing octamer-binding protein 8 1.93 0.009 
P11404 Fabp3 Fatty acid-binding protein, heart 9 1.92 0.003 
Q8BWT1 Acaa2 3-ketoacyl-CoA thiolase, mitochondrial 57 1.90 0.034 
P12658 Calb1 Calbindin 30 1.87 0.034 
P57780 Actn4 Alpha-actinin-4 100 1.85 < 0.001 
Q60953 Pml Protein PML 2 1.85 0.044 
P53657 Pklr Pyruvate kinase isozymes R/L 10 1.84 0.015 
Q920R6 Atp6v0a4 V-type proton ATPase 116 kDa subunit a isoform 4 22 1.82 0.015 
O55137 Acot1 Acyl-coenzyme A thioesterase 1 21 1.81 0.010 
P56135 Atp5j2 ATP synthase subunit f, mitochondrial 5 1.79 0.005 
O35409 Folh1 Glutamate carboxypeptidase 2 10 1.79 0.004 
P09242 Alpl Alkaline phosphatase, tissue-nonspecific isozyme 20 1.74 < 0.001 
P10493 Nid1 Nidogen-1 3 1.72 0.018 
P60710 Actb Actin, cytoplasmic 1 158 1.72 0.046 
Q91VW3 Sh3bgrl3 SH3 domain-binding glutamic acid-rich-like protein 3 5 1.70 0.046 
Q9DBN5 Lonp2 Lon protease homolog 2, peroxisomal 6 1.67 0.015 
Q9JIL4 Pdzk1 Na(+)/H(+) exchange regulatory cofactor NHE-RF3 61 1.67 < 0.001 
Q62261 Sptbn1 Spectrin beta chain, non-erythrocytic 1 148 1.67 < 0.001 
Q9D687 Slc6a19 Sodium-dependent neutral amino acid transporter B(0)AT1 4 1.64 0.001 
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Q7TPR4 Actn1 Alpha-actinin-1 53 1.63 0.003 
Q62418 Dbnl Drebrin-like protein 4 1.62 0.037 
Q9D964 Gatm Glycine amidinotransferase, mitochondrial 45 1.62 0.046 
Q9JLB4 Cubn Cubilin 42 1.62 0.028 
P16546 Sptan1 Spectrin alpha chain, non-erythrocytic 1 191 1.61 0.002 
Q8BMS1 Hadha Trifunctional enzyme subunit alpha, mitochondrial 67 1.61 0.003 
Q9D0K2 Oxct1 Succinyl-CoA:3-ketoacid-coenzyme A transferase 1 67 1.60 0.014 
Q9DCJ9 Npl N-acetylneuraminate lyase 11 1.59 0.021 
O35598 Adam10 Disintegrin and metalloproteinase domain-containing protein 10 2 1.58 0.017 
P28843 Dpp4 Dipeptidyl peptidase 4 7 1.58 < 0.001 
Q9QXT0 Cnpy2 Protein canopy homolog 2 5 1.57 0.027 
P29758 Oat Ornithine aminotransferase, mitochondrial 17 1.54 0.023 
Q9CQI6 Cotl1 Coactosin-like protein 8 1.54 0.005 
Q80X90 Flnb Filamin-B 72 1.53 < 0.001 
Q61767 Hsd3b4 3 beta-hydroxysteroid dehydrogenase type 4 16 1.53 0.008 
Q2TPA8 Hsdl2 Hydroxysteroid dehydrogenase-like protein 2 14 1.52 0.023 
Q9CZU6 Cs Citrate synthase, mitochondrial 38 1.52 0.002 
Q9QWR8 Naga Alpha-N-acetylgalactosaminidase 3 1.51 0.030 
O88502 Pde8a cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 
8A 
1 1.51 0.026 
P24527 Lta4h Leukotriene A-4 hydrolase 15 1.51 0.008 
Q9Z0E8 Slc22a5 Solute carrier family 22 member 5 2 1.50 0.023 
P11276 Fn1 Fibronectin 11 1.49 0.023 
Q8VDD5 Myh9 Myosin-9 178 1.48 0.009 
Q62468 Vil1 Villin-1 69 1.46 0.009 
Q91YI0 Asl Argininosuccinate lyase 29 1.46 0.011 
Q9CQJ8 Ndufb9 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9 12 1.45 0.026 
P10852 Slc3a2 4F2 cell-surface antigen heavy chain 15 1.44 0.021 
P55264 Adk Adenosine kinase 10 1.43 0.043 
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P13634 Ca1 Carbonic anhydrase 1 10 1.43 0.027 
P10922 H1f0 Histone H1.0 9 1.43 0.035 
Q8BH59 Slc25a12 Calcium-binding mitochondrial carrier protein Aralar1 34 1.41 0.005 
P48962 Slc25a4 ADP/ATP translocase 1 50 1.41 0.044 
Q99MR8 Mccc1 Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial 40 1.39 0.005 
P41438 Slc19a1 Folate transporter 1 2 1.38 0.043 
Q9DAW9 Cnn3 Calponin-3 4 1.38 0.027 
Q8BVE3 Atp6v1h V-type proton ATPase subunit H 26 1.36 0.019 
B2RXS4 Plxnb2 Plexin-B2 6 1.36 0.013 
Q68FD5 Cltc Clathrin heavy chain 1 170 1.35 0.048 
Q7TSV4 Pgm2 Phosphoglucomutase-2 5 1.35 0.018 
P47809 Map2k3 Dual specificity mitogen-activated protein kinase kinase 4 2 1.34 0.048 
P14824 Anxa6 Annexin A6 25 1.34 0.028 
Q9EPU0 Upf1 Regulator of nonsense transcripts 1 8 1.33 0.045 
Q64727 Vcl Vinculin 51 1.33 0.010 
P07356 Anxa2 Annexin A2 20 1.32 0.008 
Q9DCS3 Mecr Trans-2-enoyl-CoA reductase, mitochondrial 11 1.32 0.027 
Q9EPC1 Parva Alpha-parvin 8 1.31 0.008 
Q61879 Myh10 Myosin-10 61 1.31 0.001 
Q61702 Itih1 Inter-alpha-trypsin inhibitor heavy chain H1 3 1.31 0.048 
P25976 Ubtf Nucleolar transcription factor 1 2 1.31 0.050 
O35343 Kpna3 Importin subunit alpha-4 6 1.30 0.044 
Q8JZV7 Amdhd2 Putative N-acetylglucosamine-6-phosphate deacetylase 7 1.30 0.038 
Q9QUM9 Psma6 Proteasome subunit alpha type-6 8 1.30 0.033 
Table 3: Proteins up-regulated in the kidneys of Nrf2-/- mice. The expression levels of 81 proteins were found to be increased by at least 30 % (P ≤ 0.05) in 
the kidneys of Nrf2-/- mice.  Proteins are ordered by fold increase in expression in Nrf2-/- compared with Nrf2+/+ mice (n=4-6 animals per group). The average 
number of peptides used for quantification across all iTRAQ runs is shown for each protein.   
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Fig. 3: Basal Nrf2-regulated renal proteome. (A) Volcano plot depicting differentially 
expressed proteins in the kidneys of Nrf2-/- mice, compared with Nrf2+/+ counterparts. Each 
point represents a single protein. Proteins shown to be differentially expressed (at least      
± 30 % change, P ≤ 0.05) are defined in Tables 1 and 2. (B-C) Immunoblot validation of 
Gstm1, Cat and Entpd5 as proteins with decreased expression in the kidneys of Nrf2-/- mice. 
(C) Gstm1, Cat and Entpd5 band volumes were quantified by densitometry and normalised 
to β-actin. Data represent mean + S.D. of n=6 animals per group. Statistical analysis was 
performed with an unpaired t test; ** P ≤ 0.01, *** P ≤ 0.001.  
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Fig. 4: Manual interrogation of proteins identified in basal iTRAQ study allowed for 
classification of major biological processes shown to be sensitive to transgenic loss of Nrf2 
in the kidney. Proteins that were significantly (A) downregulated (n=108) or (B) upregulated 
(n=81) in the kidneys of Nrf2-/- mice were functionally categorised according to the UniProt 
database. 
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Canonical Pathway P Value Ratio Molecules 
Xenobiotic Metabolism Signaling <0.001 0.04 Gsta3, Gstm1, Abcc2, Nqo1, Aldh8, Gclc, Aldh9a1, Aldh1l1, Ces1, Hsp90ab1, 
Ugt1a7c, Cat, Aldh5a1 
Tryptophan Degradation III (Eukaryotic) <0.001 0.20 Haao, Acat1, Hsd17b4, Gcdh 
NRF2-mediated Oxidative Stress Response <0.001 0.04 Gsta3, Gstm1, Akr1a1, Prdx1, Abcc2, Cat, Nqo1, Gclc, Txn, Gclm 
Aryl Hydrocarbon Receptor Signaling <0.001 0.05 Gsta3, Aldh1l1, Gstm1, Hsp90ab1, Nqo1, Aldh8a1, Acox3, Aldh5a1, Aldh9a1 
Pentose Phosphate Pathway <0.001 0.30 Pgd, Tkt, G6pd 
LPS/IL-1 Mediated Inhibition of RXR Function <0.001 0.04 Gsta3, Aldh1l1, Gstm1, Acox1, Abcc2, Cat, Aldh8a1, Acox3, Aldh5a1, Aldh9a1 
Glutaryl-CoA Degradation <0.001 0.27 Acat1, Hsd17b4, Gcdh 
Glutathione Biosynthesis <0.001 0.67 Gclc, Gclm, Gss 
Serotonin Degradation <0.001 0.09 Aldh2, Akr1a1, Ugt1a7c, Adh1c, Aldh9a1 
Pentose Phosphate Pathway, Oxidative Branch <0.001 0.50 Pgd, G6pd 
Triacylglycerol Degradation <0.001 0.13 Faah, Ces1, Prdx6 
Superoxide Radicals Degradation 0.001 0.33 Cat, Nqo1 
Ethanol Degradation II 0.001 0.11 Aldh2, Akr1a1, Adh1c, Aldh9a1 
Noradrenaline and Adrenaline Degradation 0.001 0.10 Aldh2, Akr1a1, Adh1c, Aldh9a1 
Ketolysis 0.001 0.25 Bdh1, Acat1 
Estrogen Biosynthesis 0.001 0.09 Por, Cyp4b1, Hsd17b4 
Ketogenesis 0.002 0.20 Bdh1, Acat1 
γ-glutamyl Cycle 0.002 0.18 Gclc, Gclm, Gss 
Nicotine Degradation III 0.002 0.07 Por, Cyp4b1, Ugt1a7c 
Melatonin Degradation I 0.002 0.07 Por, Cyp4b1, Ugt1a7c 
Bile Acid Biosynthesis, Neutral Pathway 0.002 0.17 Amacr, Scp2 
Superpathway of Melatonin Degradation 0.003 0.07 Por, Cyp4b1, Ugt1a7c 
EIF2 Signaling 0.003 0.03 Rpl8, Rps2, Rpl30, Eif3a, Eif4g1, Rpl10a 
Nicotine Degradation II 0.004 0.06 Por, Cyp4b1, Ugt1a7c 
Tryptophan Degradation X (Mammalian) 0.005 0.12 Aldh2, Akr1a1, Aldh9a1 
Ethanol Degradation IV 0.005 0.11 Aldh2, cat, Aldh9a1 
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Hypoxia Signaling in the Cardiovascular System 0.007 0.05 P4hb, Hsp90a1, Nqo1 
Bupropion Degradation 0.008 0.09 Por, Cyp4b1 
Gluconeogenesis I 0.008 0.09 Gapdh, Me1 
Glutathione-mediated Detoxification 0.008 0.09 Gsta3, Gstm1 
Acetone Degradation I (to Methylglyoxal) 0.008 0.09 Por, Cyp4b1 
Retinoate Biosynthesis I 0.015 0.06 Aldh8a1, Adh1c 
mTOR Signaling 0.021 0.02 Rps2, Eif3a, Eif4g1, Eif4b 
 
Table 4: Biological processes downregulated in the kidneys of Nrf2-/- mice. Proteins identified in the iTRAQ analysis as being expressed at a lower level in the 
kidneys of Nrf2-/- mice were categorised using Ingenuity Pathway Analysis. Ratio represents the number of proteins in the dataset as a proportion of the 
total number of proteins comprising each pathway.  Proteins populating the highlighted pathways are listed under ‘Molecules’. 
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Canonical Pathway P value Ratio Molecules 
ILK Signaling <0.001 0.05 Map2k4, Flnb, Myh10, TgfB1l1, Parva, Fn1, Myh9, Flna, Actb, Actn4, Actn1 
Paxillin Signaling <0.001 0.06 Map2k4, Parva, Actb, Itga1, Vcl, Actn4, Actn1 
Actin Cytoskeleton Signaling <0.001 0.03 Myh10, Actr2, Fn1, Myh9, Flna, Actb, Mylk, Vcl, Actn4, Actn1 
Epithelial Adherens Junction Signaling <0.001 0.04 Myh10, Actr2, Myh9, Actb, Vcl, Actn4, Actn1 
Sertoli Cell-Sertoli Cell Junction Signaling <0.001 0.03 Map2k4, Sptbn1, Actb, Sptan1, Actn4, Acnt1 
Arginine Biosynthesis IV <0.001 0.40 Oat, Asl 
Remodeling: Epithelial Adherens Junctions <0.001 0.06 Actr2, Actb, Vcl, Actn4, Actn1 
Integrin Signaling <0.001 0.03 Map2k4, Actr2, Parva, Actb, Itga1, Mylk, Vcl, Actn4, Actn1 
Ketolysis 0.001 0.25 Oxct1, Hadha 
Tight Junction Signaling 0.001 0.03 Myh10, Myh9, Actb, Mylk, Sptan1, Vcl 
VEGF Signaling 0.001 0.04 Actb, Vcl, Actn4, Actn1 
Superpathway of Citrulline Metabolism 0.002 0.14 Oat, Asl 
Leukocyte Extravasation Signaling 0.002 0.03 Map2k4, Actb, Itga1, Vcl, Actn4, Actn1 
Calpain Protease Regulation (Mechanical) 0.002 0.04 Vcl, Actn4, Actn1 
Agrin Interactions Neuromuscular Junction 0.003 0.04 Map2k4, Pklr, Actb, Itga1 
Germ Cell-Sertoli Cell Junction Signaling 0.005 0.03 Map2k4, Actb, Actn4, Actn1 
Agranulocyte Adhesion and Diapedesis 0.007 0.02 Myh10, Fn1, Myh9, Actb, Itga1 
Virus Entry via Endocytic Pathways 0.007 0.03 Flnb, Flna, Actb, Cltc, Itga1 
Fatty Acid β-oxidation I 0.008 0.07 Acaa2, Eci1, Hadha 
Inhibition of Angiogenesis by TSP1 0.010 0.06 Map2k4, Hspg2 
Inhibition of Matrix Metalloproteases 0.012 0.05 Hspg2, Adam10 
Cellular Effects of Sildenafil (Viagra) 0.018 0.02 Myh10, Myh9, Actb, Mylk 
Induction of Apoptosis by HIV1 0.027 0.03 Map2k4, Slc25a4 
Mitochondrial Dysfunction 0.035 0.02 Map2k4, Ndufb9, Ndufs7, Atp5j2, Ndufa3, Dhodh 
Caveolar-mediated Endocytosis Signaling 0.040 0.03 Flnb, Flna, Actb, Itga1 
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Table 5: Biological processes upregulated in the kidneys of Nrf2-/- mice. Proteins identified in the iTRAQ analysis as being expressed at a higher level in the 
kidneys of Nrf2-/- mice were categorised using Ingenuity Pathway Analysis. Ratio represents the number of proteins in the dataset as a proportion of the 
total number of proteins comprising each pathway.  Proteins populating the highlighted pathways are listed under ‘Molecules’. 
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In order to ensure that the DMSO treatment had no impact on the expression levels 
of the reported proteins, an independent iTRAQ analysis of kidney homogenates 
from untreated Nrf2+/+ and Nrf2-/- mice (n=6 per genotype) was performed (Fig. 5), 
which showed excellent agreement with the primary study.  It was therefore 
concluded that the DMSO vehicle had little effect on the expression levels of Nrf2-
regulated proteins in the main iTRAQ study (Tables 2-3, Fig 3).  Taken together, 
these data demonstrate the vital role of Nrf2 in regulating the basal expression of 
proteins that coordinate of homeostatic processes in the kidney. 
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Fig. 5: Comparison of differentially expressed proteins in the kidneys of DMSO treated and 
untreated Nrf2-/- mice (compared to Nrf2+/+). iTRAQ proteomic analysis of kidneys from 
untreated Nrf2+/+ and Nrf2-/- mice was performed to compare the fold change in expression 
of the indicated proteins (those showing ≥ 50% increase or decrease in expression in the 
kidneys of vehicle-exposed Nrf2-/- mice) reported in the main data set. 
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2.3.3 Definition of the CDDO-Me -inducible renal proteome 
In light of the recent interest in using the Nrf2 inducer CDDO-Me as a novel 
treatment for kidney dysfunction (de Zeeuw et al., 2013a), we set out to identify 
the proteins that were differentially expressed in the kidneys (n=6 per treatment 
group) of Nrf2+/+ mice after dosing with CDDO-Me for 24h (based on the knowledge 
that 24 h exposure to CDDO-Me (3 mg/kg) elicits an upregulation of Nqo1 in the 
kidney (Fig. 2), as well as various Nrf2-regulated proteins in the liver (Walsh et al., 
2014)). The expression levels of 24 proteins were found to be up-regulated (Table 
6), whilst 18 proteins were down-regulated (Table 7), by at least 30 % (P<0.05) in 
animals dosed with CDDO-Me compared with those receiving the vehicle (Fig. 6). 
Whilst these proteins were not significantly altered by CDDO-Me in Nrf2-/- mice, 
compared with vehicle control (data not shown), it was notable that, with the 
exception of Nqo1 (induced 1.4-fold by CDDO-Me, Table 6), none of the 108 
proteins that were found to be positively regulated by Nrf2 at the basal level (i.e. 
their expression was significantly decreased in Nrf2-/- mice compared with Nrf2+/+ 
mice; Table 2) were induced by CDDO-Me under the conditions used. The relatively 
small number of proteins that were significantly modulated by CDDO-Me in Nrf2+/+ 
mice was reflected in the small number of renal processes that were found to be 
altered through manual interrogation (Fig. 7A-B) and Ingenuity Pathway Analysis of 
the iTRAQ data (Tables 8 and 9). Overall, these data suggest that a single dose of 
CDDO-Me has relatively little effect on the renal expression of proteins that are 
constitutively regulated by Nrf2 at the basal level. 
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Accession Gene 
Symbol 
Protein Peptides Fold increase P value 
P62858 Rps28 40S ribosomal protein S28 2 2.51 0.012 
Q03160 Grb7 Growth factor receptor-bound protein 7 3 1.79 0.009 
Q91WK5 Gcsh Glycine cleavage system H protein, mitochondrial 4 1.74 0.044 
Q9DBM2 Ehhadh Peroxisomal bifunctional enzyme 124 1.66 0.033 
P23780 Glb1 Beta-galactosidase 7 1.63 0.031 
P50171 Hsd17b8 Estradiol 17-beta-dehydrogenase 8 11 1.60 0.023 
Q9DCY0 Keg1 Glycine N-acyltransferase-like protein Keg1 76 1.55 0.014 
P42703 Lifr Leukemia inhibitory factor receptor 2 1.50 0.011 
Q8VE95 - UPF0598 protein C8orf82 homolog 4 1.46 0.029 
Q8BU88 Mrpl22 39S ribosomal protein L22, mitochondrial 2 1.44 0.048 
P48758 Cbr1 Carbonyl reductase [NADPH] 1 14 1.41 0.009 
Q8K010 Oplah 5-oxoprolinase 26 1.40 0.008 
Q9JHJ3 - Lysosomal protein NCU-G1 2 1.40 0.049 
Q9Z2J0 Slc23a1 Solute carrier family 23 member 1 9 1.39 0.002 
Q60649 Clpb Caseinolytic peptidase B protein homolog 4 1.39 0.011 
Q6PDY2 Ado 2-aminoethanethiol dioxygenase 2 1.38 0.048 
Q62219 Tgfb1i1 Transforming growth factor beta-1-induced transcript 1 protein 2 1.36 0.022 
Q64669 Nqo1 NAD(P)H dehydrogenase [quinone] 1 4 1.36 0.001 
Q9CYW4 Hdhd3 Haloacid dehalogenase-like hydrolase domain-containing protein 3 4 1.34 0.008 
Q8BGB2 Ttc7a Tetratricopeptide repeat protein 7A 3 1.33 0.025 
Q99J99 Mpst 3-mercaptopyruvate sulphurtransferase 8 1.33 0.009 
Q8R5L3 Vps39 Vam6/Vps39-like protein 2 1.32 0.044 
Q3TLP5 Echdc2 Enoyl-CoA hydratase domain-containing protein 2, mitochondrial 20 1.32 0.045 
Q9Z0N1 Eif2s3x Eukaryotic translation initiation factor 2 subunit 3, X-linked 9 1.31 0.028 
Table 6: Proteins up-regulated by CDDO-Me in the kidneys of Nrf2+/+ mice. The expression levels of 24 proteins were found to be increased by at least 30 % (P ≤ 0.05) in the kidneys of Nrf2+/+ mice following a single 
i.p. injection of CDDO-Me (3 mg/kg). Proteins are ordered by fold increase in expression in CDDO-Me -exposed compared with vehicle-exposed mice (n=4-6 animals per group). The average number of peptides used 
for quantification across all iTRAQ runs is shown for each protein.  None of the proteins were found to be up-regulated by CDDO-Me in the kidneys of Nrf2-/- mice (data not shown). 
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Accession Gene 
Symbol 
Protein Peptides Fold decrease P value 
Q00623 Apoa1 Apolipoprotein A-I 37 1.81 0.015 
Q9D0J8 Pt s Parathymosin 7 1.75 0.009 
Q60692 Psmb6 Proteasome subunit beta type-6 3 1.70 0.045 
P26040 Ezr Ezrin 48 1.57 0.004 
Q9D0E1 Hnrnpm Heterogeneous nuclear ribonucleoprotein M 6 1.56 0.021 
P97384 Anxa11 Annexin A11 11 1.48 0.002 
Q8BIQ5 Cstf2 Cleavage stimulation factor subunit 2 1 1.39 0.034 
P08113 Hsp90b1 Endoplasmin 45 1.38 0.049 
Q91WS0 Cisd1 CDGSH iron-sulphur domain-containing protein 1 14 1.38 0.013 
Q80UM3 Naa15 N-alpha-acetyltransferase 15, NatA auxiliary subunit 3 1.36 0.026 
P19258 Mpv17 Protein Mpv17 3 1.35 0.042 
P23116 Eif3a Eukaryotic translation initiation factor 3 subunit A 13 1.34 0.018 
Q8VE97 Srsf2 Serine/arginine-rich splicing factor 4 4 1.34 0.046 
Q6P1B1 Xpnpep1 Xaa-Pro aminopeptidase 1 11 1.33 0.012 
Q9CY58 Serbp1 Plasminogen activator inhibitor 1 RNA-binding protein 2 1.32 0.009 
Q9Z0X1 Aifm1 Apoptosis-inducing factor 1, mitochondrial 38 1.32 0.048 
P06151 Ldha L-lactate dehydrogenase A chain 43 1.32 0.022 
P25444 Rps2 40S ribosomal protein S2 21 1.30 0.020 
 
Table 7: Proteins down-regulated by CDDO-Me in the kidneys of Nrf2+/+ mice. The expression levels of 18 proteins were found to be decreased by at least 
30 % (P ≤ 0.05) in the kidneys of Nrf2+/+ mice following a single i.p. injection of CDDO-Me (3 mg/kg). Proteins are ordered by fold decrease in expression in 
CDDO-Me -exposed compared with vehicle-exposed mice (n=4-6 animals per group). The average number of peptides used for quantification across all 
iTRAQ runs is shown for each protein.  None of the proteins were found to be down-regulated by CDDO-Me in the kidneys of Nrf2-/- mice (data not shown).
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Fig. 6: CDDO-Me-inducible renal proteome.  Volcano plot depicting differentially expressed 
proteins in the kidneys of Nrf2+/+ mice 24 h after receiving a single i.p. injection of CDDO-
Me (3 mg/kg), compared with vehicle control. Each point represents a single protein. 
Proteins shown to be differentially expressed (at least ± 30 % change, P ≤ 0.05) are defined 
in Tables 5 and 6.  
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Fig. 7: Major biological processes shown to be sensitive to induction of Nrf2 activity in the 
kidney. Proteins that were significantly (A) upregulated (n=24) or (B) downregulated (n=18) 
in the kidneys of Nrf2+/+ mice exposed to CDDO-Me ere functionally categorised according 
to the UniProt database. 
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Canonical Pathway P value Ratio Molecules 
Glutaryl-CoA Degradation <0.001 0.18 Echdc2, Hsd17b8 
Tryptophan Degradation III (Eukaryotic) <0.001 0.10 Echdc2, Hsd17b8 
Fatty Acid β-oxidation I <0.001 0.07 Echdc2, Hsd17b8 
NRF2-mediated Oxidative Stress Response 0.013 0.01 Nqo1, Cbr1 
EIF2 Signaling 0.040 0.01 Rps28, Eif2s3 
 
Table 8: Biological processes upregulated by CDDO-Me in the kidneys of Nrf2
+/+
 mice. Proteins 
identified in the iTRAQ analysis as being expressed at a higher level in the kidneys of CDDO-Me 
treated Nrf2
+/+
 mice were categorised using Ingenuity Pathway Analysis. Ratio represents the 
number of proteins in the dataset as a proportion of the total number of proteins comprising each 
pathway.  Proteins populating the highlighted pathways are listed under ‘Molecules’ 
 
Canonical Pathway P value Ratio Molecules 
Hypoxia Signaling, Cardiovascular System 0.002 0.03 Hsp90b1, Ldha 
Regulation of eIF4 and p70S6K Signaling 0.009 0.01 Rps2, Eif3a 
PPARα/RXRα Activation 0.013 0.01 Hsp90b1, Apoa1, Stat5b 
EIF2 Signaling 0.013 0.01 Rps2, Eif3a 
mTOR Signaling 0.014 0.01 Rps2, Eif3a 
 
Table 9: Biological processes downregulated by CDDO-Me in the kidneys of Nrf2
+/+
 mice. Proteins 
identified in the iTRAQ analysis as being expressed at a lower level in the kidneys of CDDO-Me 
treated Nrf2
+/+
 mice were categorised using Ingenuity Pathway Analysis. Ratio represents the 
number of proteins in the dataset as a proportion of the total number of proteins comprising each 
pathway.  Proteins populating the highlighted pathways are listed under ‘Molecules’2.  
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2.3.4 Validation of CDDO-Me dosing 
The data presented in Tables 6-9 and Fig. 6-7 demonstrate that a single dose of 
CDDO-Me failed to augment the expression of proteins, other than Nqo1, that were 
shown to be regulated by Nrf2 at the basal level in the mouse kidney. The lack of 
appreciable induction of Nrf2 signalling by CDDO-Me in this study may be due to 
the exposure of the animals to a single dose of the compound for a fixed 24 h 
period, although this previously was found to be sufficient to induce a large number 
of Nrf2-regulated proteins in the mouse liver (Walsh et al., 2014). It is plausible that 
the induction of different Nrf2-regulated proteins may proceed under distinct 
timeframes.  Fig. 8 depicts immunoblotting of whole kidney homogenates for 
known Nrf2-regulated proteins, in an attempt to determine if the selected time 
period and dose of CDDO-Me used in the iTRAQ analysis (3 mg/kg for 24 hours) was 
sub-optimal.  Mice were treated with a range of doses of CDDO-Me for 24 hours, 
with appreciable increase in Nqo1 and Gstm1 expression noted following a dose of 
3 mg/kg (Fig. 8A-B).  Consequently, mice were dosed with 3 mg/kg CDDO-Me for 
different times, with appreciable induction of Nqo1 at ≥ 24 h being the only 
statistically significant result (Fig. 8C-D).  Therefore, it was determined that, whilst 
CDDO-Me significantly induces the expression of Nqo1, a single dose of the 
compound has relatively little effect on the renal expression of proteins that are 
constitutively regulated by Nrf2 at the basal level.       
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Fig. 8: Validation of CDDO-Me dosing.  (A,B) Mice were treated with the indicated doses of 
CDDO-Me for 24 h, and whole kidney homogenates were probed for Nqo1, Gstm1, Cat, 
Entpd5 and Actin by immunoblotting.  (C,D) Mice were treated with 3 mg/kg CDDO-Me for 
the indicated times, and whole kidney homogenates were probed as (A,B).  Protein band 
volumes were quantified by densitometry and normalised against β-actin.  (A,B) Data 
represent the mean + S.D. of n=2 animals per group, (C,D) Data represent the mean + S.D. 
of n=4 animals per group (representative samples from n=2 animals shown).  Statistical 
analysis was performed with an unpaired t test; *, p ≤ 0.05. 
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2.3.5 Comparative analysis of the expression of Nrf2-regulated proteins in the 
kidney and liver 
It has been previously determined that CDDO-Me induces the hepatic expression of 
6 proteins that are regulated by Nrf2 at the basal level in the mouse liver (Walsh et 
al., 2014).  However, in the mouse kidney only Nqo1 appears to be sensitive to both 
inhibition and induction of Nrf2 (Tables 2 and 6).  To provide insight into why 
CDDO-Me appears to have relatively little effect on the expression of Nrf2-
regulated proteins in the kidney, the basal expression levels of four representative 
proteins known to be regulated by Nrf2 in the liver (Walsh et al., 2014) and the 
kidney (Table 2) were analysed by immunoblotting of tissue homogenates from 
Nrf2+/+ mice (Fig. 9).  The expression of Nqo1 was found to be 9-fold higher in the 
kidney than the liver; however Gstm1 expression was over 3-fold lower in the 
kidney.  Additionally, there was no difference in expression of Cat and Entpd5 
between the tissues.  These data argue against the kidney being less sensitive to 
pharmacological induction of Nrf2 by CDDO-Me as a result of having a generally 
high basal level of Nrf2 activity.  Therefore, further work is required to define the 
ability of CDDO-Me to augment Nrf2-regulated processes in the kidney.  
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Fig. 9: Basal expression of Nrf2-regulated proteins in the kidneys and livers of Nrf2+/+ mice. 
(A) Nqo1, Gstm1, Cat, Entpd5 and Actin levels were determined by immunoblotting.         
(B) Protein band volumes were quantified by densitometry and normalised against β-actin, 
and expressed as % of kidney expression. Data represent mean + S.D. of n=4 animals per 
group. Statistical analysis was performed with an unpaired t test; ***, p ≤ 0.001.  
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2.3.6 Transcriptional regulation of Nrf2-regulated proteins in the kidney 
In order to examine the mechanisms behind the lack of appreciable increase in 
Nrf2-regulated protein expression following CDDO-Me induction, targeted PCR was 
performed on a panel of genes encoding for proteins that were found to be 
regulated by Nrf2 at the basal level (Table 2).  The differential expression of this 
sub-set of genes in the kidneys of Nrf2-/-, compared to Nrf2+/+, mice showed 
excellent agreement with the iTRAQ data (Fig. 10), but also showed that CDDO-Me 
has more of a discernible effect on Nrf2-regulated genes at the transcriptional level 
(Fig. 10).  It is likely that the acute dosing regimen used in the study did not allow 
these transcriptional effects to be translated fully to changes at the protein level 
(Schwanhausser et al., 2011).   
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Fig. 10:  Genes sensitive to genetic inhibition and/or pharmacological induction of Nrf2 in the mouse 
kidney.  A panel of genes encoding for proteins that were found to be significantly downregulated in 
the kidneys of Nrf2
-/-
 mice by iTRAQ (Table 2) were chosen for qRT-PCR analysis.  Gene expression 
levels are normalised to Ppia.  Data represent mean + S.D. of n=6 animals per group.  Statistical 
analysis of qPCR data was performed with an unpaired t test or Mann-Whitney test, * P ≤ 0.05; ** P 
≤ 0.01; *** P ≤ 0.001; N.S. non-significant. 
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2.3.7 Nrf2 regulates the provision of NADPH and GSH in the kidney  
Following iTRAQ analysis, it was noted that numerous proteins in the Nrf2-/- mouse 
were involved in the synthesis and metabolism of both NADPH (Nampt, G6pd, Pgd, 
etc.) and GSH (Gclc, Gss, Gst, etc.).  Whole kidney homogenates were analysed for 
NADPH content (Fig. 11A), where it was determined that there was a 35 % 
reduction in total NADPH in kidneys from Nrf2-/- mice compared with Nrf2+/+ mice, 
supporting a role for Nrf2 as a regulator of energy homeostasis highlighted in this 
and other research ((Wu et al., 2011a).  Total GSH was decreased by 30% in the 
Nrf2-/- mouse kidney compared with Nrf2+/+ counterparts (Fig. 11B), reflecting the 
reduction in expression of proteins involved in GSH metabolism in the Nrf2-/- 
mouse. No difference in total NADPH or GSH was seen in the kidneys of Nrf2+/+ mice 
treated with CDDO-Me, likely due to the acute dosing regimen of this study. 
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Fig. 11: Quantification of (A) total NADPH and (B) total GSH was performed on kidney 
lysates from Nrf2+/+ or Nrf2-/- mice treated with vehicle (DMSO) or CDDO-Me for 24 h.  Both 
NADPH content and GSH content are expressed as a percentage of vehicle-treated Nrf2+/+ 
mice.  Data represent mean + S.D. of n=8 animals per group.  Statistical analysis was 
performed using an unpaired t test; **, P ≤ 0.01, ***, P ≤ 0.001, N.S., non-significant.  
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2.3.8 Histological examination of Nqo1 activity in the kidney 
In light of the heterogeneous anatomical nature of the kidney, and to provide a 
histological insight into the role of Nrf2 in the regulation of renal homeostatic 
processes, we performed immunohistochemical analyses of kidney tissue from the 
previous experiments.  Given the presence of the non-functional Nrf2 protein in the 
Nrf2-/- mice (described previously), immunohistochemical staining for Nqo1 was 
used instead.  Consistent with our iTRAQ and qRT-PCR data indicating that Nqo1 is 
highly sensitive to modulation of Nrf2 activity in the kidney, there was a significant 
decrease in Nqo1 staining in the renal cortex of Nrf2-/- mice, compared with Nrf2+/+ 
counterparts    (Fig. 12).  Furthermore, there was a significant increase in Nqo1 
staining in the cortex of Nrf2+/+ mice in response to CDDO-Me (Fig. 12).  Qualitative 
analysis of the tissue sections indicated that Nqo1 staining was highest in the 
proximal tubules of these animals, consistent with Nrf2’s established role in in the 
protection of mice against proximal tubule-specific nephrotoxins (Shelton et al., 
2013).  Nqo1 staining is particularly high within the S3 segment of the proximal 
tubule, consistent with their known susceptibility to nephrotoxix injury (Aleksunes 
et al., 2010) and likely requirement for a dynamic Nrf2 response.  Taken together, 
these data further confirm the role of Nrf2 in regulating the renal expression of 
cytoprotective genes, particularly in the cortex of the mouse kidney. 
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Fig. 12: Histological examination of Nqo1 activity in the kidney.  Images in (A) are 
representative of immunohistochemical staining for Nqo1 in the cortex of Nrf2+/+ mice 24 h 
after receiving a single i.p. injection of (i) DMSO or (ii) CDDO-Me (3 mg/kg), or Nrf2-/- mice 
24 h after receiving a single i.p. injection of (iii) DMSO or (iv) CDDO-Me.  Scale bars 
represent 100 µm. Data represent mean + S.D. of n=5 animals per group.  Statistical 
analysis was performed with an unpaired T test, ;, **, P ≤ 0.01, N.S. not-significant . 
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2.4 Discussion 
Nrf2 is a critical regulator of mammalian cell defence against various forms of stress 
(Bryan et al., 2013).  As a result, Nrf2 has become an attractive therapeutic target in 
numerous pathological contexts (Copple, 2012).  Indeed, dimethyl fumarate has 
recently become the first Nrf2-inducing drug to be licensed for clinical use, in 
patients with relapsing-remitting multiple sclerosis (Lee et al., 2013).  A detailed 
understanding of the biological processes that are modulated by Nrf2 inducers will 
be critical to the development of such compounds as next-generation drug 
candidates, yet, aside from focused gene expression analyses (Aleksunes et al., 
2010), such studies are noticeably lacking in the kidney, despite an increasing 
interest in the use of Nrf2 inducers and other antioxidants for the treatment of 
renal pathologies (Ruiz et al., 2013).  In order to address this knowledge gap, we 
have performed a global proteomic analysis of the battery of proteins that are 
regulated by Nrf2 in the mouse kidney.   
The findings of this study demonstrate that the kidneys of Nrf2-/- mice are deficient 
in proteins that maintain cellular redox balance, mediate the synthesis and 
conjugation of glutathione (the effects of which are demonstrated functionally as a 
decrease in the level of total GSH in the Nrf2-/- mouse kidney, Fig. 11B) and control 
the metabolism and disposition of a wide range of xenobiotics.  Moreover, and 
consistent with recent reports indicating that Nrf2 regulates core metabolic 
processes that promote the proliferation of cancer cells (Mitsuishi et al., 2012), as 
well as hepatic NADPH levels (Wu et al., 2011a), we noted that a substantial 
proportion of the proteins expressed at a lower level in the kidneys of Nrf2-/- mice, 
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compared with their Nrf2+/+ counterparts, are known to regulate pyruvate 
metabolism, glycolysis, the supply of NADPH, and the synthesis and recycling of 
amino acids (Tables 2, 4 and 5).  The examination of NADPH supply in renal 
homogenates from the mice (Fig. 11) confirmed that the reduction in expression of 
proteins involved in the synthesis and metabolism of NADPH in the Nrf2-/- mouse 
had an effect on NADPH availability, therefore Nrf2 appears to play an important 
role in maintaining renal homeostasis by supporting anabolic processes and the 
provision of cellular fuel.   
The decreased activity of the above processes likely contributes to the enhanced 
susceptibility of Nrf2-/- mice to various renal insults (Shelton et al., 2013).  Indeed, it 
has been shown that Nqo1, shown here to be the protein that is most sensitive to 
genetic inhibition and pharmacological induction of renal Nrf2 activity, directly 
protects against cisplatin nephrotoxicity in mice (Gang et al., 2013; Oh et al., 2013).  
Therefore, modulation of Nrf2 activity may be an attractive strategy for 
antagonising stresses that are associated with the development of acute kidney 
injury.  
CDDO-Me had shown promise as a novel treatment for chronic kidney disease 
(Pergola et al., 2011b), until the recent termination of the phase III BEACON trial 
due to adverse cardiovascular events for which the underlying mechanisms are 
currently under investigation (de Zeeuw et al., 2013b; Chin et al., 2014b).  Whilst 
CDDO-Me and its analogues have been shown to protect against AKI and enhance 
Nrf2 signalling in animal models (Tanaka et al., 2008; Aleksunes et al., 2010; Wu et 
al., 2011b), a role for Nrf2 in the improved estimated glomerular filtration rate 
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observed in patients has yet to be demonstrated, to our knowledge.  In this study, 
we determined that a single acute exposure to CDDO-Me failed to augment the 
expression of proteins, other than Nqo1, that were shown to be regulated by Nrf2 
at the basal level in the mouse kidney.   
 Indeed, qRT-PCR analysis of the expression of genes whose proteins found to be 
regulated by Nrf2 at the basal level suggests that CDDO-Me augments their 
expression (Fig. 10), however its pharmacodynamic effects were less pronounced at 
the protein level.  The lack of appreciable induction of Nrf2-regulated proteins by 
CDDO-Me in this study may be due to the exposure of the animals to a single dose 
of the compound, and that the induction of different Nrf2-regulated proteins may 
proceed under distinct timeframes (Fig. 8).  Therefore, a more detailed validation of 
the dose and time-dependent response of Nrf2 to CDDO-Me could have improved 
the design of the current study.  Chronic stimulation may be necessary to provoke 
meaningful changes in the expression of Nrf2-regulated proteins in the kidney, 
however a recent study has demonstrated only minimal induction of such renal 
targets in a mouse model of systemic lupus erythematosus, following 
administration of CDDO-Me (3mg/kg) three times per week for two months (Wu et 
al., 2014b).  It is possible that alternative pharmacological modulators may 
stimulate renal Nrf2 signalling to a greater degree than CDDO-Me, due to 
pharmacodynamic and/or -kinetic factors. Therefore, in order to better understand 
the potential value of Nrf2 inducers as novel treatments for renal disease, further 
work is required to define the scope of small molecules such as CDDO-Me to 
augment Nrf2-regulated processes in the human kidney. 
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We have found that the basal Nrf2-regulated renal proteome (108 proteins with 
reduced expression levels in Nrf2-/- mice, described here) is larger than the 
equivalent hepatic proteome (45 proteins (Walsh et al., 2014)), yet only one protein 
(Nqo1) was found to be sensitive to both inhibition and acute pharmacological 
induction of Nrf2 in the kidney (Tables 2 and 6), compared with six proteins 
(Cyp2a5, Gstm3, Gstm1, Entpd5, Udgh and Ephx1) in the liver (Walsh et al., 2014).   
The qRT-PCR data, however, shows that the expression of Nqo1, Gstm1, Gsta3, Cat, 
Nampt and Dpys are altered in response to both genetic inhibition and acute 
pharmacological induction of Nrf2 (Fig. 10), suggesting that CDDO-Me has more of 
an effect at the transcriptional level, at least within the timeframe of this study.  
Therefore, whilst this data confirms that CDDO-Me can induce Nrf2-regulated genes 
in the mouse kidney, further work is required to define its ability to augment Nrf2-
regulated proteins in this context.  
One limitation of the experimental design of this study is the use, due to technical 
limitations, of homogenised whole kidney tissues, which, taking into account the 
heterogenous nature of the cells of the kidney, could have resulted in an effective 
dilution of the effects of genetic and/or pharmacological modulation of Nrf2 in 
specific regions of the kidney.  It would therefore be of interest to use laser-capture 
microdissection to isolate specific regions of the kidney in order to examine the 
regulatory roles of Nrf2 in more detail.  Indeed, the mice themselves are a 
constitutive Nrf2-/- model, so systemic changes are also evident where they might 
not be in a renal- or proximal tubule-specific Nrf2-/- model.   
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The tissue specific activity of Nrf2 is further evidenced by examination of the 
expression profiles of proteins that were recently shown to be sensitive to genetic 
inhibition or pharmacological induction of Nrf2 in the mouse liver (Walsh et al., 
2014).  One third of these proteins were found here to be similarly regulated by 
Nrf2 in the kidney, indicating that whilst there is some overlap in the biological 
processes Nrf2 controls in discrete organs, there is clearly a degree of tissue 
specificity in its transcriptional activity.  This is exemplified by data from Yates et al 
demonstrating the differential induction of Nqo1 mRNA in various mouse tissues 
following a single 6 h exposure to CDDO-Me or its structural analogues (Yates et al., 
2007), and the data in Fig. 9.  
The exact molecular roles that some of the described proteins play in the regulation 
of different homeostatic processes in the kidney should be further explored, for 
example via siRNA knockdown in renal cells.  ChIP sequencing of Nrf2-regulated 
genes has been performed in lymphoid cells treated with sulphoraphane (Chorley 
et al., 2012), and in Nrf2-/- and Keap1-/- mouse embryonic fibroblasts (Malhotra et 
al., 2010), and whilst both studies delineate multiple novel targets of Nrf2, they did 
not use primary (nor renal) tissue, an advantage of this study.  ChIP sequencing of 
renal tissue from the Nrf2+/+ and Nrf2-/- mice, treated with CDDO-Me or vehicle, 
would complement this work  to build a full genomic, transcriptomic and proteomic 
picture of the renal regulatory roles of Nrf2. 
Several animal studies have provided evidence for the downregulation of the Nrf2 
pathway during the pathogenesis of kidney disease. Indeed, Vaziri and colleagues 
have observed a higher burden of oxidative stress and a lower level of expression of 
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Nrf2  and its target genes, linked to an increase in the level of Keap1, in rat models 
of spontaneous focal glomerulosclerosis (Kim et al., 2011), surgical nephrectomy 
(Kim et al., 2010) and tubulo-interstitial nephropathy (Aminzadeh et al., 2013a). 
Furthermore, it has been shown that aged female Nrf2-/- mice develop lupus-like 
autoimmune nephritis (Yoh et al., 2001), whilst genetic ablation of Nrf2 enhances 
sensitivity to hyperglycemia-induced renal dysfunction (Yoh et al., 2008). These 
findings imply that the dysfunction of the Nrf2 pathway, and the resulting impaired 
capacity to manage levels of oxidative stress, at least partly contributes to the 
progression of different forms of kidney disease. 
In summary, we have provided evidence that Nrf2 regulates the expression of an 
array of proteins that contribute to cell defence and the maintenance of 
homeostasis in the kidney.  These data support the current interest in Nrf2 as a 
novel therapeutic target in a number of renal diseases, and provide insight into the 
means by which Nrf2 protects against acute renal insults. 
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  Chapter 3 
Identification of novel Nrf2-regulated 
microRNAs in the mouse kidney 
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3.1 Introduction 
MicroRNAs are a recently discovered RNA-regulatory element serving to negatively 
regulate the expression of genes involved in numerous important cellular 
processes.  MicroRNAs within introns or exons of protein coding genes are 
transcribed by RNA polymerase II (Lee et al., 2004), whereas microRNAs without 
sequences in introns or exons are transcribed via RNA polymerase II or III, 
depending on the presence of the relevant promoter (Bartel, 2004; Zhou et al., 
2008; Schanen et al., 2011).  MicroRNAs may also participate in regulatory loops to 
modulate their expression; for example, miR-145 is a pro-apoptotic microRNA 
dependent on p53 activation, and this activation itself can stimulate miR-145 
expression in an apoptosis-promoting loop (Spizzo et al., 2010). 
MicroRNA profiles can be both organism-specific and tissue-specific (Starkey Lewis 
et al., 2011), leading to an interest in their use as biomarkers of physiological and 
pathological events (Waldman et al., 2008).  For example, miR-122, which is highly 
enriched in hepatocytes, has recently been described as a novel blood-based 
marker of drug-induced liver injury in mice and humans (Starkey Lewis et al., 2011). 
Multiple microRNAs have been implicated in the regulation of Nrf2 expression, 
including miR-28, which targets the 3’UTR of Nrf2 mRNA in HEK cells to prevent its 
translation (Yang et al., 2011).  Additionally, miR-144 downregulates Nrf2 protein 
levels when overexpressed in a neuronal cell line (Narasimhan et al., 2012), miR-93 
downregulates Nrf2 expression when ectopically expressed in a human breast 
epithelial cell line (Singh et al., 2013) and the induction of miR-34 results in 
decreased Nrf2 expression in HEK cells (Li et al., 2011b). 
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Ochratoxin A (OTA) nephrotoxicity results in reduced Nrf2 expression, and 
concomitantly induced ROS levels (Stachurska et al., 2013).  Further investigation 
has revealed that OTA-mediated induction of miR-132 downregulates Nrf2 
expression in porcine renal proximal tubular cells, whilst inhibition of this microRNA 
counteracts OTA toxicity (Stachurska et al., 2013).  
Research into microRNA-regulation of Nrf2 expression is ongoing (Li et al., 2011b; 
Narasimhan et al., 2012), however the exact role that Nrf2 itself plays in the 
regulation of microRNA expression is relatively unexplored.  There is data 
demonstrating the involvement of microRNAs in the regulation of antioxidant genes 
(Sangokoya et al., 2010).  The expression of DICER protein is downregulated by 
oxidative stress in rat cerebral microvascular endothelial cells (CMVECs) and human 
trophoblast JAR cells (Wiesen et al., 2009; Ungvari et al., 2013), and upregulated 
with resveratrol and sulphoraphane treatment in CMVECs (Ungvari et al., 2013).  In 
silico analysis revealed the presence of an ARE sequence in the human DICER gene 
(Ungvari et al., 2013), suggesting its expression to be modulated by redox status, 
however the functional relevance of this remains unclear, due to the non-specific 
ribonuclease role of DICER in the biogenesis of microRNA (Vermeulen et al., 2005).  
Additionally, the action of Exportin-5 is thought to be modulated by cellular redox 
status (Crampton et al., 2009), indicating that redox changes can alter the 
biogenesis of microRNAs, which themselves can alter cellular redox status via 
feedback loops (Cheng et al., 2013).   
In order to provide a detailed insight into the microRNAs that are under Nrf2 
control in the kidney, we performed an unbiased microRNA array analysis of renal 
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homogenates from Nrf2+/+ and Nrf2-/- mice treated with CDDO-Me or vehicle for   
24 h.  The data, validated by targeted qPCR analysis in an independent cohort of 
animals, reveals a novel role for Nrf2 in regulating the expression of selected 
microRNAs in the kidney, which may have utility as markers of Nrf2 pathway 
activity. 
 
 
106 
 
3.2 Methods  
Animals and dosing: Non-fasted Nrf2+/+ and Nrf2-/- mice (C57BL/6 background, 
generation and genotyping described previously (Itoh et al., 1997; McMahon et al., 
2001)) of 10-12 weeks of age were used throughout the study, which was 
conducted according to the Animals (Scientific Procedures) Act 1986 and University 
of Liverpool local guidelines. Mice were housed at 19-23 °C on a 12 hour light/dark 
cycle, and given free access to food and water.  For microarray and targeted PCR 
analysis of the primary cohort, five male mice of each genotype were administered 
a single intraperitoneal (i.p.) dose of vehicle (DMSO, 100 µL/mouse) or CDDO-Me (3 
mg/kg), and sacrificed 24 h later by exposure to a rising concentration of CO2 
followed by cardiac puncture. The renal capsule and fat were removed from excised 
kidneys, which were snap-frozen, along with other organs, and stored at -80 °C.  
Five samples per treatment group ((Nrf2+/+ + DMSO,   Nrf2-/- + DMSO, Nrf2+/+ + 
CDDO-Me and Nrf2-/- + CDDO-Me) were generated.  For the second cohort, six 
untreated female mice of each genotype were sacrificed as previously described 
and relevant organs snap-frozen and stored at -80 oC. 
Reagents: Unless indicated, all reagents were purchased from Sigma Aldrich (UK). 
Sample preparation for immunoblotting: Frozen kidneys were cut in half, and 
prepared in iTRAQ buffer, with immunoblotting performed using conditions 
described in Chapter 2.  Primary antibodies (Abcam: Nqo1 (ab2346) and β-actin 
(ab6276), and secondary antibodies (the appropriate peroxidase-conjugated 
antibodies) were used as previously described, with immunoblot densitometry 
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performed using Quantity One 1D Analysis Software (BioRad), normalising to actin 
expression. 
RNA isolation: Kidney RNA was isolated using the mirVana microRNA isolation kit 
(Life Technologies, UK).  Frozen kidneys were cut in half, and wash solutions were 
prepared by adding the appropriate volumes of EtOH as per the manufacturer’s 
instructions.  Samples were weighed, and homogenised in 10 volumes of 
lysis/binding buffer (i.e. sample weight 30 mg, lysis/binding buffer 300 μL).  The 
homogenate was supplemented with 1/10 lysate volume (i.e. 30 μL) of miRNA 
homogenate additive, and kept on ice for 10 minutes.   The same volume of acid-
phenol:chloroform as lysis/binding buffer (i.e. 300 μL) was added, and the sample 
vortexed for 60 seconds.  The sample was then centrifuged at 10,000 x g for 5 
minutes at room temperature.  The aqueous, upper phase was removed from each 
sample to a new microcentrifuge tube.  Room temperature EtOH was added to the 
sample (1.25 volumes, i.e. 375 μL) which was then dispensed into a filter cartridge 
loaded onto a collection tube.  The tubes were centrifuged at 10,000 x g for 15 
seconds, and flow-through discarded.  700 μL of miRNA Wash Solution 1 (working 
solution) was added to the filter compartment of the filter-collection tube, and the 
tubes centrifuged at 10,000 x g for 10 seconds, with the flow-through being 
discarded.  Subsequently, samples were washed twice, each time adding 500 μL 
miRNA Wash Solution 2/3 (working solution) to the filter compartment, 
centrifuging at 10,000 x g for 10 seconds and discarding the flow through.  Samples 
were centrifuged at 10,000 x g for one minute to remove any residual fluid from the 
filter cartridges, which were then transferred to fresh, labelled collection tubes.  40 
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μL of 95 oC dH2O was applied to the filter, and the filter-collection tubes were 
centrifuged at maximum speed for 30 seconds to elute total RNA containing 
microRNAs.   
RNA quality assessment: RNA quality was assessed using an RNA 600 Nano Kit and 
2100 Bioanalyzer (Agilent), as previously described in Chapter 2.  Only samples with 
a RIN of >6.5 (n=4 per treatment group) were utilised for the microRNA array. 
Sample preparation for microRNA array: Samples were prepared for hybridisation 
to mouse miRNA Microarray System (Agilent, with miRNA Complete Labelling and 
Hybridisation Kit) at the Centre for Genome Research, University of Liverpool.  100 
ng of total RNA was used as the input; and processed according to the 
manufacturer’s instructions.  Briefly, both spike-in controls were prepared as 
specified.  100 ng of RNA (in 2 μL) was added to a 1.5 mL microcentrifuge tube on 
ice.  A Calf Intestinal Alkaline Phosphatase (CIP) master mix was prepared, using 0.4 
μL 10X Calf Intestinal Phosphatase Buffer, 1.1 μL diluted Labelling Spike-In Solution 
and 0.5 μL Calf Intestinal Phosphatase per reaction.  2 μL of this master mix was 
added to the 1.5 mL microcentrifuge tube containing the RNA, and gently mixed.  
The sample was then dephosphorylated at 37 oC for 30 minutes.  To denature 
samples, 2.8 μL DMSO was added, and samples were incubated at 100 oC for 7 
minutes.  Samples were immediately transferred to an ice-water bath.   
A ligation master mix was prepared, using 1 μL 10X T4 RNA Ligase Buffer, 3 μL 
Cyanine3-pCp and 0.5 μL T4 RNA Ligase per reaction.  4.5 μL ligation master mix 
was added to each sample tube, gently mixed and incubated at 16 oC for 2 hours.  
Labelled RNA was purified (i.e. DMSO and free Cyanine3-pCp removed) using Micro 
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Bio-Spin 6 columns (Bio-Rad, UK).  Following spin column preparation,   38.7 μL of 
RNase-free dH2O was added to the labelled sample.  The sample was pipetted onto 
the prepared spin column gel bed.  The microcentrifuge tubes containing the spin 
columns were then centrifuged for 4 minutes at 1000 x g.  The columns were 
discarded, and the flow-through kept on ice.  The sample was subsequently dried 
by centrifugation under a vacuum (SpeedVac, Eppendorf) for approximately 1 hour.  
Following 10X blocking agent preparation (125 μL H2O added and mixed), the dried 
samples were resuspended in 17 μL dH2O.  1 μL diluted Hyb Spike-In Solution was 
added to each sample, followed by 4.5 μL 10X blocking agent and 22.5 μL 2X Hi-
RPM Hybridisation Buffer and the samples were gently vortexed.  Samples were 
incubated at 100 oC for 5 minutes, and transferred to a ice water bath for 5 
minutes.  Samples were subsequently centrifuged at < 1500 RPM for 20 seconds, 
and the hybridisation assembly prepared. 
microRNA array hybridisation and analysis: The miRNA system microarray slides 
were prepared according to the manufacturer’s instructions at the Centre for 
Genome Research, University of Liverpool.  Eight samples per slide were loaded 
onto prepared arrays, and hybridised at 55 oC for 20 hours at 20 RPM in a 
hybridisation oven (Agilent, US).  Following hybridisation, the microarray slides 
were washed using the appropriate wash buffers.  The slides were removed from 
the hybridisation chamber, placed into the slide rack and submerged in Gene 
Expression Buffer 1 at room temperature for 5 minutes with constant mixing.  The 
slides were subsequently removed and submerged in Gene Expression Buffer 2 at 
37 oC for 5 minutes, again with constant mixing.  Slides were inserted into Agilent 
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slide holders, and read immediately using an Agilent G2505C Microarray Scanner at 
a resolution of 3 μm.  Data was extracted using Agilent Feature Extraction software 
v11.0.1.1.  Differential microRNA expression analysis was conducted using the 
limma package within the R programming environment (R-Programming-
Environment, 2005), enabling simultaneous analysis across multiple treatments and 
experiments.  Raw P values were corrected for the impact of multiple comparisons 
using the Benjamini-Hochberg procedure, and resultant FDR-adjusted P values were 
used to compare microRNA expression across the relevant groups (Nrf2+/+ + DMSO 
v Nrf2-/- + DMSO, and Nrf2+/+ + DMSO v Nrf2+/+ + CDDO-Me).  MicroRNAs detected 
in at least 3/5 samples per treatment group are reported. 
Reverse-transcription of total RNA: Reverse-transcription of total RNA to cDNA 
containing reverse-transcribed microRNAs was accomplished using the miScript II 
RT kit (Qiagen, UK).  0.5 μg total RNA (quantified using NanoDrop ND-1000 
(Labtech, UK)) was added to each reaction well, with dH2O added to make a total 
volume of 12 μL.  8 μL of a reverse transcription master mix (containing 4 μL 5x 
miScript HiFlex buffer, 2 μL 10x nucleics mix and 2 μL reverse transcriptase mix per 
sample) was added, mixing gently.  The plate was centrifuged at < 1600 RPM for 20 
seconds, and incubated at 37 oC for 60 minutes, followed by 95 oC for 5 minutes.  
Resultant cDNA samples were diluted by the addition of 140 μL of dH2O. 
qRT-PCR for Nqo1 mRNA: Primers (Table 1) were purchased from EuroFins 
(Luxembourg).  Primers were diluted to a working concentration of 10 μM.  Power 
SYBR Green (Life Technologies, UK) was used for qRT-PCR.  A master mix was 
constructed (10 μL SYBR Green, 2 μL sense primer, 2 μL antisense primer, 4 μL dH2O 
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per sample) and 18 μL added to the appropriate well of a 96-well PCR plate (Starlab, 
UK) in duplicate.  2 μL cDNA was added, and the plate centrifuged for 20 seconds at 
<1500 RPM.  PCR was performed using the ABI Prism 7000 Sequence Detection 
system (Applied Biosystems), for 1 cycle at 95 oC for 2 minutes, followed by 40 
cycles of 95 oC for 15 seconds and 60 oC for 1 minute, and then a dissociation curve 
of 95 oC for 1 minute, 65 oC for 2 minutes, 95 oC to 65oC at 2 oC/minute.  Resultant 
Nqo1 CT values were normalised to Gapdh expression. 
 
Mouse Gapdh Sense 5’-TGTCCGTCGTGGATCTGAC-3’ 
Antisense 5’-CCTGCTTCACCACCTTCTTG-3’ 
Mouse Nqo1 Sense 5’-AGCGTTCGGTATTACGATCC-3’ 
Antisense 5’-AGTACAATCAGGGCTCTTCTCG-3’ 
Table 1: qRT-PCR primer sequences for Gapdh and Nqo1. 
 
qRT-PCR for microRNAs:  Primers for microRNAs were purchased from Life 
Technologies (UK), based on their reported FASTA sequences (detailed in Table 2) 
from miRBase (www.mirbase.org, version 21).  Primers were diluted to a working 
concentration of 10 μM.  miScript SYBR Green PCR kit (Qiagen, UK) was used for 
qRT-PCR.  A master mix was constructed (10 μL SYBR Green, 2 μL microRNA primer, 
2 μL universal primer, 4 μL dH2O per sample), and 18 μL was added to the 
appropriate well of a 96-well PCR plate (Starlab, UK) in duplicate.  2 μL cDNA was 
then added, and the plate centrifuged for 20 seconds at < 1500 RPM.  PCR was 
performed using the ABI Prism 7000 Sequence Detection system (Applied 
Biosystems), for 1 cycle at 94 oC for 10 minutes, followed by 40 cycles of 94 oC for 
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15 seconds, 55 oC for 30 seconds and 70 oC for 34 seconds.  A dissociation curve (95 
oC for 1 minute, 65 oC for 2 minutes, 95 oC to 65oC at 2 oC/minute) was also 
performed.  Resultant values were normalised to U6 snRNA (Corney et al., 2007; 
Lee et al., 2012c).   
Primer Sequence 
U6 snRNA TGGCCCCTGCGCAAGGATG 
miR-28c AGGAGCTCACAGTCTATTGA 
miR-34b AGGCAGTGTAATTAGCTGATTGT 
miR-144 GGATATCATCATATACTGTAAGT 
miR-146a TGAGAACTGAATTCCATGGGTT 
miR-207 GCTTCTCCTGGCTCTCCTCCCTC 
miR-466f-3p CATACACACACACATACACAC 
miR-466h-3p TACGCACGCACACACACAC 
miR-574-3p CACGCTCATGCACACACCCACA 
miR-669p-3p CATAACATACACACACACACGTAT 
miR-1187 TATGTGTGTGTGTATGTGTGTAA 
miR-3082 GACAGAGTGTGTGTGTCTGTGT 
 
Table 2: qRT-PCR primer sequences for the indicated microRNAs.  The sequence of 
the universal microRNA primer provided by Qiagen is proprietary information. 
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3.3 Results 
3.3.1 Genetic and pharmacological modulation of Nrf2 in the mouse 
kidney 
Given that Nqo1 was found to be the most sensitive marker of renal Nrf2 activity in 
the experiments described in Chapter 2, to verify that the Nrf2 pathway was 
functional in the kidneys of Nrf2+/+ mice and non-functional in Nrf2-/- mice, prior to 
conducting microarray and targeted qRT-PCR microRNA analysis, we determined 
the expression level of Nqo1 in kidney homogenates from the animals by 
immunoblotting and qRT-PCR.  The level of Nqo1 protein (Fig. 1A-B) and mRNA (Fig. 
1C) was  significantly lower in the kidneys of vehicle-exposed Nrf2-/- mice, 
compared with Nrf2+/+ counterparts, consistent with loss of Nrf2 function. 
Moreover, whilst CDDO-Me provoked the induction of Nqo1 24 h after 
administration to Nrf2+/+ mice, this effect was abrogated in Nrf2-/- mice (Fig. 1A-C), 
validating our model of genetic and pharmacological modulation of Nrf2 in the 
mouse kidney. 
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Fig. 1: Differential activity of Nrf2 in the kidneys of Nrf2
+/+
 and Nrf2
-/-
 mice.  Mice of the indicated 
genotype were given a single acute i.p. dose of vehicle (DMSO) or CDDO-Me (3 mg/kg).  24 h later, 
Nqo1 levels were determined by (A-B) immunoblotting and (C) qPCR.  (B) Band volumes were 
quantified by densitometry and normalised against β-actin.  (C) Nqo1 mRNA levels were normalised 
to Gapdh.  Data represent mean + S.D. of n=5 animals per treatment group.  Statistical analysis was 
performed with an unpaired T test, ** P ≤0.01; *** P ≤ 0.001; N.S. not-significant.  
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3.3.2 Regulation of microRNAs by Nrf2 in the mouse kidney 
To provide a detailed insight into the microRNAs controlled by Nrf2 in the kidney at 
both the basal and inducible levels, a microRNA array was performed on total RNA 
extracted from Nrf2+/+ and Nrf2-/- mice, treated with 3 mg/kg CDDO-Me or the 
vehicle DMSO for 24 h.  Of the 1247 microRNAs for which probes were present on 
the microarray slides, 427 were detected in the mouse kidney samples.  Of these, 
50 microRNAs had significantly altered expression in the kidneys of Nrf2-/- mice, 
compared to Nrf2+/+ counterparts (Supplementary Table 1) and 116 had 
significantly altered expression in the kidneys of CDDO-Me treated Nrf2+/+ mice 
(Supplementary Table 2), compared to those treated with vehicle (Fig. 2).  23 
microRNA species were found to be significantly changed in both Nrf2-/- and Nrf2+/+ 
+ CDDO-Me kidneys (Table 3), with 2 microRNA species (miR-146a-5p and miR-342-
3p) both upregulated in Nrf2-/- and downregulated in Nrf2+/+ + CDDO-Me mouse 
kidneys.  No microRNA species were both significantly downregulated in Nrf2-/- and 
upregulated in CDDO-Me treated Nrf2+/+ mouse kidney.   
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Fig. 2: Volcano plots displaying differentially expressed microRNAs in (A) the 
kidneys of Nrf2-/- mice, compared to Nrf2+/+, and (B) the kidneys of Nrf2+/+ mice 
treated with 3 mg/kg CDDO-Me.  microRNAs differentially expressed with a P value 
of ≤0.05 (red) are reported in Supplementary Tables 1 and 2.  
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microRNA ID 
Nrf2-/- vs. Nrf2+/+ CDDO-Me vs. vehicle 
Fold change P value Fold change P value 
miR-146a-5p 1.164 0.001 0.878 0.002 
miR-15a-5p 0.916 0.047 0.889 0.007 
miR-181b-5p 0.909 0.019 0.897 0.005 
miR-195a-5p 0.923 0.048 0.862 0.001 
miR-196a-5p 0.886 0.020 0.855 0.002 
miR-196b-5p 0.857 0.002 0.877 0.004 
miR-203-3p 0.827 0.029 0.837 0.027 
miR-20b-5p 0.913 0.048 0.892 0.010 
miR-211-3p 1.305 0.014 1.239 0.029 
miR-26b-5p 0.909 0.030 0.863 0.001 
miR-2861 1.296 0.019 1.366 0.004 
miR-296-5p 1.101 0.032 1.085 0.046 
miR-29c-5p 0.910 0.017 0.919 0.020 
miR-301a-3p 0.894 0.024 0.849 0.001 
miR-3102-5p 1.282 0.007 1.272 0.005 
miR-322-5p 0.867 0.008 0.874 0.007 
miR-335-5p 0.841 0.005 0.879 0.019 
miR-342-3p 1.180 0.001 0.916 0.042 
miR-3960 1.468 0.016 1.480 0.009 
miR-455-5p 0.830 0.003 0.812 0.001 
miR-5126 1.296 0.016 1.472 0.001 
miR-690 0.902 0.038 0.812 <0.001 
miR-9-5p 0.920 0.022 0.745 <0.001 
 
Table 3: MicroRNA species differentially expressed as a result of both genetic 
inhibition (Nrf2-/-) and pharmacological induction (CDDO-Me) of Nrf2 in the mouse 
kidney (P ≤ 0.05, n=5). 
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3.3.3 qRT-PCR validation of Nrf2-regulated microRNAs 
Of the 23 microRNA species detailed in Table 3, miR-146a was chosen for targeted 
qRT-PCR validation of its sensitivity to changes in Nrf2 activity, utilising the 
knowledge that it has previously been shown to downregulate NF-κB (Taganov et 
al., 2006).  The remaining 21 microRNA species were either upregulated or 
downregulated in response to both genetic and pharmacological modulation of 
Nrf2, respectively, and as such are not good candidates as markers of Nrf2 activity.  
Therefore, based on the reported data in Supplementary Tables 1 and 2, further 
microRNA species were chosen for targeted qRT-PCR validation of their sensitivity 
to changes in Nrf2 activity.   
MiR-466h-3p (Hunsberger et al., 2012), 574-3p (Alvarez-Mora et al., 2013) and 1187 
(Yu et al., 2012) were significantly upregulated in Nrf2+/+ mice treated with CDDO-
Me, and were chosen based on their reported involvement in cellular stress 
responses.  MiR-34b was significantly downregulated in the CDDO-Me treated 
Nrf2+/+ mouse  kidney, and is involved in cancer signalling suppression and stress 
responses (He et al., 2007; Yamakuchi et al., 2008).  miR-28c was also significantly 
downregulated in the CDDO-Me treated Nrf2-/- mouse kidney, as was miR-144, and 
both are reported to negatively regulate Nrf2 expression (Sangokoya et al., 2010; 
Yang et al., 2011).  MiR-3082 was chosen as a result of its relatively large increase in 
expression in the CDDO-Me treated mouse kidney, compared to the vehicle 
treated.  MiR-466f-3p and miR-669p-3p expression was significantly increased in 
the CDDO-Me treated Nrf2+/+ mouse kidney compared with the vehicle 
(Supplementary Table 2), and was decreased in the Nrf2-/- mouse kidney compared 
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with the Nrf2+/+, but not significantly (P>0.05).  Finally, miR-207 was chosen for 
targeted analysis because its expression was increased in the CDDO-Me treated 
mouse kidney, and decreased in the Nrf2-/- mouse kidney, compared to controls, 
but not significantly (P = 0.08 and 0.06, respectively).  Total RNA was extracted from 
kidney homogenates of Nrf2+/+ and Nrf2-/- mice, exposed to vehicle or CDDO-Me for 
24 hours.  This was evaluated for quality, and reverse-transcribed to cDNA for 
quantification by real-time PCR (Fig. 3).   
MiR-28c expression was significantly reduced in the CDDO-Me treated Nrf2+/+ 
mouse kidney (Fig. 3), in agreement with the microRNA array data (Supplementary 
Table 2).  Furthermore, the expression of miR-28c in the kidneys of Nrf2-/- mice 
treated with CDDO-Me was not different from the vehicle-treated Nrf2-/- mice, 
suggesting this microRNA species to be regulated by Nrf2.  MiR-34b was 
significantly upregulated in the Nrf2-/- mouse kidney, again consistent with the 
microRNA array data (Supplementary Table 1).  The expression of both miR-144 and 
miR-146a was significantly increased in the Nrf2-/- mouse kidney, but no significant 
difference in expression was found in the CDDO-Me treated Nrf2+/+ mouse kidney.  
MiR-466h expression was upregulated in the CDDO-Me treated mouse kidney, in 
agreement with the microRNA array data (Supplementary Table 2), and this 
targeted analysis also revealed its expression to be downregulated in the Nrf2-/- 
mouse kidney (the microRNA array data also showed this, but the difference was 
not significant).  The expression of miR-574-3p was significantly increased in the 
kidneys of CDDO-Me treated Nrf2+/+ mice (Fig. 3), consistent with the microRNA 
array data (Supplementary Table 2).  The expression of miR-574-3p was also 
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significantly induced in the kidneys of Nrf2-/- mice treated with CDDO-Me, 
significantly different from the vehicle-treated Nrf2-/- mouse kidney, indicative that 
this microRNA species may not be under the regulation of Nrf2; rather that it 
responds to an off-target effect of CDDO-Me signalling.   
MiR-1187 expression was not significantly altered in the qPCR (Fig. 3) however it 
does appear that the expression of this microRNA is reduced somewhat in the   
Nrf2-/- mouse kidney (Fig. 3).  The expression of miR-3082 was significantly reduced 
in the Nrf2-/- mouse kidney (Fig. 3), and there was no significant difference in 
expression in the CDDO-Me treated Nrf2+/+ mouse kidney, which was not consistent 
with the microRNA array data (Supplementary Table 2).  The expression of miR-
466f-3p, miR-207 and miR-669p-3p was not significantly altered in the qPCR (Fig. 3), 
demonstrating the robustness of the microRNA array data (Fig. 2).  On the whole, 
the microRNA array data was in agreement with the targetted qRT-PCR analysis, 
validating the altered expression of the selected microRNA species in response to 
modulation of Nrf2 activity in the mouse kidney.  
 
 
121 
 
 Fig. 3: microRNA species differentially expressed following modulation of Nrf2 activity in the mouse kidney.  qRT-PCR was performed on cDNA derived from mouse kidney.  Data represents 
mean and S.D. of n=5 animals per treatment group.  Data is normalised to Nrf2
+/+
 + vehicle.  Statistical analysis was performed with an unpaired T test, * P ≤ 0.05, ** P ≤ 0.01, n=5.
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3.3.4 Further validation of selected microRNA responses to 
modulation of Nrf2 in the female mouse kidney 
In order to further validate the differential expression of the panel of microRNAs in 
response to modulation of Nrf2, a second cohort of animals (female Nrf2+/+ and 
Nrf2-/- mice) were chosen, their kidneys harvested and RNA isolated and reverse-
transcribed as before.  Fig. 4 confirms their genotyping through measurement of 
Nqo1 expression at protein and mRNA levels, as previously described for the data 
presented in Fig. 2.  The level of Nqo1 protein (Fig. 4A-B) and mRNA (Fig. 4C) was  
significantly lower in the kidneys of female Nrf2-/- mice, compared with Nrf2+/+ 
counterparts, consistent with loss of Nrf2 function. 
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Fig. 4: Differential expression of the Nrf2 target gene Nqo1 in the kidneys of female Nrf2
+/+
 and Nrf2
-
/-
 mice.  Nqo1 levels were determined by (A-B) immunoblotting and (C) qPCR.  (B) Band volumes 
were quantified by densitometry and normalised against β-actin.  (C) Nqo1 mRNA levels were 
normalised to Gapdh.  Data represent mean + S.D. of n=6 animals per treatment group.  Statistical 
analysis was performed with an unpaired T test, ** P ≤0.01; *** P ≤ 0.001. 
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qPCR analysis of the selected microRNA species in female mouse kidneys (Fig. 5) 
showed excellent agreement with both the microRNA array (Table 3) and targeted 
qPCR (Fig. 3) analysis of male mouse kidneys.  miR-466h and miR-3082 expression 
were significantly reduced in the female Nrf2-/- mouse kidney, as in the male cohort, 
and the expression of miR-144 and 34b was significantly increased in the female 
Nrf2-/- mouse kidney.  The renal expression of miR-207, miR-466f-3p and 669p-3p 
did not change significantly in response to genetic inhibition of Nrf2 (Fig. 5), 
consistent with the targeted PCR analysis of the male cohort (Fig. 3).  The 
expression of miR-574-3p and miR-1187 was significantly upregulated and 
downregulated, respectively, in the female Nrf2-/- mouse kidney (Fig. 5), despite 
there being no change in expression in the male cohort (Fig. 3).  miR-28c expression 
was significantly increased in the female Nrf2-/- mouse kidney (Fig. 5), whereas 
there is no discernible difference in the male cohort; suggesting that the change in 
miR-28c expression is subtle, or gender specific.  miR-146a expression was 
significantly upregulated in the female Nrf2-/- mouse cohort, as in the male cohort.  
This data validates a number of microRNAs than can be used in further 
experimentation to determine their value as novel markers of Nrf2 activity. 
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Fig. 5: microRNA species differentially expressed in the female Nrf2-/- mouse kidney.  qRT-PCR was performed on cDNA derived from mouse 
kidney.  Data represents mean and S.D of n=6 per group, and are normalised to Nrf2+/+.  Statistical analysis was performed with an unpaired T 
test, * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001. 
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3.4 Discussion 
The transcription factor Nrf2 regulates the expression of multiple defence 
processes to combat cellular stress (Bryan et al., 2013).  Genes and proteins under 
Nrf2 control in the kidney have been detailed in Chapter 2, and whilst previous 
work has identified microRNAs that regulate Nrf2 expression, there is a lack of 
information on microRNAs regulated by Nrf2 itself.  This unbiased analysis of renal 
microRNAs that are altered in response to genetic and pharmacological 
manipulation of Nrf2 represents the first step into fully characterising the renal 
microRNA-ome, which could reveal novel mechanisms of Nrf2 function and markers 
of its activity.   
MicroRNAs enable cells to ‘fine-tune’ translation, and as such changes in microRNA 
expression are likely to be slight.  Nevertheless, the findings of this study 
demonstrate that following manipulation of Nrf2 in the mouse kidney, the 
expression of several microRNAs is significantly altered.   
MiR-466h is a promising candidate marker of Nrf2 activity in the kidney, being 
significantly decreased following genetic inhibition of Nrf2, and significantly 
increased following pharmacological induction of the transcription factor in the 
microRNA array and targeted qPCR data (Table 3, Fig. 3 and 5).  MiR-466h is 
involved in the oxidative stress response, being upregulated following cerebral 
ischaemia in rats (Hunsberger et al., 2012), which is consistent with an increase in 
Nrf2 expression to combat ischaemia-induced ROS generation.  MiR-466h has been 
shown to have a pro-apoptotic role in ovarian cells in vitro (Druz et al., 2011) and 
cerebral ischaemia in vivo (Hunsberger et al., 2012), suggesting that regulation of 
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miR-466h is more complex than simply being a marker of Nrf2 activity.   MiR-466h 
has been described as being upregulated following glucose depletion (Druz et al., 
2012), which, taken with the findings of Chapter 2, that proteins involved in energy 
homeostasis (namely those in the glycolytic and pentose phosphate pathway) are 
expressed at a lower level in the Nrf2-/- mouse kidney compared to the Nrf2+/+ (Fig. 
2) it appears that miR-466h, whilst being predictive of Nrf2 activity, also is a marker 
of the glycolytic state of the cell. To better determine the correlation of miR-466h 
with Nrf2 activity, an enzyme-linked immunosorbent assay could be performed, 
linking miR-466h levels with those of Nrf2-regulated proteins defined in Chapter 2.  
It would also be of interest to use antagomiRs to modulate the level/activity of miR-
466h and better define a link between the expression of this microRNA and energy 
metabolism. Nevertheless, in mouse renal tissue, from the panel of microRNAs 
selected, miR-466h correlates best with the changes in Nrf2 expression, and as such 
is a standout candidate for further investigation as a potential marker of Nrf2 
activity in relevant biological matrices.   
Another strong candidate for use as a marker of Nrf2 activity is miR-28c.  Displaying 
the opposite expression pattern to miR-466h (significantly upregulated in the Nrf2-/- 
mouse kidney, significantly downregulated in the CDDO-Me treated Nrf2+/+ mouse 
kidney (Fig. 3 and 5)), miR-28c has previously been shown to regulate Nrf2 
expression in breast epithelial cells, in a Keap1-independent manner (Yang et al., 
2011), with miR-28c expression correlating inversely to Nrf2 expression.  Indeed, 
ectopic expression of miR-28 reduces Nrf2 mRNA and protein expression, whilst 
removing the miR-28 targeting seed sequence in the 3’UTR of the Nrf2 gene 
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abrogates the effect of miR-28 (Yang et al., 2011).  MiR-28 expression is markedly 
decreased in renal cell carcinoma (Wang et al., 2015a), a cancer previously 
described in this thesis as associated with an increase in Nrf2 activity (Chapter 1, 
Section 1.4.3, (Adam et al., 2011; Ooi et al., 2011; Ooi et al., 2013)).  Here we have 
demonstrated that miR-28c expression is modulated following pharmacological and 
genetic manipulation of Nrf2 in the mouse kidney.  These observations are 
consistent with a role for miR-28c in the mechanism of action of CDDO-Me as an 
inducer of Nrf2 although further work is needed to test this directly.   
The microRNA array data shows miR-144 to be significantly reduced in the kidneys 
of CDDO-Me treated Nrf2+/+ mice, compared to the vehicle.  Targeted analysis of 
miR-144 expression using qPCR demonstrated less obvious changes following 
CDDO-Me administration (Fig.3), however miR-144 was shown to be upregulated in 
the Nrf2-/- mouse kidney, compared to Nrf2+/+ in the microRNA array and qPCR data 
(Fig. 3 and 5).   MiR-144 has been characterised elsewhere as a negative regulator 
of Nrf2 in erythrocytes (Sangokoya et al., 2010), with sickle cell leukaemia patients 
having high expression of miR-144, and a reduced tolerance for oxidative stress 
(Sangokoya et al., 2010).  Two distinct targeting sites for miR-144 exist in the 3’UTR 
of Nrf2 mRNA (Sangokoya et al., 2010), suggestive of its role in negatively regulating 
Nrf2.  However, as with miR-28, we found that expression of miR-144 was increased 
in the Nrf2-/- mouse kidney, suggestive of a feedback loop. 
The expression of both miR-28c and miR-144 are induced in the Nrf2-/- mouse 
kidney, compared to the Nrf2+/+, and reduced in the CDDO-Me treated Nrf2+/+ 
mouse kidney, compared to the vehicle.  This could potentially be a mechanism for 
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controlling the strength and/or duration of Nrf2 activation in response to 
pharmacological stimulation, and they could contribute toward the regulation of 
Nrf2 target genes (Fig. 6).  Further work to ensure the validity of this novel axis 
could involve determining if CDDO-Me treatment can induce Nrf2 in the presence 
of a miR-28c antagonist, to define the contribution of miR-28c to Nrf2 signalling.   
  
Fig. 6: Schematic overview of the postulated relationship between the Nrf2 inducer CDDO-
Me, miR-28c, miR-144 and Nrf2.  An increase in Nrf2 activity following CDDO-Me 
administration is accompanied by a decrease in miR-28c and miR-144 expression, and a 
corresponding decrease in the ability of these microRNA species to translationally repress 
Nrf2 mRNA (determined in (Yang et al., 2011)). 
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Decreased expression of miR-574-3p has been associated with the progression of 
both gastric (Su et al., 2012) and bladder cancer (Tatarano et al., 2012).  Functional 
studies indicate that miR-574-3p overexpression inhibits the metastatic capabilities 
of gastric cancer cells (Su et al., 2012), and recent research has suggested a role for 
this microRNA species in oxidative stress, as it is significantly downregulated in 
patients with Fragile X syndrome (Alvarez-Mora et al., 2013).  The microRNA array 
data indicates significant changes in the expression of miR-574-3p following genetic 
inhibition and pharmacological activation of Nrf2 (Table 3), however the qPCR data 
is less convincing; the only significant difference in expression of miR-574-3p was 
between CDDO-Me and vehicle treated kidneys of both Nrf2+/+ and Nrf2-/- mice (Fig. 
3).  Since this work was performed, research has been published describing miR-
574-3p as a genotoxic stress-responsive microRNA, with expression of both Nrf2 
(Xing et al., 2012) and miR-574 induced following X-Ray irradiation (the latter in the 
A549 lung cancer cell line (Ishikawa et al., 2014)).  However, the Nrf2 inducer 
curcumin was found to decrease the expression of miR-574-3p in a nasal 
pharyngeal carcinoma cell line (Gao et al., 2014), in contrast to our observation that 
miR-574-3p is induced in the kidneys of CDDO-Me treated mice.  As previously 
mentioned, microRNA expression profiles differ between organs, and expression 
profiles of microRNAs change dramatically in cancers (Su et al., 2012).  Further work 
would involve the use of a larger number of Nrf2+/+ and Nrf2-/- animals, treated with 
CDDO-Me or other Nrf2 inducers, in order to fully determine the response of miR-
574-3p to changes in renal Nrf2 activity. 
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The miR-34 family are induced by p53 in response to DNA damage or stress (He et 
al., 2007), and direct the depletion of cell cycle proteins (He et al., 2007; Yamakuchi 
et al., 2008), promoting apoptosis.  The miR-34 family are also deregulated in 
cancer (Wang et al., 2014), but not consistently, for example in hepatocellular 
carcinoma miR-34a has been shown to be both upregulated (Pineau et al., 2010; 
Wang et al., 2014) and downregulated (Li et al., 2009; Dang et al., 2013).   MiR-34b 
expression was shown here, for the first time, to be induced in the Nrf2-/-, 
compared with the Nrf2+/+ mouse kidney in the microRNA array and qPCR data 
(Table 3, Fig. 3 and 5), consistent with the notion that this microRNA family are 
induced in situations where cells or tissues may experience different types of stress 
(He et al., 2007).  The induction of miR-34b in the Nrf2-/- mouse kidney may reflect a 
capacity of this microRNA to determine disease states.  As a marker of Nrf2, the 
miR-34 family may not be the most useful, as it lacks a direct correlation with Nrf2 
levels, and it appears that miR-34 deregulation is common in situations where Nrf2 
may not necessarily be involved. 
The expression of miR-146a has been determined elsewhere to negatively regulate 
the activation of NF-κB (Saba et al., 2014).  The data presented in Fig. 3 and 5 show 
a significant increase in miR-146a expression in the Nrf2-/- mouse (Fig. 3 and 5).  
Nrf2-/- mice have an exaggerated Nf-κB response following scratch injury-induced 
stress (Pan et al., 2012), which suggests that this microRNA is upregulated in 
response to an increase in NF-κB activity (ostensibly to combat this upregulation of 
NF-κB signalling), and as such is a good marker of NF-κB signalling, rather than Nrf2.  
The data presented in Fig. 3 shows a lack of significant downregulation of miR-146a 
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in the CDDO-Me treated Nrf2+/+ mouse kidney, suggesting that this microRNA is not 
regulated directly by Nrf2. 
MiR-207 expression was not significantly altered in either cohort (Fig. 3 and 5), 
indicative of the robustness of the data.  MiR-207 has been shown to be 
upregulated following exposure to ionising radiation (Tan et al., 2014), enhancing 
apoptosis in cochlear hair cells (Tan et al., 2014).  The upregulation of Nrf2 
following ionising radiation has been characterised (McDonald et al., 2010), so 
perhaps there is a link between miR-207 and Nrf2 which may be more evident in a 
different cell type. 
MiR-1187, which represses Caspase 8 (Yu et al., 2012), has been described 
elsewhere to be significantly downregulated in mice with acute liver failure, 
contributing to the induction of hepatic apoptosis (Yu et al., 2012).  The microRNA 
array data (Supplementary Table 2) showed that miR-1187 expression was 
significantly increased in CDDO-Me treated Nrf2+/+ mice, compared to the vehicle, 
and in the female mouse cohort miR-1187 was significantly reduced in the Nrf2-/- 
mouse kidney, compared to the Nrf2+/+ (Fig. 5).  Further work to determine the 
contribution of this microRNA species toward the enhanced propensity for hepatic 
injury in the Nrf2-/- mouse (Enomoto et al., 2001) could be examined through the 
use of microRNA mimics.  
Due to the relatively recent discovery of microRNAs, not every species has been 
‘assigned’ a particular role to date.  miR-3082 was chosen here as part of the panel 
for targeted qPCR validation because of the relatively large increase in its 
expression in the CDDO-Me treated Nrf2+/+ mouse kidney, compared to the vehicle 
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(Supplementary Table 2).  There is a target sequence for miR-3082 in the Keap1 
gene (www.targetscan.org, v6.2).  Therefore the upregulation of miR-3082 in 
response to CDDO-Me could downregulate the translation of Keap1, contributing to 
the activation of Nrf2 signalling.  MiR-669p-3p was chosen as in the microarray data 
it was significantly upregulated in the CDDO-Me treated Nrf2+/+ mouse kidney 
(Supplementary Table 2), however a biological function for this microRNA has yet to 
be determined.  There is some suggestion that miR-466f-3p, which was found to be 
increased in the CDDO-Me treated Nrf2+/+ mouse kidney compared to the vehicle 
(Supplementary Table 2), assists in cell cycle control in bone marrow stem cells 
(Gong et al., 2014), however further information is lacking.  Indeed, more recently 
discovered microRNAs are still being functionally characterised through use of 
mimics and antagomiRs, and so the full implications of the data described here are 
currently unknown. 
Previous work by a different group described the expression of miR-27 as being 
decreased following low micromolar CDDO-Me stimulation in 3 diffferent 
pancreatic cancer cell lines (Jutooru et al., 2010).  However, here miR-27 expression 
was not significantly altered in Nrf2-/- compared with Nrf2+/+ mouse kidney, or in 
CDDO-Me compared with vehicle-treated Nrf2+/+ mouse kidney.  It is possible that 
miR-27 expression may be tissue-specific, or only expressed in certain types of 
cancer.  Additionally, miR-27 may simply be increased in response to relatively high 
concentrations of CDDO-Me which are known to induce apoptosis (Chapter 4), 
rather than as a consequence of Nrf2 activation (which is seemingly the case with 
miR-574-3p, Fig. 3), and so no effect would be seen in the Nrf2-/- mouse.  In order to 
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distinguish the effects of Nrf2 induction from the effects of CDDO-Me, the 
microRNA expression of Keap1-/- mouse kidneys could be analysed. 
Biomarkers by definition must be easy to measure (Starkey Lewis et al., 2012).  
Therefore, in order to determine the utility of microRNAs as useful markers of Nrf2 
activity, future work should determine if the microRNAs shown here to be sensitive 
to changes in renal Nrf2 activity can be (a) detected and (b) shown to be capable of 
reporting Nrf2 activity in serum or urine from animals in which the activity of Nrf2 
has been modulated.  If successful, these findings should be translated to humans, 
e.g. through the analysis of biofluids from patients receiving Nrf2-inducing drugs 
such as CDDO-Me or dimethyl fumarate. 
Differences in microRNA expression are often transient and relatively small, and 
because of this they may have a use in determining dynamic changes in Nrf2 
activity.  One caveat of using microarrays to determine microRNA expression is that 
the microRNA species reported as having significantly different expression are often 
the ones that have the highest difference in expression, compared to their relative 
control.  Because of this, targeted qPCR analysis assists in validating the results of 
the microarray.   
One limitation of the experimental design of this study is the use of a single 
timepoint of exposure to CDDO-Me.  MicroRNAs are transient by nature, so it is 
possible that microRNAs transcribed a short period of time after CDDO-Me 
administration may have been missed in the current analysis.  Moreover, it is 
possible that the differentially expressed microRNAs reported here reflect systemic 
changes in Nrf2 activity, and not those that are specific to the kidney.  Adaptation 
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of other pathways to the general loss of Nrf2 function, rather than a loss of direct 
transcriptional regulation by the transcription factor, may also account for some of 
the changes in microRNA expression detected in the Nrf2-/- mice.  Further analysis 
of other tissues of Nrf2-/- mice, and Nrf2+/+ mice exposed to CDDO-Me would help 
address this point.  Transient and small changes in expression of microRNAs may 
therefore have been missed, based on the limitations of the assay and experimental 
design involved.  
Using the microRNA array to first determine the expression profiles of 427 mouse 
microRNAs, and subsequently validating a selection of them using targeted qPCR, 
this study represents the first mechanistic analysis of Nrf2-regulated microRNA 
expression in the kidney, and shows for the first time a novel role for Nrf2 in 
regulating the expression of several microRNAs.  This work has identified promising 
candidates (including miR-28c, miR-144 and miR-466h-3p) for a microRNA-based 
marker of Nrf2 in the kidney, and has furthered our understanding of the biological 
roles of Nrf2 in the kidney. 
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MicroRNA ID 
Nrf2-/- vs. Nrf2+/+ 
Fold change P value 
miR-455-3p 0.771 0.001 
miR-203-3p 0.827 0.029 
miR-365-3p 0.829 0.005 
miR-455-5p 0.830 0.003 
miR-335-5p 0.841 0.005 
miR-149-5p 0.850 0.009 
miR-196b-5p 0.857 0.002 
miR-322-5p 0.867 0.008 
miR-92a-3p 0.876 0.016 
miR-196a-5p 0.886 0.020 
miR-301a-3p 0.894 0.024 
miR-3068-3p 0.897 0.017 
miR-690 0.902 0.038 
miR-192-3p 0.909 0.011 
miR-29b-3p 0.909 0.023 
miR-26b-5p 0.909 0.030 
miR-181b-5p 0.909 0.019 
miR-29c-5p 0.910 0.017 
miR-20b-5p 0.913 0.048 
miR-139-5p 0.914 0.032 
miR-9-5p 0.920 0.022 
miR-200c-3p 1.104 0.033 
miR-30a-5p 1.123 0.003 
miR-6378 1.134 0.044 
miR-551b-3p 1.145 0.047 
miR-143-3p 1.146 0.001 
miR-874-3p 1.155 0.001 
miR-705 1.160 0.020 
miR-146a-5p 1.164 0.001 
miR-142-5p 1.165 0.048 
miR-1198-5p 1.170 0.006 
miR-342-3p 1.180 0.001 
miR-6236 1.183 0.010 
miR-6351 1.190 0.007 
miR-125a-3p 1.197 0.017 
miR-6392-3p 1.203 0.046 
miR-3081-5p 1.234 0.039 
miR-182-5p 1.252 0.000 
miR-1931 1.261 0.026 
miR-3102-5p 1.282 0.007 
miR-133b-3p 1.294 0.022 
miR-2861 1.296 0.019 
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miR-5126 1.296 0.016 
miR-211-3p 1.305 0.014 
miR-3058-3p 1.349 0.003 
miR-1896 1.421 0.001 
miR-134-5p 1.443 0.005 
miR-3960 1.468 0.016 
miR-34a-5p 1.519 0.001 
miR-205-5p 1.621 0.027 
 
Supplementary Table 1: MicroRNAs differentially expressed in the Nrf2-/-, 
compared to Nrf2+/+ mouse kidney (P ≤ 0.05, n=5). 
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MicroRNA ID 
CDDO-Me vs. vehicle 
Fold change P value 
miR-181d-5p 0.744 <0.001 
miR-9-5p 0.745 <0.001 
miR-34b-5p 0.745 <0.001 
miR-10a-3p 0.748 <0.001 
miR-33-5p 0.756 <0.001 
miR-181c-5p 0.775 0.002 
miR-450a-5p 0.792 0.001 
miR-30c-2-3p 0.805 <0.001 
miR-690 0.812 <0.001 
miR-503-5p 0.812 0.004 
miR-455-5p 0.812 0.001 
miR-3069-3p 0.812 <0.001 
miR-144-5p 0.816 0.017 
miR-551b-5p 0.819 0.030 
miR-5130 0.828 0.016 
miR-1839-5p 0.830 <0.001 
miR-28c 0.832 0.004 
miR-872-5p 0.832 0.003 
miR-218-5p 0.836 0.001 
miR-203-3p 0.837 0.027 
miR-28a-5p 0.838 0.001 
miR-1231-5p 0.838 <0.001 
miR-301a-3p 0.849 0.001 
miR-532-5p 0.850 <0.001 
miR-100-5p 0.851 0.008 
miR-204-5p 0.852 0.001 
miR-140-5p 0.852 0.004 
miR-196a-5p 0.855 0.002 
miR-9-3p 0.856 0.037 
miR-210-3p 0.860 0.016 
miR-19a-3p 0.861 0.003 
miR-1949 0.862 0.013 
miR-32-5p 0.862 0.005 
miR-195a-5p 0.862 0.001 
miR-26b-5p 0.863 0.001 
miR-1940 0.864 0.019 
miR-361-5p 0.866 0.001 
miR-10b-5p 0.868 <0.001 
miR-130a-3p 0.871 0.004 
miR-340-5p 0.872 0.001 
miR-532-3p 0.873 0.002 
miR-322-5p 0.874 0.007 
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miR-152-3p 0.876 <0.001 
miR-30e-3p 0.876 0.004 
miR-196b-5p 0.877 0.004 
miR-146a-5p 0.878 0.002 
miR-335-5p 0.879 0.019 
miR-770-3p 0.880 0.007 
miR-1264-5p 0.880 0.003 
miR-193a-5p 0.881 0.003 
miR-10a-5p 0.885 0.001 
miR-15a-5p 0.889 0.007 
miR-362-3p 0.890 0.016 
miR-20b-5p 0.892 0.010 
miR-155-5p 0.894 0.049 
miR-128-3p 0.894 0.008 
miR-374c-5p 0.896 0.009 
miR-1839-3p 0.896 0.001 
miR-181b-5p 0.897 0.005 
miR-5100 0.898 0.005 
miR-497-5p 0.898 0.038 
miR-350-3p 0.899 0.040 
miR-181a-5p 0.900 0.012 
miR-425-5p 0.903 0.003 
miR-200b-5p 0.903 0.042 
miR-484 0.909 0.028 
miR-101b-3p 0.912 0.007 
miR-1906 0.912 0.011 
miR-106b-5p 0.914 0.010 
miR-342-3p 0.916 0.042 
miR-30a-3p 0.917 0.006 
miR-378c 0.918 0.041 
miR-29c-5p 0.919 0.020 
miR-324-5p 0.922 0.013 
miR-30b-5p 0.923 0.009 
miR-25-3p 0.928 0.035 
miR-200a-3p 0.928 0.017 
miR-200b-3p 0.933 0.001 
miR-222-3p 0.940 0.017 
miR-669a-3-3p 1.155 0.018 
miR-466h-5p 1.195 0.022 
miR-18b-3p 1.197 0.040 
miR-467b-3p 1.200 0.046 
miR-6538 1.205 0.038 
miR-669e-5p 1.208 0.006 
miR-466g 1.226 0.047 
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miR-877-3p 1.226 0.024 
miR-706 1.231 0.005 
miR-211-3p 1.239 0.029 
miR-3091-5p 1.239 0.022 
miR-574-3p 1.241 0.017 
miR-669c-3p 1.241 0.004 
miR-5620-3p 1.259 0.013 
miR-3102-5p 1.272 0.005 
miR-1188-3p 1.276 0.006 
miR-3473c 1.285 0.019 
miR-669p-3p 1.289 0.004 
miR-466f-3p 1.304 0.032 
miR-466q 1.307 0.023 
miR-5132-3p 1.323 0.004 
miR-467f 1.339 0.009 
miR-466i-3p 1.347 0.014 
miR-2861 1.366 0.004 
miR-466m-5p 1.375 0.018 
miR-669l-5p 1.395 0.001 
miR-468-3p 1.398 0.025 
miR-466h-3p 1.401 0.003 
miR-669n 1.408 0.011 
miR-466i-5p 1.447 0.002 
miR-1187 1.456 0.006 
miR-5126 1.472 0.001 
miR-3960 1.480 0.009 
miR-32-3p 1.523 0.010 
miR-877-5p 1.537 0.001 
miR-574-5p 1.547 0.001 
miR-3082-5p 1.550 0.005 
 
Supplementary Table 2: MicroRNAs differentially expressed in the CDDO-Me, 
compared to vehicle treated Nrf2+/+ mouse kidney (P ≤ 0.05, n=5). 
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Chapter 4 
Examination of the relationship between 
potency towards Nrf2 and cytotoxicity of 
semi-synthetic triterpenoids and novel 
mono- and  tri-cyclic cyano enones 
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4.1 Introduction 
Nrf2 regulates the expression of a battery of genes with diverse physiological roles 
including the antioxidant response, xenobiotic metabolism, lipid metabolism, and 
the regulation of energy production (Ma, 2013), some of which have been further 
delineated in Chapter 2.   It is therefore evident that Nrf2 plays an important role in 
cellular homeostasis, which is emphasised by the enhanced susceptibility of Nrf2-/- 
mice to a number of diseases and chemical toxicities (Copple et al., 2008; Shelton et 
al., 2013).  The converse is also true; induction of Nrf2 has been shown to protect 
against various pathologies, including kidney injury (Tanaka et al., 2008; Pergola et 
al., 2011a; Shelton et al., 2013), cancer (Jeong et al., 2006) and diabetes (Li et al., 
2014).  This has culminated in the recent licensing of the small molecule Nrf2 
inducer dimethyl fumarate (DMF) for use in the clinical treatment of multiple 
sclerosis (Lee et al., 2013).   
The triterpenoid Nrf2 inducer CDDO-Me was until recently a promising therapeutic 
candidate for treatment of chronic kidney disease (CKD).  An unexpected side effect 
of CDDO-Me in a clinical trial designed to assess the capacity of the drug to treat 
cancer was the improvement of estimated glomerular filtration rate (eGFR, a 
measure of renal function) (Hong et al., 2012).  This knowledge was subsequently 
used to inform a successful clinical trial seeking to improve the clinical outcome of 
patients with moderate to severe chronic kidney disease and type II diabetes 
(Pergola et al., 2011b), which was followed up with a larger, phase III clinical trial in 
patients with end-stage CKD (de Zeeuw et al., 2013b).  The latter clinical trial was, 
however, prematurely terminated due to a high incidence of adverse events and 
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deaths in the treatment arm; the causes of which were not clear at the time that 
the work described here was conducted.  One possible reason for the adverse 
effects of CDDO-Me in end-stage CKD patients is that this patient cohort was 
inappropriate, given that the induction of Nrf2 signalling has previously been shown 
to prevent, but not reverse, a number of experimental pathologies (Zhang, 2013).  
Additionally, no adverse side effects were reported in the clinical trial of CDDO-Me 
as a cancer therapy (Hong et al., 2012), so it is unclear whether the adverse events 
were specific to the CKD patient population.    
Nrf2 induction hinges on the ability to prevent Keap1 repression of Nrf2, allowing 
for the transcription of genes under Nrf2 control.  It is generally accepted that small 
molecule Nrf2 inducers modify cysteine residues of Keap1, allowing Nrf2 to evade 
Keap1 repression (Dinkova-Kostova et al., 2002; Bryan et al., 2013).  Thiol reactivity 
is a common feature of small molecule Nrf2 inducers (Dinkova-Kostova et al., 2002; 
Bensasson et al., 2010; Dinkova-Kostova, 2012; Bryan et al., 2013).   Many existing 
and withdrawn drugs are known to provoke off-target toxic effects through 
generation of electrophilic, thiol-reactive metabolites (Park et al., 2011).  For 
example, hepatotoxicity results following acetaminophen overdose due to the 
generation of a reactive toxic metabolite that depletes intracellular glutathione, 
inducing oxidative stress (Hinson et al., 2010). 
 If the adverse events associated with CDDO-Me are not due to induction of Nrf2 
per se, and instead are due to off-target effects associated with general compound 
structure (as theorised in (Chin et al., 2014c)), then there is a clear need for the 
development of second-generation Nrf2 inducers, rationally designed to induce a 
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lesser degree of toxicity.  It is for this reason that TBE-31 and MCE-1, lead 
compounds from novel tri- and mono-cyclic cyano enone classes are under 
investigation (Fig. 1).   
The aim of this chapter is to elucidate the relationship between thiol reactivity, 
potency towards Nrf2 and toxicity for triterpenoids and other Nrf2 inducers, to 
determine if the drive to enhance potency of the triterpenoids (which has 
culminated in the synthesis of CDDO-Me) has inadvertently produced more toxic 
molecules.  This will inform the ongoing design and development of small molecule 
Nrf2 inducers, which continue to hold promise as novel drug candidates.  Some of 
the content of this chapter has been published in Toxicological Sciences, ‘Chemical 
tuning enhances both potency toward Nrf2 and in vitro therapeutic index of 
triterpenoids’ (Copple et al., 2014). 
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Fig.1: Chemical structures of Nrf2 inducers used in this study.  CDDO-Me and related triterpenoid 
analogues (TP-72 to TP-319), Nrf2 inducers that have entered the clinic (DMF and SUL), the 
experimental tricyclic and monocyclic cyano enone Nrf2 inducers TBE-31 and MCE-1. 
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4.2 Methods 
Materials: Unless stated, all reagents were obtained from Sigma-Aldrich (Poole, 
UK). 
Chemistry: The synthesis of CDDO-Me and related triterpenoids (Honda et al., 
2000; Honda et al., 2002), TBE-31 (Favaloro et al., 2002; Honda et al., 2007) and 
MCE-1 (Zheng et al., 2012) has been previously described.  Compounds were kindly 
supplied by Dr. Tadashi Honda (Stony Brook University, USA).   
Cell culture: Rat H4IIE-ARE8L cells, stably expressing a luciferase reporter regulated 
by an eight-times repeated antioxidant response element were generated as 
described (Kratschmar et al., 2012), and kindly provided by Prof. Alex Odermatt 
(Basel University, Switzerland).  Mouse Hepa1c1c7 and human HepG2 cells were 
obtained from ATCC.  Cells were maintained at 37 oC in a 5 % CO2 atmosphere in 
Dulbecco’s Modified Eagle’s Medium supplemented with 584 mg/L L-glutamine, 
10% fetal bovine serum (Life Technologies, Paisley, UK) in Nunc T75 vented flasks 
(Fisher Scientific).  The media for H4IIE-ARE8L cells was supplemented with 1mM 
HEPES and 1X nonessential amino acids, whereas the media for Hepa1c1c7 and 
HepG2 cells was further supplemented with 100 U/mL penicillin and 100 μg/mL 
streptomycin.  H4IIE-ARE8L, Hepa1c1c7 or HepG2 cells were plated in Nunc 96 well 
flat bottomed plates (Fisher Scientific) at 10,000 cells per well.   For drug 
treatments, compounds were dissolved in DMSO, with concentrations of the 
solvent in the media controlled to <0.5 %.   
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Determination of cellular ATP content:  Following exposure of H4IIE-ARE8L, 
Hepa1c1c7 or HepG2 cells to the indicated compounds for 24 h, cellular ATP 
content was quantified using the CellTiter-Glo Luminescent Cell Viability assay 
(Promega, Southampton, UK) in accordance with manufacturer’s instructions.  
Essentially,     20 μL ATP reagent was added to each well, and the plate was mixed 
on a plate shaker at 700 RPM for one minute.  The plate was subsequently stored in 
the dark at room temperature for 5 minutes, and then 100 μL of each well content 
was transferred to a 96 well white luminescence plate (Grenier Bio-One).  
Luminescence was determined using the Thermo Scientific VarioSkan Flash 3001 
device.  Data are normalised to the ATP content of vehicle-treated cells. 
Determination of ARE8L reporter activity: H4IIE-ARE8L cells were plated as 
described previously.  Following exposure to the indicated compounds for 24 h, 
reporter assays were performed essentially as described (Kratschmar et al., 2012), 
using the Bright-Glo Luciferase Assay system (Promega) in accordance with the 
manufacturer’s instructions.  Briefly, media was removed from the plate and 100 μL 
Glo lysis buffer was added.  Plate was mixed on a plate shaker at 700 RPM for one 
minute, and 80 μL per well was added to a 96 well white luminescence plate.  20 μL 
Bright Glo reporter assay reagent was added, and the plate was subsequently 
mixed on a plate shaker at 700 RPM for 15 seconds.  Luminescence was determined 
as described previously.  Data are normalised to the reporter activity detected in 
vehicle-treated cells. 
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Calculation of in vitro therapeutic index: The concentrations of each compound 
that provoked a two-fold increase in the activity of the ARE8L reporter transgene 
(CD value) and a two-fold decrease in the cellular ATP content (LC50 value) in H4IIE-
ARE8L cells was determined by nonlinear regression analysis of the respective 
concentration-response curves, using GraphPad Prism 6 (GraphPad software).  The 
in vitro therapeutic index is expressed as a ratio of LC50 divided by CD.   
Total protein determination:  Following drug treatment, Hepa1c1c7 cells were 
washed twice with PBS and lysed with RIPA buffer, and protein content was 
determined using the Bicinchoninic assay, as described in Chapter 2.   
Immunoblotting: Cell lysates (20 μg total protein) were loaded onto NuPAGE 4-12 
% Bis-Tris Precast gel (Life Technologies), and immunoblotting performed as 
described in Chapter 2.   
PI-FACS analysis: Propidium iodide (PI) flow cytometry was performed to quantify 
the population of sub-G0/G1 phase cells.  Following drug treatment, cells were 
washed twice with Hank’s Buffered Saline Solution (HBSS) and suspended in ice-
cold 70 % ethanol overnight at -20oC.  Cells were washed once in HBSS, and pelleted 
at 2000 RPM for 3 min.  Pellets were resuspended in HBSS containing 40 µg/ml PI, 
0.1 mg/ml RNase, 3.8 mM sodium citrate.  Samples were incubated in the dark at 
37 oC for 30 min and subsequently analysed using a Becton-Dickinson FACSCanto II 
FACS unit.  PI fluorescence was measured in the FL-2 channel, with a maximum of 
10,000 cells quantified per sample.  Samples were mixed after every 3 readings. 
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4.3 Results 
4.3.1 Concept of the in vitro therapeutic index 
By calculating the concentrations of a compound that provoke a two-fold increase 
in the activity of the Nrf2-sensitive ARE8L reporter transgene (CD, concentration of 
doubling), and a two-fold decrease in cellular ATP content (the LC50) in H4IIE-ARE8L 
cells, the ratio of LC50 divided by the CD can be used to determine the therapeutic 
index.  Figure 2 depicts examples of hypothetical compounds, with that in A having 
a large in vitro therapeutic index as a result of having a high potency toward Nrf2 
(i.e. low CD value) and minimal toxicity (a high LC50 value).  The hypothetical 
compound depicted in B has a low in vitro therapeutic index, due to its low potency 
toward Nrf2 (high CD value) and high toxicity (low LC50).  This concept has been 
used to examine the relationship between Nrf2 induction potency, toxicity and in 
vitro therapeutic index for a number of small molecule inducers of Nrf2. 
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Fig.2: Hypothetical examples of the method used to determine therapeutic index.  (A) depicts a 
compound with a high therapeutic index, with low concentrations needed to provoke a two-fold 
increase in the activity of ARE8L reporter transgene (CD, blue circles), and high concentrations 
required to deplete cellular ATP by two-fold (LC50, red squares).  (B) depicts a compound with a low 
therapeutic index, with high concentrations required to provoke a two-fold increase in the ARE8L 
reporter transgene activity and low concentrations required to induce toxicity. 
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4.3.2 Therapeutic indices of clinically validated Nrf2 inducers 
The relationship between toxicity and potency of Nrf2-inducing compounds was 
first examined with the clinically validated molecules sulphoraphane (SUL, 
(Houghton et al., 2013)) and dimethyl fumarate (DMF, (Lee et al., 2013)), alongside 
CDDO-Me (Fig. 3).  H4IIE-ARE8L cells were exposed to the indicated concentrations 
of CDDO-Me, SUL and DMF.  All three compounds were able to induce the activity 
of the Nrf2 reporter transgene in a concentration-dependent manner.  At high 
concentrations, all three compounds provoked a loss of cell viability, associated 
with a decrease in ARE8L reporter transgene activity, likely due to the disruption of 
critical cellular processes, and/or a lack of ATP, which is required for 
bioluminescence generation. 
The calculation of CD values revealed an order of potency for inducing Nrf2 of 
CDDO-Me>SUL>DMF (Table 2).  Calculation of the LC50 values also revealed a rank-
order of toxicity of CDDO-Me>SUL>DMF (Table 2).     A similar rank-order of toxicity 
was observed in human HepG2 and mouse Hepa1c1c7 cells, indicating the 
translational robustness of the data (Fig. 4, Table 1).  
Ostensibly, the similar rank orders of CD and LC50 values for CDDO-Me, SUL and 
DMF indicates that potency towards Nrf2 is inherently related to toxicity.  However, 
it was notable that the CD values of CDDO-Me, SUL and DMF spanned four orders 
of magnitude, whereas the associated LC50 values spanned just two orders of 
magnitude.  This observation implied that potency and toxicity could be dissociated. 
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Fig.3: Therapeutic indices of (A) CDDO-Me, (B) SUL and (C) DMF in H4IIE-ARE8L cells.  Following 24h 
exposure to the indicated compound, luciferase reporter activity (blue circles) and ATP content (red 
squares) were quantified as a measure of Nrf2 induction and toxicity respectively.  Data represent 
the mean and SD (n=3).   
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Fig.4: Toxicity of clinically validated Nrf2 inducers in (A) rat H4IIE-ARE8L, (B) mouse Hepa1c1c7 and 
(C) human HepG2 hepatoma cells.  Following 24h exposure to the indicated compound, ATP content 
was quantified as a measure of toxicity.  Data represents the mean and SD (n=3).   
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 LC50 (μM) 
CDDO-Me SUL DMF 
Rat H4IIE-ARE8L cells 1.4 ± 0.3 35.1 ± 4.1 276.5 ± 14.4 
Mouse Hepa1c1c7 cells 0.7 ± 0.2 52.5 ± 15.3 288.0 ± 4.4 
Human HepG2 cells 0.9 ± 0.03 60.8 ± 19.2 >300 
 
Table 1: LC50 values of CDDO-Me, SUL and DMF in rat H4IIE-ARE8L cells, mouse Hepa1c1c7 cells and 
human HepG2 cells.  Following 24h exposure to the indicated compound, ATP content was 
quantified as a measure of toxicity.  Data represents the mean and SD (n=3).  
  
 
 
156 
 
4.3.3 Therapeutic indices of triterpenoid Nrf2 inducers 
To further examine the relationship between Nrf2 induction potency and toxicity of 
small molecules within a refined chemical space, eight structurally-related 
triterpenoid analogues of CDDO-Me were selected based on their reported abilities 
to induce Nqo1 in Hepa1c1c7 cells (Dinkova-Kostova et al., 2005).  Following 
exposure to H4IIE-ARE8L cells for 24h, TP-72, TP-151, TP-162, TP-198, TP-222, TP-
225, TP-233 and TP-319 were shown to evoke concentration-dependent increases 
in Nrf2 reporter transgene activity (Fig. 5).  The potencies of the triterpenoids 
towards Nrf2 in H4IIE-ARE8L cells were in agreement with their previously reported 
potencies towards Nqo1 in Hepa1c1c7 cells (Dinkova-Kostova et al., 2005).  The 
triterpenoids induced loss of cell viability at micromolar concentrations, with the 
exception of TP-72, which at the highest achievable concentration (100 μM) did not 
deplete ATP (Fig. 5).  Calculation of in vitro therapeutic indices for each compound 
confirmed that an increase in potency was associated with a relative enhancement 
of in vitro safety (Fig. 5, Table 2). 
Like CDDO-Me, the triterpenoids found to have the highest therapeutic indices (TP-
151, TP-162, TP-225 and TP-319) possess a nitrile group at position C-2 on ring A.   
The nitrile group enhances electrophilicity and imparts reversibility of the Michael 
acceptor enone group (Honda et al., 2011).  Research into novel triterpenoid 
compounds and derivatives suggests that the reactivity of a Michael acceptor is 
indicative of biological potency (Zheng et al., 2012).  Substitution of the nitrile 
group at C-2 on the A ring with a carboxyl group (TP-222) produces a compound 
with 10-100 times lower in vitro therapeutic index than TP-151, TP-162, TP-225 and 
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TP-319, whereas a second nitrile group (C-17 on TP-225), provides the highest 
therapeutic index of the compounds tested (Table 2).  Substitution of a long chain 
hydrocarbon at C-17 produced one of the least potent Nrf2 inducers (TP-233), and 
shorter chained compounds tend towards higher therapeutic indices (compare TP-
151 and TP-319, Table 2).  TP-72 and TP-198 both lack a nitrile group at C-2, but 
their therapeutic indices still differ, likely due to the positioning of the enone on 
ring C (Table 2).  TP-72 lacks both correct positioning of the enone and a nitrile 
group on the A ring, and as such has a potency toward Nrf2 that is 30,000 times less 
than CDDO-Me, and does not induce cell death at the highest possible 
concentration of 100 μM (Table 2).  Taken together, these data serve to emphasise 
that an increase in potency toward Nrf2 is associated with a relative enhancement 
of in vitro safety (Fig. 5, Table 2). 
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Fig.5: Pharmacological potencies and toxicities of triterpenoids in H4IIE-ARE8L cells.  Cells were 
exposed to the indicated triterpenoids for 24 h.   Luciferase reporter activity (blue circles) and ATP 
content (red squares) were subsequently quantified as measures of Nrf2 induction and toxicity, 
respectively.  Data represent the mean and SD (n=3).  
 
 
159 
 
 4.3.4 Therapeutic indices of novel tricyclic and monocyclic cyano 
enone Nrf2 inducers 
In light of recent evidence of clinical adverse toxic events associated with CDDO-Me 
(de Zeeuw et al., 2013b), it is apparent that there is a need for next-generation Nrf2 
inducers with comparatively acceptable safety and efficacy.  TBE-31 and MCE-1 
were selected for investigation because of their established potencies toward Nrf2 
in vitro and in vivo (Honda et al., 2007; Dinkova-Kostova et al., 2010b; Zheng et al., 
2012), and as representatives of novel tricyclic and monocyclic cyanoenone classes.  
H4IIE-ARE8L cells were exposed to the indicated concentrations of TBE-31 and MCE-
1 for 24h and the therapeutic indices calculated as before (Fig. 6, Table 2).  Both 
compounds exhibit relatively high therapeutic indices; TBE-31 has a comparable 
therapeutic index to CDDO-Me, and contains two nitrile groups to modulate enone 
reactivity.  MCE-1, which contains a single nitrile group, has a therapeutic index 
comparable to sulphoraphane (Table 2).  Both TBE-31 and MCE-1 are therefore 
promising second-generation Nrf2 inducers with relatively good in vitro safety and 
efficacy profiles. 
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Fig.6: Pharmacological potencies and toxicities of (A) TBE-31 and (B) MCE-1 in H4IIE-ARE8L cells.  
Cells were exposed to the indicated concentrations of the compounds for 24 h.   Luciferase reporter 
activity (blue circles) and ATP content (red squares) were subsequently quantified as measures of 
Nrf2 induction and toxicity, respectively.  Data represent the mean and SD (n=3).   
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4.3.5 Correlation of potency towards Nrf2, toxicity and in vitro 
therapeutic index of Nrf2 inducing compounds 
Table 2 depicts pharmacological potencies (CD), toxicities (LC50) and resulting in 
vitro therapeutic indices of the 13 compounds studied here.  Figure 7 depicts the 
correlation of potency towards Nrf2 with (A) toxicity and (B) in vitro therapeutic 
index for the compounds.  Evidently, with an increase in potency toward Nrf2 there 
is an increase in toxicity, however this increase is not to the same degree (i.e. not 
equivalent, Fig. 7A).  Indeed, the CD values span four orders of magnitude, whereas 
the associated LC50 values span just two orders of magnitude.  As a result, an 
increase in potency is associated with an increase in therapeutic index, i.e. a 
relative enhancement of in vitro safety (Fig. 7B).   
Compound CD (μM) LC50 (μM) Therapeutic index 
TP-225 0.0005 ± 0.0001 1.6 ± 0.2 3448.3 ± 698.2 
CDDO-Me 0.001 ± 0.0001 2.1 ± 0.5 1818.1 ± 356.3 
TBE-31 0.003 ± 0.001 3.8 ± 0.5 1620.0 ± 652.7 
TP-162 0.02 ± 0.009 18.4 ± 4.6 1397.7  ± 415.1 
TP-151 0.01 ± 0.004 16.3 ± 3.7 1373.3 ± 201.5 
TP-319 0.005 ± 0.001 1.9 ± 0.2 417.7 ± 72.1 
MCE-1 0.03 ± 0.01 4.6 ± 2.1 152.4 ± 57.3 
SUL 0.4 ± 0.1 51.9 ± 2.6 140.6 ±38.4 
TP-222 0.2 ± 0.02 7.2 ± 0.3 33.5 ± 2.1 
DMF 20.5 ±8.7 184.4 ± 4.8 10.0 ± 3.7 
TP-198 1.6 ± 0.6 8.1 ± 1.4 5.5 ± 1.4 
TP-233 4.6 ± 2.1 10.4 ± 2.6 2.6 ± 1.4 
TP-72 29.1 ± 2.7 >100 N.D. 
 
Table 2: Pharmacological potencies, toxicities and in vitro therapeutic indices of Nrf2 inducers in 
H4IIE-ARE8L cells.  Data represent the mean and SD (n=3), N.D. not determined. 
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Fig.7:   Correlation of potency toward Nrf2, toxicity and in vitro therapeutic index of clinically 
validated (red squares), triterpenoid (blue circles) and novel cyano enone (green diamonds) Nrf2 
inducing compounds.  Correlation between potency towards Nrf2 and (A) toxicity [Pearson 
correlation coefficient 0.75, P = 0.005] or (B) in vitro therapeutic index [Pearson correlation 
coefficient -0.93, P = <0.0001].  CD and LC50 values and therapeutic indices for each compound were 
calculated as described. 
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4.3.6 Investigation of the mechanism of toxicity of next-generation 
tricyclic and monocyclic cyano enone compounds 
 
4.3.6.1 Comparable toxicity of TBE-31 and MCE-1 in different cell lines 
The relatively high therapeutic indices of TBE-31 and MCE-1 (Fig. 6, Table 2) give an 
indication of their suitability for future clinical use, however data on their pre-
clinical toxicity is lacking.  Firstly, the translational robustness of the data generated 
in rat H4IIE-ARE8L cells was assessed (Fig. 8).  Rat H4IIE-ARE8L, mouse Hepa1c1c7 
and human HepG2 cells were exposed to the indicated concentrations of TBE-31, 
MCE-1 and CDDO-Me for 24 h.  It was shown that the compounds provoke 
consistent degrees of toxicity across the different cell lines (Table 3).    
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A
B
C
 
Fig.8:   Toxicity of CDDO-Me, TBE-31 and MCE-1 in (A) rat H4IIE-ARE cells, (B) mouse 
Hepa1c1c7 cells and (C) human HepG2 cells.  Following 24 h exposure to the indicated 
compound, ATP content was quantified as a measure of toxicity.  Data represents the mean 
and SD (n=3).   
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 LC50 (μM) 
CDDO-Me TBE-31 MCE-1 
Rat H4IIE-ARE8L cells 1.4 ± 0.3 3.8 ± 0.9 4.1 ± 1.8 
Mouse Hepa1c1c7 cells 0.7 ± 0.2 2.3 ± 0.4 9.3 ± 0.6 
Human HepG2 cells 0.9 ± 0.03 16.1 ± 2.6 21.1 ± 6.2 
 
Table 3: LC50 values of CDDO-Me, TBE-31 and MCE-1 in rat H4IIE-ARE8L cells, mouse 
Hepa1c1c7 cells and human HepG2 cells.  Following 24h exposure to the indicated 
compound, ATP content was quantified as a measure of toxicity.  Data represents the mean 
and SD (n=3).   
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4.3.6.2 High concentrations of TBE-31 and MCE-1 provoke caspase 3 
activation in Hepa1c1c7 cells 
Whilst indicative of drug-induced changes in the metabolic activity of cells, assaying 
ATP content does not give much information on the mechanism of cell death.  It has 
previously been demonstrated that triterpenoids such as CDDO-Me provoke loss of 
cell viability via the induction of apoptosis (Kim et al., 2002), and so further work 
was performed to determine the mechanism of cell death induced by TBE-31 and 
MCE-1.  Hepa1c1c7 cells were treated with the indicated concentrations of CDDO-
Me, TBE-31 and MCE-1 for 24 h, and lysates subsequently probed for caspase 3 by 
western blotting.  The data in Fig. 9 indicates that all three compounds provoke 
caspase 3 cleavage from the pro- form to the processed, apoptosis-inducing active 
form in a concentration-dependent manner.  Indeed, the concentrations of each 
compound that induce caspase 3 processing are close to the LC50 values (Table 3) 
determined with the ATP assay.  These findings indicate that TBE-31 and MCE-1 
initiate cell death via apoptosis associated with caspase 3 activation.   
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Fig.9:   Hepa-1c1c7 cells were exposed to the indicated concentrations of (A,B) CDDO-Me, (C,D) TBE-
31 or (E,F) MCE-1 for 24 h. The processing of caspase 3 from its inactive 32 kDa form to its 
proteolytically active 17 kDa form was determined in whole cell lysates by Western blotting. 
Staurosporine (STS; 1 μM) was used as a positive control for caspase 3 activation. Actin was probed 
as a loading control. Active caspase 3, normalised to actin, is expressed as a percentage of the level 
in vehicle (DMSO)-exposed cells.  Blots are representative of n=3 independent experiments.  
Densitometry data represent the mean and SD (n=3).    
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4.3.6.3 FACS analysis of TBE-31 and MCE-1-treated Hepa1c1c7 cells 
demonstrates the induction of apoptosis at high concentrations 
To provide further evidence for apoptosis being the major mechanism of cell death 
induced by TBE-31 and MCE-1, propidium iodide staining and flow cytometry was 
performed on Hepa1c1c7 cells 24 h after exposure to the compounds, or CDDO-Me 
(Fig.10).  Fig 10A depicts examples of the histograms generated, demonstrating (i) a 
population of non-apoptotic cells following vehicle treatment, and (ii) a large 
proportion of cells with hypodiploid/fragmented DNA undergoing apoptosis 
following exposure to 20 μM CDDO-Me.  Fig 10B depicts a concentration-
dependent increase in the population of propidium iodide-stained cells, 
representative of sub G0/G1 phase apoptotic cell population.  Taken together with 
our observation of caspase 3 processing (Fig. 9), these data demonstrate that     
TBE-31 and MCE-1 provoke apoptotic cell death at high concentrations in a similar 
manner to the triterpenoid CDDO-Me.     
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Fig.10: The number of cells in the sub G0/G1 phase of the cell cycle were quantified following 
propidium iodine staining by flow cytometry.  Hepa-1c1c7 cells were exposed to the indicated 
concentrations of CDDO-Me, TBE-31 or MCE-1 for 24 h.  (Ai) is a histogram depicting a large 
proportion of non-apoptotic cells following DMSO treatment; (ii) depicts an apoptotic cell 
population following 20 μM CDDO-Me treatment.  (B) depicts a concentration-dependent increase in 
apoptotic cells following compound treatment.  Data represent mean and SD (n=3).    
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4.4 Discussion 
The pharmacological induction of Nrf2 has shown promise for the treatment of 
numerous diseases in animal models (Ruiz et al., 2013; Shelton et al., 2013), 
however the clinical development of one inducer, CDDO-Me, was recently halted 
due to adverse cardiovascular events in late-stage chronic kidney disease patients 
(de Zeeuw et al., 2013b).  Key properties of Nrf2 inducers include electrophilicity 
and reactivity towards protein thiols (Bensasson et al., 2010), but reactivity towards 
unintended targets is known to be a primary trigger of drug toxicity.  It is therefore 
pertinent to address whether therapeutic targeting of Nrf2 could be undermined by 
the chemical reactivity of small molecule inducers, and to question if the drive to 
generate more potent and efficacious Nrf2 activators could also inadvertently 
generate more toxic compounds. 
Here, the in vitro therapeutic index has been determined for clinically validated 
Nrf2 inducers (CDDO-Me, SUL and DMF), a selection of triterpenoid analogues of 
CDDO-Me and the novel tricyclic and monocyclic cyano enones TBE-31 and MCE-1.  
The data demonstrates an increase in potency toward Nrf2 is associated with a 
relative increase in in vitro safety indicating that it is possible to generate potent 
Nrf2-inducing small molecules that are not inherently toxic to mammalian cells.   
The cessation of the BEACON trial for safety concerns due to ‘excess serious events 
and mortality’ provoked a literary response questioning the focus of the trial, and 
discussing the possible causes of mortality (Tayek et al., 2013; Chin et al., 2014c).  
The data highlighted heart failure events and death from cardiovascular disease 
occurring in a higher proportion of patients in the treatment arm (de Zeeuw et al., 
 
 
171 
 
2013b).  CDDO-Me is known to elevate blood pressure (de Zeeuw et al., 2013b; Chin 
et al., 2014c), and patients experiencing latter stage (3b, 4) CKD progression treated 
with CDDO-Me had a propensity toward elevated systolic and diastolic blood 
pressure, and decreased sodium and water output (de Zeeuw et al., 2013b; Chin et 
al., 2014c).  Whilst in the early stages of investigation, this off-target effect is 
thought to be due to modification of endothelin signalling (Chin et al., 2014c), 
highlighting the need for rational design of Nrf2 activating compounds to limit off-
target effects.  Therefore, a better understanding of the pharmacodynamic actions 
of Nrf2 inducers is needed to improve the selection or exclusion of certain patient 
cohorts for future clinical trials.  In light of the above, it will be important to 
determine the effects of next-generation Nrf2 inducers such as TBE-31 and MCE-1 
on endothelin signalling prior to any future clinical trials.   
Notably, the animal population most closely resembling the BEACON trial clinical 
population (latter-stage renal failure, 3b, 4), Zucker Diabetic Fatty rats (which 
spontaneously develop obesity and diabetes linked to enhanced oxidative stress) 
displayed a similar phenotype to the BEACON trial clinical population (increased 
blood pressure, weight loss) following exposure to a CDDO-Me analogue (de Zeeuw 
et al., 2013b; Zoja et al., 2013).  These adverse events have been attributed to 
impurities in the batch of drugs used to treat the animals (Chin et al., 2013), 
however this rodent group did not experience any of the beneficial effects of 
CDDO-Me noted in previous animal studies (Aminzadeh et al., 2013b; Chin et al., 
2013; Ruiz et al., 2013; Van Laecke et al., 2014).  Therefore, Zucker Diabetic Fatty 
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rats may be a suitable model in which to further examine the mechanisms 
underlying the adverse effects of CDDO-Me in late-stage CKD patients. 
Despite the utility of the in vitro therapeutic index as a means to compare the 
relationship between Nrf2 induction and toxicity in simple cell models, it cannot 
determine whether a compound will provoke adverse reactions in animals or 
humans.  Indeed, the relatively low in vitro therapeutic index of DMF would 
indicate that it is a poor candidate for clinical use, yet DMF was recently licensed for 
the management of multiple sclerosis (Lee et al., 2013).  Similarly, the relatively 
high in vitro therapeutic index of CDDO-Me would theoretically make it a good 
candidate for clinical exploration, however the results of the BEACON trial (de 
Zeeuw et al., 2013b) suggest otherwise, demonstrating the limitations of the 
controlled in vitro system used here, and the complexities of in vitro to in vivo 
extrapolation.  TP-225 demonstrates the largest in vitro therapeutic index of the 
compounds studied here, indicating it to be a good candidate for clinical use.  
Indeed, it is known to induce Nrf2 and reduce lesions following topical 
administration to UV-exposed SKH-1 mice (Dinkova-Kostova et al., 2008), but 
unpublished data derived from (Dinkova-Kostova et al., 2008) has shown it to have 
very poor oral bioavailability (Albena Dinkova-Kostova, personal communication), 
limiting progress in the clinic, a factor which the in vitro therapeutic index is not 
able to predict.   
One limitation of using the induction of a luciferase reporter transgene as a marker 
of potency towards Nrf2 is that it does not indicate the protective effects of the 
various compounds.  A further study in which the the H4IIE-ARE8L cells were 
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concomitantly exposed to a model toxin and different Nrf2 inducers would provide 
further information about the protective concentrations of these compounds in 
vitro, which, if linked to subsequent toxicity, would provide mechanistic 
information about the potential clinical utility of these Nrf2 inducers.  This could be 
further assessed by monitoring the induction of a variety of Nrf2-regulated genes, 
to understand the relative effectiveness of these Nrf2 inducers at provoking a 
cytoprotective response. 
In conclusion, the data described here indicates that the drive to produce potent 
small molecule Nrf2 inducers is not associated with the generation of more toxic 
compounds in vitro, suggesting that the cause of the adverse cardiovascular events 
reported in the BEACON trial is related to poor patient population selection and/or 
off-target signalling, rather than inherent structural toxicity or the induction of Nrf2 
per se.  Recent work examining the role off-target endothelin signalling may have 
played in the cessation of the BEACON trial (Chin et al., 2014c) emphasises the need 
to test other Nrf2 inducing compounds to ensure this effect is structural, rather 
than Nrf2-mediated.  Such studies are vital if next-generation Nrf2 inducers such as   
TBE-31 and MCE-1 are to enter clinical trials. 
The therapeutic promise of CDDO-Me has not been extinguished, as it is currently 
undergoing a phase II clinical trial assessing its safety and efficacy in patients with 
pulmonary arterial hypertension (LARIAT, NCT02036970), with the rationale being 
to capitalise on the anti-inflammatory properties of CDDO-Me by way of 
suppression of pro-inflammatory mediators in multiple cell types.  It is specified 
that patients enrolled in the trial must have adequate renal function as a result of 
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the adverse events reported in the BEACON trial.  Notably, Chapter 2 delineates the 
relatively small number of Nrf2 target proteins that are upregulated in the healthy 
mouse kidney in response to a single acute exposure to CDDO-Me, whilst evidence 
for the pharmacological induction of Nrf2 in the human kidney, and a role for this in 
the beneficial effect of CDDO-Me in CKD patients (de Zeeuw et al., 2013b) is 
currently lacking.  This calls into question the rationale of targeting Nrf2 in CKD 
patients, although more work is needed in this area.   
Nevertheless, Nrf2 inducers continue to hold promise as novel treatments for a 
range of diseases, and the work presented here indicates that enhancement of 
pharmacological potency is not inherently linked to an increase in toxicity, which 
will aid the assessment of benefit:risk for Nrf2 inducers in different patient cohorts.   
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Chapter 5 
General Discussion 
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Introduction 
The transcription factor Nrf2 has previously been demonstrated to afford 
protection against acute kidney injury (Shelton et al., 2013) and chronic disease 
(Ruiz et al., 2013) in various experimental models, however, at the commencement 
of the research described here, the physiological and pharmacological roles of Nrf2 
in the kidney were relatively poorly understood, compared to other organs.  This 
thesis has sought to address these knowledge gaps through proteomic, 
transcriptomic and targeted analysis of animal and cell-based models in which Nrf2 
is modulated via genetic and/or pharmacological interventions, and through 
investigation of the relationship between pharmacological potency and toxicity of 
established and novel Nrf2 inducers. 
 
Role of Nrf2 in protection against acute kidney injury 
The investigations described in Chapters 2 and 3 sought to define the molecular 
processes governed by Nrf2 in the kidney.  Whole renal homogenates from Nrf2+/+ 
and Nrf2-/- mice, treated with CDDO-Me or vehicle, were utilised in a multifaceted 
approach using both iTRAQ proteomics and a microRNA array to define the proteins 
and microRNAs under Nrf2 control in the kidney. 
The key finding of the work presented in Chapter 2 was that the proteins regulated 
by Nrf2 in the kidney were involved in a wide range of homeostatic processes, 
including the maintenance of redox balance, the synthesis and conjugation of 
glutathione, the metabolism and disposition of a wide range of xenobiotics, 
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pyruvate metabolism, the supply of NADPH and the synthesis and recycling of 
amino acids (Fig. 1 and 2).  That Nrf2 may play an important role in the regulation of 
these processes has a wide implication for the development of novel Nrf2-targeting 
drugs, but also in the understanding of the physiological roles of Nrf2 in the kidney. 
 
 
Fig. 1: Schematic of proteins involved in xenobiotic metabolism, the antioxidant pathway 
and glutathione synthesis shown here to be regulated by Nrf2 at the basal level in the 
mouse kidney. 
 
 
178 
 
 
Fig. 2: Schematic of proteins involved in energy homeostasis shown here to be regulated by 
Nrf2 at the basal level in the mouse kidney. 
 
The involvement of Nrf2 in the regulation of glycolysis and the pentose phosphate 
pathway is relatively unexplored (Kraft et al., 2004; Heiss et al., 2013; Holmstrom et 
al., 2013), and determining the impact of Nrf2 on the production of cellular energy 
is a newly emerging field (Mitsuishi et al., 2012; Hayes et al., 2014).  Fig. 2 depicts 
the renal proteins shown to be positively regulated by Nrf2 in the iTRAQ study 
within an overall scheme of glycolysis and the pentose phosphate pathway.  
Additionally, the production of NADPH and FAD has been determined here and 
elsewhere to be regulated by Nrf2 (Wu et al., 2011a; Holmstrom et al., 2013); 
consistent with our observation that Nrf2 regulates the expression of Nampt, G6pd 
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and Pgd, enzymes that controls the production of NADPH (Frederiks et al., 2007; 
Bowlby et al., 2012).   
The enhanced sensitivity to AKI in the Nrf2-/- mouse (Liu et al., 2009; Aleksunes et 
al., 2010; Shelton et al., 2013) is consistent with the data described in this thesis, in 
that proteins involved in the maintenance of redox balance and xenobiotic 
metabolism are decreased in the Nrf2-/- mouse, and increased following CDDO-Me 
administration.  It is likely the cumulative effects of these Nrf2-regulated proteins 
that reduce the efficiency (or ablate the capacity) of redox balance, xenobiotic 
metabolism and general ability to cope with stress, such as AKI.  Furthermore, an 
increased ROS burden has been associated with increased cytoskeletal remodelling 
(Stanley et al., 2014), consistent with the data presented in Chapter 2, Table 5 
describing the increase in expression of proteins associated with alterations in 
epithelial junction signalling and actin cytoskeleton remodelling in the antioxidant-
impaired Nrf2-/- mouse.  Whether this is a protective response, or is a consequence 
of reduced antioxidant capacity requires further investigation. 
As described in Chapter 3, a number of microRNA species have been found to be 
differentially expressed in both the Nrf2-/- and CDDO-Me treated Nrf2+/+ mouse 
kidney, and further validation of these findings will (a) provide important insights 
into the regulatory roles of Nrf2 in the kidney given that a number of these 
microRNAs as yet do not have an assigned function, and (b) may identify a 
microRNA-based biomarker of Nrf2 activity.    
Given the nature of the negative regulatory role of microRNAs, the general ablation 
of microRNA biogenesis in a proximal-tubule specific model of IR injury results in 
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enhanced resistance (Wei et al., 2010).  However, podocyte-specific ablation of 
microRNA biogenesis results in severe renal impairment (Shi et al., 2008), 
suggesting a complex role for microRNAs in renal physiology that is not cell-specific.  
Indeed, a number of the microRNAs found here to be regulated by Nrf2 in the 
kidney do not yet have an assigned function (e.g. miR-3082, miR-669p-3p, miR-
466f), emphasising the need for further work to determine the relationship 
between the increased susceptibility of the Nrf2-/- mouse to AKI, and the role(s) that 
differential expression of specific microRNA species may have, especially in the 
context of the different sections of the nephron. 
Adverse drug reactions are a significant clinical problem, estimated to cost the NHS 
1.6 million bed days and £466 million per year (Pirmohamed et al., 2004), and pose 
a substantial barrier to the development and use of novel medicines.  Nrf2 is known 
to protect against the adverse reactions associated with exposure to paracetamol 
(Enomoto et al., 2001), cisplatin (Aleksunes et al., 2010) and bleomycin (Cho et al., 
2004) in mice.  Inter-individual variation in susceptibility to adverse drug reactions 
in humans is well documented (Edwards et al., 2000); however, as yet this has not 
been correlated to variation in Nrf2 activity.  Given that disruption of Nrf2 reduces 
the renal expression of at least 108 proteins in Nrf2-/- compared to Nrf2+/+ mice 
(Chapter 2, Table 2), and the kidney plays an important role in the metabolism of 
various drugs (Lohr et al., 1998; Perazella, 2009), the potential for inter-individual 
variation in the activity of the Nrf2 pathway in the kidney, and more generally, 
should be determined in human populations with respect to susceptibility to 
adverse drug reactions.  Such heterogeneity (for example in expression of renal 
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transporter and detoxication enzymes), could predispose some individuals to renal 
diseases or nephrotoxic insults, or render them relatively resistant, and thus may be 
an informative marker of patient health. 
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Therapeutic targeting of Nrf2 – potential mechanisms and implications 
Following the cessation of the CDDO-Me ‘BEACON’ clinical trial due to unforeseen 
adverse clinical events (de Zeeuw et al., 2013b), questions were raised whether the 
drive to generate more potent and efficacious Nrf2 inducers had inadvertently 
generated inherently more toxic compounds (Fig. 3).  Through examination of 
cellular responses to a battery of Nrf2-inducing compounds, the work presented in 
Chapter 4 determined that an increase in potency towards Nrf2 is associated with 
an increase in in vitro therapeutic index, and as such a relative enhancement of in 
vitro safety (Copple et al., 2014). 
 
 Fig. 3: Overview of adverse effects observed in recent clinical trials of CDDO-Me (Pergola et 
al., 2011b; de Zeeuw et al., 2013b).  Dashed line shows proposed CDDO-Me mediated 
downregulation of the endothelin A receptor (EtAR), which leads to a decrease in sodium 
retention (Camer et al., 2014) and an increase in fluid volume, contributing to an increase in 
blood pressure and eGFR, at the cost of decreasing filtration capacity and increasing urinary 
albumin. 
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The termination of the CDDO-Me ‘BEACON’ trial can most likely be attributed to 
poor patient selection and not due to inherent toxicity of CDDO-Me.  Since the 
termination of the trial (and after the work in this thesis was completed), more 
details about the adverse events have been published, suggesting that patients with 
a baseline B-type natriuretic peptide (BNP, a peptide secreted by the heart 
functioning to decrease systemic vascular resistance and increase natriuresis, the 
excretion of Na+ at the kidney)  of ≥200 pg/mL had an increased risk of heart failure 
when treated with CDDO-Me, compared to the placebo (Chin et al., 2014b).  Renal 
failure is associated with an increase in BNP, and a corresponding increase in  fluid 
volume (Cowie et al., 2002).  BNP levels were increased in the CDDO-Me group, 
compared to the placebo in the ‘BEACON’ study (de Zeeuw et al., 2013b), likely as a 
result of an off-target effect of CDDO-Me in modulating the renal endothelin system 
(Chin et al., 2014c). The role of Nrf2 in the modulation of endothelin signalling by 
CDDO-Me has not been examined.  Because the patients enrolled in the ‘BEACON’ 
study already had higher than usual fluid retention, it seems likely that the effect of 
CDDO-Me on endothelin signalling compounded this issue, and resulted in the 
adverse cardiac events (Camer et al., 2014; Chin et al., 2014a; Chin et al., 2014c; 
Chin et al., 2014b).  Converse to the renal system, suppression of the cardiac 
endothelin signalling is protective against hypertension and heart failure (Nasser et 
al., 2014), therefore the tissue-specificity of this off-target effect of CDDO-Me must 
be investigated; emphasising the need to consider whole animal physiology when 
determining the pharmacological effects of CDDO-Me and alternative Nrf2-inducing 
drugs. 
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To our knowledge, the mechanism behind the improvement of eGFR by CDDO-Me  
(Hong et al., 2012) has yet to be shown to be Nrf2-dependent, and our 
immunohistochemical analysis (Chapter 2, Fig. 11) did not reveal particularly 
intense staining of Nrf2 and Nqo1 on the glomerular podocytic membrane.  
Likewise, the mechanism of action of dimethyl fumarate (licensed as a treatment 
for multiple sclerosis (Lee et al., 2013)) has also yet to be determined as Nrf2-
dependent.  The contribution of Nrf2 induction to the beneficial effects of CDDO-
Me in CKD and other diseases requires further investigation, especially given that 
CDDO-Me targets other cellular signalling pathways (Fig. 4), albeit generally at 
higher concentrations than those required to induce Nrf2.  In particular, the role of 
NF-κB inhibition in the therapeutic effects of CDDO-Me, DMF and other Nrf2 
inducers is a key knowledge gap that will inform the utility of such drugs in the 
treatment of different diseases.  Therefore, further work is needed to define the 
pharmacological and toxicological consequences of targeting Nrf2 in renal and other 
diseases. 
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Fig. 4: Known pharmacological targets of CDDO-Me and its derivatives.  In addition to 
activating the Nrf2 pathway, CDDO-Me has also been shown to induce PPARγ expression 
resulting in an increase in fat storage and glucose metabolism in both normal physiological 
conditions and in acute kidney injury (Wu et al., 2011b).  CDDO-Me mediated induction of 
PPARγ, and BAX (Konopleva et al., 2002), and inhibition of Bcl-2 (Wang et al., 2015b) and 
STAT (Liby et al., 2006) are pro-apoptotic.  Finally, inhibition of the NF-κB pathway reduces 
the expression of pro-inflammatory genes (Shanmugam et al., 2014).  The relative 
contributions of these pharmacological effects to the ability of CDDO-Me to improve eGFR 
in CKD patients is not known. 
 
CDDO-Me is currently being investigated in a trial (‘LARIAT’, NCT02036970) for 
patients with pulmonary arterial hypertension (but not elevated BNP or renal 
dysfunction), based on the proposed beneficial reduction of cardiac endothelin 
signalling highlighted in the ‘BEACON’ trial (Chin et al., 2014b), and the compound’s 
known anti-inflammatory activity (Shanmugam et al., 2014) and ability to improve 
metabolic function (Chapter 2, (Reisman et al., 2012)), via Nrf2-regulation of energy 
metabolism.  Additionally, the Japanese pharmaceutical company Kyowa Hakko 
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Kirin have recently restarted a Phase II clinical trial treating CKD patients with 
CDDO-Me, but with the proviso that these patients have a BNP of <200 pg/mL.  This 
highlights that lessons have been learned from the CDDO-Me ‘BEACON’ trial.  
The induction of Nrf2 by CDDO-Me has been associated with significant weight loss 
in cynomolgus monkeys (Reisman et al., 2012), and induction of Nrf2 in mouse 
astrocytes has been shown to upregulate a number of genes involved in glycolysis 
(Kraft et al., 2004) consistent with the data presented here indicating that Nrf2 
positively regulates the expression of proteins that contribute to glycolysis and 
energy metabolism.  Sulphoraphane treatment has been reported to reduce weight 
gain in a mouse model of diabetic nephropathy (Zheng et al., 2011), whilst dimethyl 
fumarate prevents weight gain in a mouse Huntington’s Disease model (Ellrichmann 
et al., 2011).  Furthermore, the induction of traumatic haemorrhage injury in rats 
results in a decrease in Nrf2 protein activity and energy production, which was 
rescued with resveratrol treatment (Jian et al., 2014).  These observations suggest 
that the modulation of Nrf2 may be a novel strategy for stimulating weight loss.  
However, pharmacological activation of Nrf2 may also carry the potential to 
adversely affect energy metabolism and weight in certain disease states.  This 
aspect of patient safety should be considered during the development of novel 
Nrf2-inducing drugs. 
The clinical future of Nrf2 inducing compounds is not as bleak as first thought at the 
termination of the ‘BEACON’ trial.  RTA-408, a derivative of CDDO, is currently 
undergoing eight clinical trials for a wide range of diseases including combatting 
advanced solid tumours (NCT02029729), in patients with melanoma (NCT02259231) 
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and mitochondrial myopathy (NCT02255422).  These clinical trials have exclusion 
criteria for patients with a baseline BNP of >200 pg/mL and for patients with a 
history of specific cardiac disorders.  The exclusion criteria have highlighted the 
possibility of using CDDO derivatives in treating a much wider range of diseases.  
Better understanding of patient selection and the physiological and 
pharmacological roles of Nrf2 suggest that CDDO-Me and other Nrf2 inducing 
compounds may still hold promise as novel treatments for disease. 
 
Biomarkers of Nrf2 activity 
Due to the lack of available biomarkers of Nrf2 activity, multiple methods, both in 
vitro and in vivo, have been established to determine the value of monitoring Nrf2 
activity for the detection of pharmacological and toxicological events.  The use of 
the reporter cell line detailed in Chapter 4 (H4IIE-ARE8L, (Copple et al., 2014)), and 
cell lines expressing fluorescent-tagged Nrf2 or its target genes (Wink et al., 2014) 
represent a step towards deriving an easily-measureable Nrf2 response.  In 
addition, the KeratinoSensTM assay is now recommended by the OECD as part of a 
panel of in vitro tests for identifying skin sensitising compounds based on the 
induction of a ARE-luciferase reporter construct (Emter et al., 2010).  Similarly, 
transcriptomic signatures have been used to define responses to toxicity and 
identify novel renal biomarkers of injury in the non-transformed human proximal 
tubule cell line RPTEC/TERT1 following exposure to a variety of nephrotoxins 
(Aschauer et al., 2014).  Analysis of primary cells would allow for the consolidation 
of key markers of Nrf2 activity, which would aid the continuing drive to utilise cell 
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models to predict toxicity of new drugs, and define the contribution of Nrf2 to such 
responses. 
Whilst in vitro work has utility, due to the limited physiological relevance of cell 
lines and the rapid dedifferentiation of primary cells (Van der Hauwaert et al., 2013)  
these cells are often only proximal tubule-like, and the physiological response in 
context with the whole organism is therefore not accurate, and translational 
markers of Nrf2 activity are unable to be analysed.  The development of Nrf2-luc 
reporter mice (OKD48-luc, producing bioluminescence measureable through whole 
animal or ex vivo organ imaging upon activation of the Nrf2 response (Oikawa et al., 
2012)) has enabled the measurement of Nrf2 activity in real time in vivo, and 
therefore provides an excellent route to examine the relationship between drug 
disposition, organ toxicity and the activation of the Nrf2 response.  However, the 
translational value of Nrf2-luc mice is likely to be limited, as drug metabolism varies 
between species, and may not accurately reflect the Nrf2 pathway response in 
humans. 
Patient peripheral blood mononuclear cells (PBMCs) represent one avenue of 
investigation for utilisation of a clinical biomarker of Nrf2 activity.  NQO1 mRNA was 
reported to be increased 5-fold in the PBMCs of patients administered CDDO-Me as 
a treatment for solid tumours and lymphomas (Hong et al., 2012).  Aldo-keto 
reductase activity in PBMCs was shown to be increased following Nrf2 induction, 
representing a promising translational marker of Nrf2 activity (Jung et al., 2013).  
Currently it is unclear whether NQO1 and aldo-keto reductase measurement in 
PBMCs represents the status of Nrf2 activation in the whole body or in target 
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organs, and therefore the lack of a measureable biomarker of Nrf2 activity is 
hindering the detailed assessment of the response of the Nrf2 pathway in humans.  
Additionally, HO-1 has been detected in the urine and plasma of patients with acute 
kidney injury (Zager et al., 2012), however this protein is known to be regulated by 
multiple mechanisms other than Nrf2 (Alam et al., 2003), and was not detected in 
the iTRAQ study in Chapter 2, therefore its utility as a generic biomarker of Nrf2 
activity is questionable. 
Monitoring Nrf2 activity in patients would aid in understanding the functional 
consequences of Nrf2 manipulation.  The lack of appropriate markers of Nrf2 
activity leads to problems in determining both the basal state and the extent of 
inter-individual variation in expression of Nrf2 in patients.  Quantifying the basal 
expression of Nrf2 could assist in the personalisation of drug regimens.  Indeed, 
measurement of the basal state of Nrf2 in patients enrolled in the CDDO-Me 
‘BEACON’ clinical trial could have provided new knowledge about the contribution 
of Nrf2 towards the adverse effects, and about the pathological changes in the 
patient population following CDDO-Me administration. 
Current clinical biomarkers of renal disease in humans include the use of proteins 
and mRNA (for example, detection of nephrin mRNA in podocytic injury (Wang et 
al., 2007), and albumin following albuminuria), however more accurate next-
generation biomarkers of renal disease are required as current ones are often 
unreliable (Nayak et al., 2013).  Circulating microRNAs represent a largely 
unexplored resource of potential biomarkers of disease that may be more effective 
than current protein or mRNA-based biomarkers, in part due to their transient 
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nature that is well suited to dynamic measurement.  In the case of paracetamol 
hepatotoxicity, miR-122 expression is detectable in plasma at levels above normal 
earlier than typical markers of hepatic injury (Starkey Lewis et al., 2011).     
Impaired Nrf2 activity is associated with chronic kidney disease (Kim et al., 2010; 
Aminzadeh et al., 2013a), and therefore the measurement of microRNAs and 
proteins responsive to Nrf2 activity in an easily available biofluid could provide 
insights into disease state and/or prognosis.  Whether the proteins (e.g. Gstm1, 
Nqo1, Cat) and microRNAs (e.g. miR-28c, miR-144 and miR-466h) shown here to be 
regulated by Nrf2 can accurately reflect the activity of Nrf2 in a manner befitting of 
a biomarker should be investigated by triangulating suitable in vitro and in vivo 
models with clinical data.  A possible route could involve the correlation of a protein 
or microRNA known to be regulated by Nrf2 with a biomarker of renal disease (such 
as Kim-1) through the use of in-situ hybridisation and the subsequent correlation of 
trends in expression of this particular biomarker of renal disease in an easily 
accessible biofluid from patients with CKD.  The identification of such a biomarker 
would allow the relevance of Nrf2 as a therapeutic target and critical node in the 
toxicological response to drugs to be examined in humans.  
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